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Abstract 
Aim: To compare the strengths and limitations of different offloading devices in the 
treatment of diabetic foot ulcers. 
 
Method: Systematic review.  
 
Background: Diabetes is a chronic disease where neuropathy and peripheral vascular 
disease, associated with foot deformity, trauma and high plantar pressures contribute to 
the development of foot ulceration. For those with existing ulcers, if the foot is subject 
to continuous high pressures, tissue damage persists and healing will be impaired. 
Therefore, the use of offloading devices becomes fundamental for the treatment of these 
ulcers.
 
 
 
Findings: Following a systematic search of the literature, 14 studies were included in 
this review. Healing rates, healing times and reduction in ulcer size were improved with 
the use of total contact casting, compared with other offloading devices. The main 
adverse effects associated with use of the device were infection, maceration and 
abrasion. Cost, compliance and quality of life issues were rarely included within the 
studies. 
 
Conclusion: Offloading is a key treatment strategy for the management of diabetic foot 
ulceration and total contact casts were found to be the most effective devices to achieve 
ulcer healing. However, they are not without complications and further, their impact on 
cost, compliance and quality of life is not well understood. 
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Chapter1. Background 
1.1. Introduction 
This chapter will give an international and national overview of the incidence and 
prevalence of diabetes mellitus (DM). Then it will focus on diabetic foot ulcers (DFUs) 
characteristics, incidence, costs and complications. Finally, the chapter will analyse 
offloading for the treatment of DFUs. 
 
1.2. DM: an overview 
Diabetes is a chronic disease (International Diabetes Federation (IDF) 2012a) and 
according to IDF (2012b) projections in 2011 the prevalence of DM in the world was of 
8.3% and it will increase to 9.90% by 2030. Furthermore, in 2011 the number of deaths 
related to DM was of 4.593.109 people (IDF 2012b). Focusing on Irish figures, in 2011 
the national prevalence of DM was 6.07%, and by 2030 it will rise to 7.49%, the 
number of deaths in the population between 20-79 years of age was 1.457 deaths in 
2011 (IDF 2012b). Additionally, the mean diabetes expenditure per person with 
diabetes in 2011 was €6.629.00 (IDF 2012b). It is clear that the prevalence of people 
with DM in the world and, more specifically, in Ireland is growing and this growth 
impacts negatively on the economy, society, healthcare services, and mainly on the 
individual. 
 
Diabetes occurs when the pancreas cannot produce insulin or its production is impaired 
(IDF 2012a, World Health Organization (WHO) 2012). This hormone is important for 
the body to function, as it allows glucose to enter the cells and be used as energy (IDF 
2012a). However, if the body lacks insulin, high levels of glucose in the blood will 
15 
 
occur and overtime these will promote tissue damage at the microvascular and 
macrovascular level (IDF 2012a, WHO 2012). At the microvascular level the damage 
occurs in the small blood vessels and can lead to complications like retinopathy, 
nephropathy and neuropathy. In terms of macrovascular damage, this occurs in larger 
blood vessels and can lead to complications like cardiovascular disease and peripheral 
vascular disease (PVD) (IDF 2012a, WHO 2012). From the many complications that 
can arise, neuropathy and PVD alone or in conjunction can, with the influence of other 
factors, lead to the development of DFUs, and if untreated, can lead to amputation, both 
of which have a negative impact on the individual. 
 
1.3. Diabetic Foot Ulcers 
DFUs are lesions characterised by a skin break involving loss of epithelium, which can 
extend through the dermis and deeper tissue, and in some cases involve muscle and 
even bone (Reiber et al. 1998, Boulton 2004b). Although, neuropathy and PVD are the 
primary factors for the presentation of DFUs, other risk factors play an important role in 
the development, aggravation and healing outcomes of DFUs (Boyko et al. 1999, 
Reiber et al. 1999, Merza and Tesfaye 2003, Boulton 2004b, Lavery et al. 2008, Wu 
and Armstrong 2005). 
 
1.3.1. DFU: Neuropathy and PVD 
Neuropathy results from continued peripheral nerve damage of motor, sensory and 
autonomic fibres, that affect sensation, innervation of the muscles of the foot and its 
circulation (Reiber et al. 1998, Jeffcoate and Harding 2003, Merza and Tesfaye 2003, 
Boulton 2004b, National Institute of Diabetes and Digestive and Kidney Diseases 
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(NIDDK) 2009). Motor neuropathy causes muscle wasting, atrophy and weakness 
which leads to foot deformities, such as claw and hammer toe that in turn predispose the 
individual to restricted joint mobility, balance problems and gait instability (Reiber et 
al. 1998, Merza and Tesfaye 2003, Boulton 2004b, Cavanagh et al. 2005, Singh et al. 
2005). Sensory neuropathy leads to decreased or loss of protective sensation to pain, 
pressure and loss of proprioception (inability to recognize the feet position) (Reiber et 
al. 1998, Merza and Tesfaye 2003, Boulton 2004b, van Deursen 2004). The loss of 
protective sensation places the individual at risk of continuously harming the foot 
without realising it (Laing 1998, Wu and Armstrong 2005). Autonomic neuropathy 
refers to altered microvascular blood flow that results in warm feet, and decreased sweat 
production, resulting in dry skin, predisposing callus formation, which is hyperkeratosis 
that develops around the ulcer, and skin breakdown (Reiber et al. 1998, Merza and 
Tesfaye 2003, Boulton 2004b, Lavery et al. 2008). 
 
PVD causes reduced blood supply in the lower extremities and consequently poor foot 
perfusion (Boyko et al. 1999, Spencer 2008). The individual with PVD presents a cool, 
red shiny and dry foot (Elkles and Wolfe 1991, Jeffcoate and Harding 2003). The 
presence of PVD contributes to DFUs formation and delayed healing as it influences the 
ability to fight infection because, poor perfusion adversely impacts on the ability of 
cells, necessary for wound repair, to reach the wounded area. Further, the delivery of 
nutrients, antibiotics and oxygen are compromised (Reiber et al. 1998, Boyko et al. 
1999, Merza and Tesfaye 2003, Boulton 2004b). 
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In a study by Reiber et al. (1999) where the causal pathways for the incidence of DFUs 
were analysed (n=148), in 78% of the subjects neuropathy was the most common cause 
of ulceration, while PVD (ischemia) represented 35% of cases. Another study by Oyibo 
et al. (2001) (n=194), 67% of FUs were neuropathic, 26.3% were mixed aetiology and 
just 1.0% were ischaemic. The study by Pompers et al. (2007) reported, in a cohort of 
1,229 subjects, that PVD was present in 49% of the subjects whereas neuropathy was 
diagnosed in 86%.  Finally in the study by Lavery et al. (2008) of 87 subjects with a 
total of 103 ulcers, 92.2% were neuropathic and 23.3% were ischaemic. These figures 
support the fact the neuropathy and PVD are the main precursors of DFUs. 
Nevertheless, other factors also play an important role in the development of FUs. 
 
1.3.2. DFU: Other Causal Pathways 
Within the research (Reiber et al. 1998, Boyko et al. 1999, Reiber et al. 1999, Merza 
and Tesfaye 2003, Boulton 2004b, Wu and Armstrong 2005, Lavery et al. 2008) it is 
well established that other risk factors such as foot deformities, trauma, callus, pressure, 
inappropriate footwear and oedema also contribute to DFUs development, aggravation 
and healing outcomes. Furthermore, infection, being one of the possible consequences 
of DFUs, also has a negative impact in healing outcomes particularly when associated 
with PVD, due to poor perfusion of the lower limb (Prompers et al. 2008).  
In a study by Reiber et al. (1999), (n=148), trauma and foot deformities where present 
in 77% and 63% of the subjects, respectively. In the same study oedema was present in 
37% of the subjects and callus in 30%. Another study by Lavery et al. (2008), of 87 
subjects with 103 ulcers identified, deformity was present in 63.1% of the subjects, 
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callus in 60.2% and high pressures in 52.4%, whilst inappropriate footwear and trauma 
were the contributing factors in 19.4% and 10.7% of the subjects.  
From the contributing factors mentioned, foot deformity is influenced by changes due to 
motor neuropathy that causes atrophy of the intrinsic muscles of the foot, which in turn 
will pull the toes out of shape leading to hammer/claw toes, which are rigid contractures 
of the toes (Reiber et al. 1999, Merza and Tesfaye 2003, Lavery et al. 2008). Oedema is 
related to cardiac and venous disorders that promote fluid accumulation in the lower 
limbs and feet (Reiber et al. 1998). In relation to callus formation this is influenced by 
increased vertical and shear stresses, and dry skin (Reiber et al. 1998, Reiber et al. 
1999). Overall, these structural changes of the foot, together with neuropathy, PVD and 
the action of pressure, trauma and inappropriate footwear will predispose the individual 
to the formation and poor healing of DFUs.  
 
1.3.3. DFUs: Prevalence, Incidence and Cost  
With respect to prevalence and incidence, it is estimated that the incidence of DFUs in 
the USA is between 2-3% and the point prevalence is around 5-7% (Posnett et al. 2009). 
In relation to Europe it is suggested that between 1.0-1.4million people have a DFUs at 
any time (Posnett et al. 2009). The prevalence of DM is expected to rise from 8.3% in 
2011 to 9.90% by 2030 (IDF 2012b) increasing the number of cases of DFUs. In Ireland 
according to the HSE (2009) it is estimated that there are 20,470-41,020 cases of DFUs 
and around 5234 cases were treated in 2003 in Irish hospitals.  
 
In terms of costs with DFUs in a 2003-2004 study in 14 DF centres in 10 European 
countries the authors concluded that, for the treatment of DFUs the average direct and 
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indirect cost was around €10.000, based on the data from 821 patients from the 
participating countries (Pompers et al. 2008). In the USA in 2001, the cost of DFUs and 
amputations was 10.1 billion dollars and in the same year in the UK the annual cost, of 
diabetes foot related complications (excluding amputations), was £252 million pounds 
(Boulton et al. 2005). In a 2001-2002 Irish audit of 30 patients admitted with DFUs, 
with an average hospitalization of 20-30 days, the net in hospital cost was €704.689 
with an average €23,489.63 per patient (Smith et al. 2004). 
This data shows that DFUs are an increasing health problem that impacts greatly on 
economy and society. 
 
1.3.4. DFUs: Amputation and QoL 
Individuals with DM are at risk of developing DFUs and around 15% of these if 
untreated, or poorly managed, can result in limb amputation, which has a mortality rate 
of around 30-80% (McDermott-Scales et al. 2009). Amputation involves the surgical 
removal of a non-viable part of the limb (Boulton 2004b). According to a study by 
Pecoraro et al. (1990) of 80 subjects requiring first time amputation, the main factors 
leading to limb amputation were failure of wound healing in 81% of cases, infection and 
gangrene were associated with 42% of cases, trauma that resulted in ulceration 
accounted for 72% of the cases, neuropathy was found to be present in 82% of cases 
and PVD in 46% of cases. These figures show that individuals often present with more 
than one confounding factor predisposing ulceration and influencing wound healing. 
Following a more detailed analysis, PVD emerges as the only independent cause that 
led to amputation of the limb. Moreover, in a French incidence study by Fosse et al. 
(2009), 95% of amputations were preceded with ulceration confounded by PVD and 
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neuropathy. In a study by Vamos et al. (2010), in the UK between, 2004-2008 49.487 
non-traumatic amputations were performed from which 51% occurred in diabetic 
patients. Of these 59.6% were minor amputation and 42.6% were major amputations. 
Thus, if poorly managed DFUs increase the incidence of non-traumatic amputations, 
raising the costs associated with DFUs not only at an economic level but also at a social 
and human level (Margolis et al. 2005).  
 
In relation to the impact that both DFUs and amputation have on the individual, an Irish 
study of 38 subjects identified that depression, anxiety, social discomfort and body 
image were the main issues identified as having the greatest impact in the individuals 
quality of life (QoL) (Coffey et al. 2009). Focusing on DFUs, in the study by Brod 
(1998), mobility issues were identified by subjects as having the greatest impact on 
participants QoL. Additionally, Brod (1998) identified frustration and anger as feelings 
that emerged due to mobility issues. Vileikyte (2001) and Vileikyte et al. (2004) 
reported in their review that individuals identified mobility difficulties as having an 
impact in their daily activities, which in turn affected their professional and social life, 
creating anxiety and poor QoL. Furthermore, Vileikyte (2001) mentions that individuals 
also experienced fear of developing new ulcers. 
DFUs are an important health issue that needs to be addressed. It is fundamental to 
implement prevention and treatment practices that will improve individuals QoL and 
bring better cost-effectiveness for the health services. 
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1.4. Offloading the Diabetic Foot 
DFUs develop due to a combination of different physiological, structural and 
environmental factors. When these factors are combined they promote skin tear and the 
progression of a small break into a possible deep and large ulcer that if untreated can 
lead to infection and gangrene, rendering the limb unviable and amputation as the only 
solution (Laing 1998, Merza and Tesfaye 2003, Boulton 2004b, Leung 2007). Thus, 
prevention, early recognition and treatment are fundamental to salvage the limb and to 
allow individuals to have a better QoL (Brod 1998, Boulton 2004a, Bakker et al. 2011). 
 
Neuropathy, PVD, pressure, foot deformities, oedema, trauma and callus all play a 
major role in the development and maintenance of DFUs (Boulton 2004b, Cavanagh et 
al. 2005, Wu and Armstrong 2005, Lavery et al. 2008). Although, there is a bigger 
emphasis around neuropathic foot ulcers, as these are more common (Cavanagh et al. 
2005), ischaemic ulcers are also a reality (Laing 1998, Boulton 2004b, Bakker et al. 
2012). 
 In relation to neuropathic ulcers, these develop because the foot is subject to high 
pressures, due to loss of sensation and unperceived mechanical load, that with time or 
with the help of callus, foot deformities and minor trauma will result in an ulcer (Laing 
1998, Boulton 2004a, Boulton 2004b, Cavanagh et al. 2005). Ischaemic ulcers form due 
to continuous low pressures applied over time, in a dry, cold foot (Laing 1998). These 
ulcers are also precipitated by new footwear, minor trauma and foot deformities and 
once they have formed they are difficult to heal because, the foot needs a good blood 
supply, which is impaired in individuals with PVD (Laing 1998, Bakker et al. 2012). 
Neuroischaemic ulcers have characteristics of both neuropathic and ischaemic ulcers, 
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however it is important to establish which condition is more predominant (Laing 1998) 
so that a more focused treatment may be planned and implemented. 
 
Pressure plays a central role in the development of DFUs and its management becomes 
essential not only to prevent the development of new ulcers but also to allow the healing 
process to take place (Caravaggi et al. 2000, Armstrong et al. 2001, Reiber et al. 2002, 
van Deursen 2004, Piaggesi et al. 2007, Faglia et al. 2010).  
Pressure results from mechanical loading of the feet when the individual engages in 
activities like walking and standing, exposing the plantar surface of the feet to reaction 
forces that act upon the foot tissue causing compression and sometimes shear stress (van 
Deursen 2004). This pressure and stress is aggravated by foot deformities like hammer 
and claw toes, prominence of metatarsal heads, hallux valgus and limited joint mobility 
(Boulton 2004a, van Deursen 2004). For these reasons, offloading the foot and 
accommodating its deformities with the use of appropriate footwear is essential for the 
treatment of DFUs (van Deursen 2004).  
 
Offloading is both a treatment and prevention intervention which relieves, reduces or 
redistributes plantar pressure to avoid the concentration of high pressures in DFUs, in 
the diabetic ulcer free foot and also to protect pressure points in the foot (Burden et al. 
1983, Cavanagh et al. 2000, Cavanagh et al. 2005, Leung 2007, Edmonds et al. 2008: 
85). Besides managing plantar ulcers, offloading is also important when the ulcer is 
located on the heel and on the lateral aspect of the midfoot and forefoot (Cavanagh et al. 
2005).  
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Offloading is a central intervention in the treatment and management of DFUs (Reiber 
et al. 2002, Armstrong et al. 2005, Katz et al. 2005, Piaggesi et al. 2007, Faglia et al. 
2010). Indeed, a wide variety of offloading devices have been compared and evaluated 
to try to bring a better understanding on their efficacy and to identify which device has 
better healing outcomes. Although, the most effective approach is total offloading/non-
weight bearing, this practice is often impractical so the use of devices to achieve the 
maximum pressure relief possible are often standard practice (Cavanagh et al. 2005).  
 
1.4.1. Offloading Devices 
In terms of offloading devices there is a great variety available that can be used when 
there is an active ulcer or only when pressure redistribution is necessary. Some of the 
devices available are included in the following categories casts, therapeutic shoes, 
orthoses, felt padding and foam (see appendix 1 for list of devices in each category) 
(Edmonds et al. 2008, Spencer 2008). 
The different offloading devices available are all important for the treatment of DFUs. 
However, total contact cast (TCC) is considered the most effective device, as it cannot 
be removed easily by the individual allowing for better compliance (Caravaggi et al. 
2000, Armstrong et al. 2001, Reiber et al. 2002, Jeffcoate and Harding 2003, Beuker et 
al. 2005, Leug 2007, Faglia et al. 2010).  
Nonetheless, the consensuses around the best way of offloading DFUs is not well 
established yet as various authors recommend different devices for offloading DFUs 
(Caravaggi et al. 2000, Armstrong et al. 2001, Armstrong et al. 2005, Katz et al. 2005, 
Piaggesi et al. 2007, Faglia et al. 2010). Thus, for the purpose of this systematic review 
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the writer wishes to explore the following question: What is the impact of offloading in 
the treatment of DFUs? 
Taking this into account the aim of this review is to compare the strengths and 
limitations of different offloading devices in the treatment of DFUs.  
The objectives of this review are to: 
 Identify the most effective offloading device in the treatment of the DFUs. 
 Identify the strengths and limitations of the different offloading devices in the 
studies reviewed. 
 Determine the impact that offloading devices have in patients QoL, in the studies 
reviewed. 
 
1.5. Summary 
Around 6% of the Irish population has DM and its prevalence is growing. As the 
number of people suffering from diabetes increases the incidence of its complications 
also increases. Diabetes causes tissue damage in the small and large bloods vessels that 
with time can develop PVD and neuropathy that play a primary role in the development 
of DFUs. Neuropathy is characterised by nerve damage causing loss of protective 
sensation in the foot, whilst PVD leads to an impaired blood supply of the foot. These 
two risk factors in combination with trauma, foot deformities, callus, oedema, 
inappropriate footwear and/or pressure can contribute to skin breakdown and the 
development of FUs. Although, all these factors play an important role in the DFU 
causal pathway, pressure is a factor always present in the development or maintenance 
of DFUs whether they are neuropathic, ischaemic or mixed aetiology. Pressure results 
in the mechanical loading of the foot’s surface, though this concentrates more in the 
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plantar aspect of the foot. Taking into account, that in order for DFUs to heal it is 
fundamental to minimize mechanical loading, offloading is a key intervention for both 
prevention and treatment of DFUs, as it will allow for the redistribution and relief of 
pressure in the feet. To achieve this various offloading devices, insoles, orthoses and 
casts, can be used. From these TCCs appear in the literature as the “gold standard” for 
the treatment of DFUs. However, it is important to analyse the research around 
offloading for the treatment of DFUs to gain a better understanding of the effectiveness 
of the various devices.  
 
1.6. Conclusion 
DFUs are a complex and debilitating complication of DM. Although, various 
interventions are essential for the treatment of these ulcers, offloading, by alleviating 
and redistributing pressure, is crucial for this treatment to be effective. 
 
 
 
 
 
 
 
 
26 
 
Chapter 2.Methodological Issues in Systematic Reviews 
2.1. Introduction 
Initially this chapter will explore the concept of research particularly in nursing and how 
this is important for evidence-based practice (EBP). Subsequently, it will analyse, in 
greater depth, the concept of systematic review (SR) and its importance and role as a 
research method. 
 
2.2. Nursing Research and EBP 
An Bord Altranais (ABA) (2007) main focus is in promoting and assuring high 
standards of nursing practice, education, training and professional conduct. For this 
objective to be attained research, which is an integral part of education, training and 
professional development, becomes cornerstone for nursing development as a 
profession and science.  
  
Since 1980, that the Working Party on General Nursing considered nursing research 
essential for the continuous development of this profession due to its growing 
complexity (Department of Health and Children (DoHC) 2003), and in 2003 the DoHC 
issued a final report, which states that knowledge acquisition is necessary for the 
development of any profession. Thus, it is clear that research is needed to create new 
knowledge and re-validate the existing knowledge. Therefore, research is a crucial link 
between knowledge acquisition and practice development (DoHC 2003). Furthermore, 
it is important to recognise that research, and more specifically nursing research, aims at 
‘solving clinical problems, evaluating practice, evaluating policy and generating and 
testing theory’ (Watson et al. 2008: 4). Ultimately, research will promote nurses 
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knowledge and enhance their practice, enabling them to provide evidence-based, and 
efficient healthcare services to society (ABA 2007: 6). 
 
According to Watson et al. (2008), there is primary and secondary research, the first is 
used when data pertaining to a certain question, that arises from practice, is being 
explored either through qualitative or quantitative methods. The second relates to 
research based on data that is brought together through, for example, a SR. 
Independently of the type of research being used this will allow nurses to integrate EBP 
into their care and to use it in their clinical decision-making (Sackett et al. 1996, Upton 
1999, Holland and Watson 2012). Evidence-based practice, involves using up-to-date 
evidence, based on current research, in clinical decision making (Sackett et al. 1996) as 
experience alone is not enough to reach high standards of clinical practice, knowledge 
and professional development. EBP is paramount not only to integrate the highest 
quality research for best practice but also to allow for best clinical decision-making, 
where the nurse is certain to be delivering the utmost care to their patients (Sackett et al. 
1996).  
EBP phases can be summarised as follows (Upton 1999: 549, Gerrish and Lacey 2010: 
495, Holland and Watson 2012: 104): 
1. Identifying a clinical problem,  
2. Formulating a question regarding the problem identified,  
3. Identifying the evidence, 
4. Critically assessing the evidence, 
5. Develop a strategy for implementing the evidence into clinical practice, 
6. Evaluate the impact and results of intervention applied. 
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This process is central to gather quality research and to examine its strengths and 
limitations not only in terms of the appropriateness of the methods employed but also in 
terms of the validity of its conclusions (Evans 2003, Holland and Watson 2012). 
Conversely, it is important to determine which evidence is the best evidence (Evans 
2003, Holland and Watson 2012). Sackett et al. (1996) argues that the best evidence 
accurately informs and answers clinical questions, being RCTs and SRs of RCTs the 
‘gold standard’ and when these are not available one must follow a hierarchy and find 
the next best evidence. Evans (2003) adds that to determine best evidence, the focus 
should include the appropriateness (psychosocial aspects of the intervention) and 
feasibility (the impact of the evidence and how this would be implemented) of the 
evidence and not exclusively its effectiveness (whether an intervention works as 
anticipated) (Evans 2003:79). These dimensions evaluate in a broad and complete way 
how research was conducted and if it achieved what it set to achieve. Furthermore, these 
dimensions give some insight into the person, how the research affected the person and 
if it is suitable and relevant for the wider community. Ultimately, it assesses if the 
research can be used for future decision making in terms of cost-effective practices, 
implementation of new policies and particularly professional practice actualisation and 
development.  
 
2.3. SRs: rationale and methodological issues 
2.3.1. Rationale for conducting SRs 
SRs play a central role in EBP and, to bring together valid and reliable information that 
can be used to allow informed clinical decision-making which, in turn, will support 
policymakers in the development of cost-effective and best evidence guidelines that will 
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promote best clinical practice, patient and community satisfaction (Cook et al. 1997a, 
Verhagen et al. 1998, Dixon-Woods et al. 2001, Jones 2004, Mays et al. 2005, Fineout-
Overholt et al. 2008, Thomas and Harden 2008, Smith et al. 2011). 
 
Mulrow (1994), grounds the basis for conducting SRs in a number of principles some of 
which pertain to research in general and others focus more in the SR of quantitative 
research. The first reason is related to the fact that today around 20.000 journals publish 
an estimated two million articles every year (Mulrow 1994, O’Mathúna 2010) rendering 
it impossible for nurses to take in all the available research information produced. 
Therefore, SRs help reduce the amount of information available (Mulrow 1994). 
Another rationale is the fact that, professionals and decision makers will use the 
information in SRs to identify and justify hypothesis through which guidelines and 
policies can be produced (Mulrow 1994). Moreover, SRs are a research technique that: 
follows a rigorous method; allows for generalizability; assesses the reliability of 
primary research; identifies any gaps or contradictory information in data (Mulrow 
1994). Consequently, SRs can be a mean of shaping the way qualitative and quantitative 
research are used and brought together, for nurses to base their practice and contribute 
not only for the production of guidelines and management change but also for the 
highest standards of care for patients, their family and the community (Mulrow 1994, 
O’Mathúna 2010). 
 
2.3.2. SR: its’ background and definition 
New demands in healthcare practices where decisions have to be based on the best 
evidence available and the fact that research data is constantly growing (Egger et al. 
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2001, Centre for Reviews and Dissemination (CRD) (2008) has made SRs fundamental 
for healthcare professionals to have up-to-date evidence and also to find where evidence 
is lacking (Egger et al. 2001). However, this need for SRs has been part of the research 
community for some time.  
An important pioneer was Archie Cochrane, an epidemiologist, who argued that 
healthcare professionals did not have ‘…access to reliable reviews of the available 
evidence’ (Egger et al. 2001: 449) making it difficult to practice and make decisions 
based on best evidence (Egger et al. 2001). Cochrane conducted a SR of RCT’s where 
steroids had been used by women in premature births and its’ conclusion was that there 
was a reduction of babies deaths of up to 50% (Egger et al. 2001, Watson et al. 2008, 
Moore 2012). From this SR, Cochrane identified that it was fundamental to undertake 
SRs and to make them available for healthcare professionals, and in 1993 the Cochrane 
Collaboration in the UK was launched (Egger et al. 2001, Watson et al. 2008, Moore 
2012). Besides the Cochrane Collaboration there are other organisations committed in 
the development and publishing of SRs like the Joanna Briggs Institute, the National 
Institute of Health and Clinical Excellence, the EBP Centre Program and the 
International Campbell Collaboration (Fineout-Overholt et al. 2008, Smith et al. 2011) 
 
A SR is a research method that objectively and rigorously retrieves, summarizes, 
critically interprets and evaluates all the available published and unpublished primary 
research relating to a specific subject/healthcare problem (Bero and Jadad 1997, Cook et 
al. 1997, Mulrow et al. 1997, National Health and Medical Research Council 
(NHMRC) 2000, Magarey 2001, White and Schmidt 2005, Fineout-Overholt et al. 
2008, O’Mathúna 2010, McGowan 2012). It is possible to understand that, SRs follow a 
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very strict method in order to acquire and gather the utmost level of evidence, where the 
quality of the research being summarised is key for the quality of the review (Cook et 
al. 1997, Watson et al. 2008, Higgins and Green 2011). In fact, not every literature 
review is systematic and there are differences that have to be recognised so that nurse’s 
practice is only evidence based (Holland and Watson 2012). 
 
Literature reviews (LR) are normally conducted by experts of a particular area, who 
summarise articles in a subjective way that is supportive of the reviewer opinion and is 
not representative of all the evidence available (Magarey 2001, Lipp 2007, Watson et al. 
2008, McGowan2012). Furthermore, LRs do not follow a scientific method, do not 
report how the selection and analysis of the articles was done, and lack quality appraisal 
of the included articles (Magarey 2001, Whitney 2004, Watson et al. 2008, McGowan 
2012). This leads to a biased LR, as the reviewer opinions are often part of the review 
and there is no clarity of the method by which the LR was conducted, limiting the 
confidence that the reader can have in its results (Cook et al. 1997, Lipp 2007, Watson 
et al. 2008). Thus, the difference between SRs and LRs is that the first is 
comprehensive, takes into consideration studies quality and follows a transparent and 
rigorous method (Victor 2008). All these characteristics are crucial for the results and 
evidence obtained to be rigorous, valid and reliable (Victor 2008). In terms of rigour, 
this will measure the strength of the SR ensuring that all the steps for conducting the 
review were followed, that any confounding factors were eliminated and that the reader 
thrusts the results and conclusions (Gerrish and Lacey 2010). In relation to reliability, 
this will look into the consistency of the review and validity will allow the reader to be 
sure that the SR answers the question it set to answer and the methods employed in its 
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process are without bias, making sure the SR is trustworthy (Watson et al. 2008, Gerrish 
and Lacey 2010). 
Therefore, the difference between a LR and a SR is that, a SR has to follow a rigorous 
protocol which sets the steps that have to be followed, in a systematic way, so that the 
conclusions obtained are best evidence and allow for its application in practice. Being a 
research method, SRs will follow the same steps of any other primary research method 
(NHMRC 2000). 
 
2.3.3. Steps in SR 
To conduct a SR it is necessary to establish a protocol that has a thorough description of 
the methods that will be used (Victor 2008). Although the process is the same, different 
authors identify a different number of steps for conducting SRs. McGowan (2012), 
Magarey (2001) and Fineout-Overholt (2008) mention seven steps; White and Schmidt 
(2005) identify three steps; NHMRC (2000), Victor (2008), Whitney (2004), Khan et al. 
(2003) and Lavis et al. (2005) indicate five steps; and the CRD (2008) mentions nine 
steps. Bringing all the different number of steps suggested it is possible to enumerate 
the steps to conduct a SR as the following (NHMRC 2000, Egger et al. 2001, Magarey 
2001, Khan et al. 2003, Whitney 2004, Lavis et al. 2005, White and Schmidt 2005, 
CRD 2008, Fineout-Overholt 2008, Victor 2008, McGowan 2012): 
 Background, 
 Research question formulation, 
 Identification of inclusion and exclusion criteria, 
 Search strategy, 
 Study selection, 
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 Data extraction, 
 Quality appraisal, 
 Data analysis and synthesis. 
 
2.3.3.1. Background 
The background is an important component as this will provide the reasons for 
undertaking the SR around a particular topic and will allow the reader to have a better 
view of the current knowledge around that topic (CRD 2008, Watson et al. 2008). For 
example in a SR by Happell and Gaskin (2012: 148) entitled, The attitudes of 
undergraduate nursing students towards mental health nursing: a systematic review, a 
summary of their background is given. 
 
2.3.3.2. Research question formulation 
Framing the question for the SR is an important step, as through this, the problem of 
focus in the review can be identified (Magarey 2001, Khan et al. 2003, Whitney 2004, 
Holland and Watson 2012). The research question should be clear and well structured 
(Khan et al. 2003), and should include four components ‘…patient group being 
investigated, intervention, comparative interventions and the outcomes used to measure 
the effect.’ (Magarey 2001: 377, Whitney 2004). Furthermore, to the components 
mentioned above the CRD (2008) explores the PICOS formula where P stands for 
participants, I for intervention, C for comparators, O for outcomes and S for study 
design. This formula allows the reviewer to establish the inclusion and exclusion criteria 
for the review (CRD 2008).  
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In their review Happell and Gaskin (2012: 148-149) report on two research questions 
and, identify the aim and objectives of their SR. 
 
2.3.3.3. Identification of inclusion and exclusion criteria 
Another important aspect of the SR process is to determine the inclusion/exclusion 
criteria, which will further aid in the selection of appropriate studies. This should not be 
too narrow, as it may miss important research, nor to broad that the research retrieved is 
to disparate and as a consequence difficult to compare (White and Schmidt 2005, CRD 
2008). Examples of inclusion/exclusion criteria are the study design, the intervention 
and the outcomes (White and Schmidt 2005).  
In the review by Happell and Gaskin (2012: 149-150) the inclusion and exclusion 
criteria is identified. 
 
2.3.3.4. Outline of the search strategy 
The search strategy is a core step because through it the reviewer will gain access to the 
information from which the evidence and recommendations are drawn (Smith et al. 
2011). To retrieve all the pertinent articles, the search strategy needs to be extensive, 
comprehensive, but sensitive so that the maximum of articles are retrieved (White and 
Schmidt 2005, Smith et al. 2011). Moreover, it is necessary that the reviewer clearly 
states the search strategy in terms of databases searched, search terms used, so that bias 
can be avoided, to allow for search strategy replication and for the retrieval of all 
published and unpublished studies pertaining to the topic, as much as possible (Magarey 
2001, Watson et al. 2008). In terms of unpublished literature, often termed as grey 
literature, this is literature publicly available through special channels and is not part of 
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the normal systems of publication (Benzies et al. 2006). Grey literature can include 
theses, government reports, and, conference abstracts, and the majority is not peer-
reviewed (Magarey 2001, Benzies et al. 2006). Peer-reviewing consists in giving the 
research to a group of experts that will evaluate if it followed the protocol flawlessly, if 
every step was conducted appropriately and if it reports what it intended to report 
(Watson et al. 2008).  
The review by Happell and Gaskin (2012: 150), reports a detailed search strategy. It is 
also important to provide a detail of the results of the search strategy before and after 
limits were applied, as these limitations can lead to the exclusion of valuable studies 
(Smith et al. 2011, Holland and Watson 2012).  
 
2.3.3.5. Study selection 
Study selection is done taking into account the inclusion/exclusion criteria and this can 
be a difficult process because the reviewers need to screen all the articles retrieved and 
access those relevant for the topic being researched (Smith et al. 2011). Study selection 
involves a few steps, first the titles and abstracts are read and any duplicates are 
identified, after selecting the relevant articles full text copies are obtained for data 
extraction and critical appraisal in terms of their quality is done (CRD 2008, Smith et al. 
2011). Happell and Gaskin (2012) do not clearly report study selection in their review. 
 
2.3.3.6. Data extraction 
After choosing the studies for inclusion in the SR, it is necessary to data extract as this 
will allow the reviewer to have a concise picture of the studies characteristics (Magarey 
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2001, White and Schmidt 2005, Victor 2008). For data extraction various templates are 
available and the data to be extracted includes: 
 Authors, 
 Date of study and geographical location, 
 Study setting, 
 Inclusion/exclusion criteria, 
 Sample size, 
 Study design, 
 Intervention details, 
 Outcome measures, 
 Analysis, 
 Results, 
 Conclusions, 
 Recommendations. 
 
This is just an example of the information that can be extracted and this will vary 
according to the template being used. Furthermore, it is recommended that data 
extraction is done by the reviewers of the studies independently, as they might interpret 
the results differently (White and Schmidt 2005). 
In the SR of Happell and Gaskin (2012) a table of data extraction pertaining to survey 
studies obtained and one pertaining to the quasi-experimental studies obtained was 
included.  
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2.3.3.7. Quality Appraisal 
Quality appraisal is a core step when undertaking a SR, as it will allow the reviewer to 
have access to the best evidence available (Victor 2008). Only by thoroughly evaluating 
the quality of the studies included in the review will the review originate reliable 
evidence based information that can be used by nurses in their practice (Victor 2008, 
Smith et al. 2011). According to the CRD (2008) research studies can vary greatly in 
terms of their methodological thoroughness, and if a study is not conducted properly or 
if deviations from the established protocol happen without being reported, bias can 
occur and the results and effects of interventions of the study can be questioned. 
To be able to evaluate the findings of the research to be included in a review it is 
paramount to quality assess (White and Schmidt 2005: 57, CRD 2008: 33): 
 Suitability of study design to the research question, aims and objectives, 
 Assess the presence or potential risk of bias,  
 Outcomes measures, 
 Quality of the intervention, 
 Quality of reporting. 
 
2.3.3.7.1. Suitability of study design to the research question, aims and objectives 
When assessing the quality of a study it is essential to evaluate if the study design 
chosen is appropriate from the point of view of the research question, the aims and 
objectives proposed (CRD 2008). For example, if an intervention is being assessed but 
it is unethical to randomly assign participants to a particular group, then another type of 
design should be used (CRD 2008). It is important to be knowledgeable of study 
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designs in quantitative and qualitative research so that an appropriate method can be 
employed. 
 
2.3.3.7.2. Assess the presence or potential risk of bias 
Bias is a systematic deviation from the truth and is a consequence of poorly conducted 
research that can enhance results and the true value of the findings, which could 
ultimately lead to bad decisions in practice (CRD 2008: 34). There are various types of 
bias: publication bias, time-lag bias, citation bias, language bias, outcome reporting 
bias, selection bias, performance bias, detection bias, and attrition bias (Egger et al. 
2001, Magarey 2001, Moore 2012).  
 
Publication bias relates to the publication of studies, with the same type of data, 
depending on the results favourability, this can influence the conclusions of the SR as it 
could support a beneficial treatment or fail to identify an adverse effect of a treatment 
(Egger et al. 2001, Moore 2012). 
 
Time-lag bias impacts in the way the strength of evidence for or against a particular 
intervention is determined (Moore 2012) thus, influencing the results of SRs because 
positive results will dominate the research literature, before the, also important, negative 
results are published (Egger et al. 2001). 
 
Citation bias is related to the way authors of a study conveniently include or exclude 
research articles for citation and, this is influenced by the trend of the results (Egger et 
al. 2001, Moore 2012). This will affect the SR as only positive results will be part of the 
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research being summarized, moreover the actual SR could be biased if it manipulates its 
inclusion/exclusion criteria to obtain, previously known, positive articles. 
 
Language bias refers to the inclusion of research articles from a particular language and 
the consequent exclusion of potential significant research from other languages (Egger 
et al. 2001, Moore 2012). Language bias occurs when the search strategy is limited to a 
language of interest to the reviewer. However, it is necessary to note that in some cases 
there is a lack of access to translation services, and financial funds to pay for the 
translation (Smith et al. 2011, Moore 2012). Nevertheless, the reviewer should 
acknowledge this limitation and report the difference in the number of articles retrieved 
with and without language limits. This type of bias can affect the consistency of the SR 
as only part of the body of evidence is being assessed and summarised. 
 
Outcome reporting bias occurs when the researchers overlook the results of some of the 
outcome measures and decide not to report them, thus reporting the more positive 
results and conclusions (Egger et al. 2001, Moore 2012). This will consequently 
influence the results and outcomes of the SR. 
 
Selection bias is related to the method used to allocate the participants to the treatment 
or control group (Magarey 2001). To avoid selection bias, concealment and blinding are 
two necessary methods. Concealment means that the researchers do not know to which 
of the groups the participants will be allocated to and blinding means that the 
researchers do not know which treatment the participants will receive (Magarey 2001). 
 
40 
 
Performance bias occurs if there is external or internal factors that cause a difference in 
the interventions being researched, modifying it, and thus influencing the results 
obtained (Magarey 2001).   
 
Detection bias relates to the process of appraising the results of the outcomes, as this 
has to be conducted in the same way for the treatment and control group (Magarey 
2001). 
 
Attrition bias happens when there are dropouts, as this will influence the number of 
participants and cause a difference between study groups (Magarey 2001). Taking into 
account that these dropouts could be due to the interventions being studied it is 
imperative that the reasons for the dropouts are reported (Magarey 2001). 
 
2.3.3.7.3. Outcome measures 
According to the CRD (2008) assessing outcome measures is related to the assessment 
of the reliability and validity of the outcome measures being used. This means that the 
study, established outcome measures that are attainable and relevant, according to the 
research question and objectives of the study, and that they will help to understand the 
effect of the intervention being study (CRD 2008). 
 
2.3.3.7.4. Quality of the intervention  
When assessing the quality of the intervention(s) proposed in the study it is necessary to 
evaluate if these where used properly, if they were implemented has described in the 
protocol, if the participants received the intervention as planned and if it was 
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consistently applied for every participant (CRD 2008). This is an important aspect of 
the study because if the interventions are changed or flawed the results obtained might 
not represent reality, thus, influencing the quality of the study in general. 
 
2.3.3.7.5. Quality of reporting 
Quality of reporting is related to whether the study reports and identifies 
methodological issues such as allocation concealment and details about the intervention 
being studied (CRD 2008). Moreover, the CRD (2008) mentions that this type of quality 
assessment is not representative of the general quality of the study being reviewed. 
Besides assessing studies quality it is also important and necessary that the quality of 
the SR process is, in itself, assessed (Victor 2008). Happell and Gaskin (2012) did not 
report on quality appraisal or bias analysis. 
 
2.3.3.8. Data Analysis and Synthesis 
After quality appraising the studies included in the SR, these can be analysed and then 
synthesised. Depending on the type of studies included data analysis and synthesis will 
be conducted using quantitative or qualitative methods (Magarey 2001). For analysis 
and synthesis of quantitative research meta-analysis is used when only trials are being 
analysed and synthesised (Watson et al. 2008). If other types of quantitative study 
designs are being reviewed (such as quasi-experimental studies) a narrative form of 
synthesis should be used (Victor 2008). For analysis and synthesis of qualitative 
research meta-synthesis or thematic analysis and synthesis can be used (Lipp 2007, 
Victor 2008).  
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In the study by Happell and Gaskin (2012), meta-analysis was not practical, and 
although the authors do not explicitly report the type of data analysis and synthesis that 
was done, the only conclusion plausible from examining the study is that a narrative 
summary was conducted.  
 
2.3.4. SR of Quantitative Research: meta-analysis 
Quantitative research is a method to collect data that can be translated into numerical 
data and through its measurements, tries to explain the information obtained, to describe 
variables and to predict and examine relationships of cause and effect (Watson et al. 
2008). Quantitative research methods can include RCTs, quasi-experimental and 
observational studies (CRD 2008, Watson et al. 2008). An example of a quantitative 
research study is the study by Gethin and Cowman (2008) where the method used was a 
prospective, open label, multicentre randomised control trial. 
 
Meta-analysis is a ‘…specific methodological and statistical technique for combining 
quantitative data’ (Mulrow et al. 1997: 389). In meta-analysis, to combine different 
data it is necessary that the individual studies, that will be systematically reviewed, have 
similar clinical problems and research methodologies (Moore 2012). Meta-analysis is an 
important method as it increases the power of the study, which is‘...the probability that 
a trial will detect, as statistically significant, an intervention effect of a specified size’ 
(Cochrane Collaboration Glossary Online (CCGO) 2011). 
Due to the fact that similar studies are combined, the sample size also increases which 
further increases the power of the review. Conducting meta-analysis also influences the 
precision of the review (Moore 2012), which is in statistical terms ‘A measure of the 
likelihood of random errors in the results of a study, meta-analysis or measurement’ 
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(CCGO 2011). Another advantage of conducting meta-analysis is the fact that new 
problems and questions that arise from the combined studies can be answered, 
contributing to the body of knowledge and to EBP (Moore 2012). Furthermore, meta-
analysis contributes for the proposal of new hypotheses and can help in solving 
differences in studies results (Moore 2012). 
 
Before, conducting meta-analysis it is essential to ascertain the studies homogeneity as 
only studies with comparable problems, participants and methods, can be combined, 
because the summary of disparate data can yield misleading results and conclusions that 
will impact negatively in clinical practice (Moore 2012). Besides assessing data 
heterogeneity, it is fundamental to assess for bias in the study as this can alter 
significantly the results of the review
1
. 
 
According to Moore (2012) there are three types of data relevant for conducting meta-
analysis. These are dichotomous or binary data, continuous data and survival or time to 
event data (Watson et al. 2008, Moore 2012). According to the CCGO (2011) 
dichotomous data is ‘Data that can take one of two possible values, such as 
dead/alive…’ In terms of continuous data, this is ‘Data with a potentially infinite 
number of possible values within a given range’ for example, height (CCGO). 
Relatively to time to event data, this is ‘A description of the data in studies where the 
analysis relates not just too whether an event occurs but also when’ (CCGO 2011). 
 
Thus, it is important to highlight that meta-analysis besides combining similar data from 
research, aims at determining the general treatment effect of all included research and is 
                                                          
1
 Refer to sub-heading Quality Appraisal, for further detail on types of bias. 
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conducted in two steps (Watson et al. 2008, Moore 2012). The first step is to determine 
a summary statistics that in terms of dichotomous data is reported as the odds ratio or 
relative risk and in continuous data is reported as the weighted mean difference (Watson 
et al. 2008). The second step is to determine the overall treatment effect based on the 
summary statistics (Watson et al. 2008). 
 
Meta-analysis is an important method for the SR of quantitative data, and if properly 
conducted can provide essential information to practice in terms of the validity of the 
evidence. 
 
2.3.5. SR of Qualitative Research  
Qualitative research gathers verbal and observational data to understand, interpret and 
describe participant’s life experiences of a certain phenomenon (Watson et al. 2008: 
17). Some of its methodologies include ethnography, phenomenology, and grounded 
theory (Gerrish and Lacey 2010). Moreover, qualitative research includes different 
designs such as structured or semi-structured interviews (CRD 2008). The choice of the 
design will depend on the methodology used. An example of a qualitative research 
study is the study by Hynes et al. (2010) where a qualitative exploratory approach was 
used through semi-structured interviews. 
 
SRs focus has been mainly in summarising evidence from RCTs (Evans and Pearson 
2001). However, qualitative research has become more prominent and its data can 
complement quantitative research as it gathers important information from patient, 
professionals and care givers experiences, about a certain treatment or intervention, that 
ultimately can help improve practice and add to the body of knowledge, necessary for 
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EBP (Dixon-Woods et al. 2001, Evans and Pearson 2001, Jones 2004). Even though 
evidence from qualitative research is important, there still exists some resistance in 
terms of the appropriateness of systematically reviewing qualitative studies (Evans and 
Pearson 2001, CRD 2008).  
 
Qualitative research review, occurs through the use of meta-synthesis which is ‘…the 
critical review, analysis, interpretation and comparison or integration of findings, or 
processed data, from primary qualitative studies’ (Jones 2004). The CRD (2008), 
reports other methods that can be used for the synthesis of qualitative research, such as 
meta-ethnography, thematic analysis/synthesis and content analysis. The choice of 
method will depend on the research question of the studies included and the 
methodology used in the primary study (CRD 2008). 
 
Quality assessment of primary qualitative studies for inclusion in SR is an important 
step as the data as to be of high standards so the evidence summarised can inform 
clinical practice, and will also highlight the strengths and limitations of the evidence 
being synthesised (CRD 2008). A few appraisal tools exist including the Critical 
Appraisal Skills Programme and the Quality Framework (CRD 2008), yet the quality 
assessment criteria proposed by Popay et al. (1998) cited by Horsburgh (2003) will be 
analysed in more detail. According to these authors there are three criteria for assessing 
the quality of qualitative research: interpretation of subjective meaning, description of 
social context and attention to lay knowledge. 
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Interpretation of subjective meaning is concerned with assuring that only the 
participant’s interpretation and description of what is being researched is the core of the 
researcher analysis and interpretation (Popay et al. (1998) cited by Horsburgh 2003, 
Holland and Watson 2012). Description of social context, is concerned with the clear 
report of the environment where the participants were at the time of research, has this 
can influence easing or constraining the participants actions and the way they share 
information (Popay et al. (1998) cited by Horsburgh 2003, Holland and Watson 2012). 
Finally, attention to lay knowledge means that it is necessary that the participant’s 
points of view and knowledge are given the same value, of those of specialists or 
professionals in the area being researched (Popay et al. (1998) cited by Horsburgh 2003, 
Holland and Watson 2012). This is important because the accuracy and the process of 
assessing the information will influence the credibility of the studies (Holland and 
Watson 2012). 
 
2.4. Summary 
The development of nursing as a profession and a science is essential and can be 
attained through research. Additionally, research is a process that will allow 
professionals to base their practice in the best evidence available. Therefore, EBP is 
crucial for safe clinical practice and patient and community satisfaction. 
SRs are at the top of the hierarchy of evidence as they summarise, analyse, interpret and 
report the results of research in the same topic, either from qualitative or quantitative 
research. Being a research method it has to follow a protocol that will inform on the key 
steps that have to be included for a reliable and valid SR, some of these are: research 
question formulation, data extraction, quality appraisal, data analysis and synthesis. 
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Although, all steps are important, quality appraisal is fundamental because if in the 
studies included the research design is not appropriate and if bias is identified this can 
influence negatively the results of the review, which in turn will have a damaging 
impact on clinical practice. 
SRs from qualitative research are summarised through meta-synthesis and quantitative 
data through meta-analysis as these combine and interpret studies which have similar 
designs, participants and interventions, thus augmenting the credibility of the results in 
favour or against the intervention under research. 
 
2.5. Conclusion 
It is possible to conclude that SRs are an essential research method in an environment 
where studies are constantly being published and nurses are not able to keep up with the 
evidence. So, SRs by employing accurate research methods and by consistently and 
deeply analysing research evidence from both qualitative and quantitative research will 
allow nurses to access best evidence information that can not only allow for EBP, but 
also for evidence based clinical decisions that are crucial for the quality of nursing care. 
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Chapter3. Methods of this SR 
3.1. Introduction 
This chapter will describe the methods by which this SR was conducted. It will focus on 
the objectives and outcome measures of the review, identifying the target population 
and interventions being researched, as well as the inclusion criteria of the studies in the 
review. Further, it will report on the search strategy identifying the databases searched 
and search terms used. Finally this chapter will report on how the data were collected 
and how they were analysed. 
 
3.2. Objectives and Outcome Measures of the Review 
3.2.1. Objectives 
The purpose of this SR was to understand the impact that offloading has in the treatment 
of DFUs.  
Besides this main objective, this SR was also concerned with: 
 Identifying the most effective offloading device in the treatment of the DFUs. 
 Identifying the strengths and limitations of the different offloading devices. 
 Determining the impact that offloading devices have in the QoL of the patient. 
 
3.2.2. Outcome Measures 
The primary outcome measure of this SR was ulcer healing rate in terms of percentage 
of ulcers healed, healing time and reduction in ulcer size. The secondary outcome 
measures were: adverse effects, such as infection, or any other effect that can be 
attributed to the use of the offloading device, compliance, cost and QoL. 
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3.3. Criteria for Inclusion of studies in the Review 
All studies, in English or Portuguese, where different types of casts, therapeutic shoes 
and other orthotic devices have been compared and analysed in adult patients with only 
DFUs were included. Studies where participants are reported to have foot deformities 
and artropathies were excluded.  
 
3.4. Search Strategy 
For the purpose of this SR a search strategy was established, so that the writer could 
access the available primary and secondary research relating to offloading for the 
treatment of DFUs. 
For the search strategy of this review, the following search terms were used: 
 Diabetic Foot, 
 Orthosis/Orthotic Devices/Orthoses, 
 Foot Orthosis/Foot Orthoses, 
 Casts/Plaster Cast/Surgical Cast, 
 Shoes. 
 
The variance noted in some of the terms is due to differences in the MeSH tool of each 
database searched. All the terms used in the search strategy were MeSH terms. 
In terms of the databases searched these included CINAHL, Medline, Embase, 
Cochrane Library and Web of Knowledge, refer to appendix 2 to 6 for a detailed 
summary of the search strategy in each data base. 
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According to the different databases searched, different limits had to be applied since 
some limits were not available in some of the databases. In general the limits applied 
were: research article and language – English or Portuguese. Only the search conducted 
in Medline the type of studies to be retrieved was limited to: control clinical trial, RCT, 
meta-analysis. 
Besides searching the databases, the reference list of the chosen articles were also 
analysed and any relevant research articles were retrieved. The manual Diabetic Foot 
Care by Edmonds et al. (2008), more specifically the reference list of chapter 4 was 
analysed and some articles retrieved. 
No contact was made with authors or any other industry for published and/or 
unpublished work. 
 
3.5. Data Extraction, Analysis and Synthesis 
For the purpose of this SR data from the retrieved research articles was extracted using 
the data extraction table provided by the RCSI for all the studies retrieved (see appendix 
7) except for the SRs. For these a table adapted from the table “Characteristic of 
Included Reviews” from the Cochrane Handbook was used (Higgins and Green 2011) 
(see appendix 8). Specifically, the following data were extracted from all studies except 
SRs: author, date of study, title, source, study geographical location, research 
question/aim/objectives, care setting, type of wound, inclusion/exclusion criteria, 
sample size, patient characteristics, design details, study type, allocation, intervention 
details, outcome measures, analysis, results, conclusions and recommendations. 
Relatively to the SRs the following data were extracted: review author, date of review, 
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source, geographical location, population, interventions and comparison interventions, 
outcomes for which data was reported. 
 
For quality appraisal this was undertaken using the risk of bias assessment from 
RevMan 5.2 tool (The Cochrane Collaboration 2013) for all RCTs retrieved. The EBL 
Critical Appraisal Checklist (see appendix 9) was used for any other quantitative studies 
retrieved. For the SRs retrieved quality appraisal was done assessing if all steps, as 
described in The Cochrane Handbook (Higgins and Green 2011), that have to be 
followed for conducting a SR were reported (see appendix 10). 
 
Following data extraction, a narrative summary was undertaken this, included a general 
description of the characteristics of the retrieved studies, followed by a description of 
the individual interventions under investigation in each study. This was followed by 
quality analysis of the RCTs, the SRs and the other quantitative studies. Data synthesis 
was narratively done for each individual study as each study compared different 
interventions, making it impossible to undertake meta-analysis. However, in all RCTs 
dichotomous data was analysed in terms of risk ratio (RR) and continuous data was 
analysed in terms of mean differences (MD) and were presented in a forest plot. 
 
3.6. Summary 
The purpose of this SR was to understand the impact that offloading has in the treatment 
of DFUs. Its primary outcome measure was healing rates, in terms of healing times and 
reduction in ulcer size. Its secondary outcomes were adverse effects, cost, compliance 
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and QoL issues. The search strategy was conducted in CINAHL, Medline, Embase, 
Web of Knowledge and Cochrane Library databases, using diabetic foot, 
orthosis/orthatic devices/orthoses, foot orthesis/foot orthoses, cast/plaster cast/surgical 
cast, shoe as MeSH terms. All articles retrieved in English or Portuguese were analysed 
and those were patients had foot deformities and arthropathies were excluded. Data 
extraction was done using data extraction tables. For quality analysis according to the 
type of study different tools were used. For RCTs risk of bias was assessed, for other 
qualitative studies the EBL appraisal checklist was used and SRs were quality appraised 
assessing if they reported all the steps for conducting SRs. Data was then synthesised 
generally and then in relation to each individual intervention identified. Results for 
RCTs were presented in terms of RR or MD depicted in forest plots. All studies were 
narratively synthesised. 
 
3.7. Conclusion 
This SR has as its main objective to understand the impact that offloading has in the 
treatment of DFUs. For this a search strategy was conducted and the quantitative studies 
and SRs retrieved, were data extracted, quality appraised and analysed in order to access 
the results of the studies and comprehend how well these relate to current practice in the 
treatment of DFUs. 
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Chapter 4.Results 
4.1. Introduction 
This chapter will give a detailed description of the results obtained from the search 
strategy in terms of number of articles retrieved for this SR. This will be followed by a 
general description of the studies obtained in terms of study designs, geographical 
location, study settings, populations, sample size and interventions. In relation to the 
interventions explored for this review, these will be described individually. Finally, this 
chapter will appraise the quality of the studies retrieved and summarise the results 
taking into account the outcome measures of interest for this SR. 
 
4.2. Search Strategy: Results 
For the purpose of this SR a search strategy was conducted and its details were 
described in the previous chapter. From the search strategy (see Figure 1) 289 records 
were identified in the databases and an additional 6 records were obtained. Two of these 
records were retrieved from the reference list of grey literature, more specifically the 
manual Diabetic Foot Care by Edmonds et al. (2008), in particular chapter 4. The 
remaining four were retrieved after screening the reference lists of articles used for 
preparing chapter 1 of this SR. After removal of duplicates, the titles of the remaining 
articles were read, yielding a total of 102 for further screening. The abstracts of these 
records were read and the full-text of 25 records was retrieved. From these 25 articles, 
14 met the inclusion criteria and as such formed the base for this review. These records 
will be narratively summarised and analysed.   
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Figure 1: Search Strategy Flow Diagram  Adapted from Prisma 2009 Flow Diagram 
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4.3. Included and Excluded Studies 
From the 25 articles retrieved 14 were included (see appendix 11), for data extraction, 
data analysis and quality appraisal, and 11 were excluded, see appendix 12 for exclusion 
reasons. 
 
4.4. Description of Studies 
4.4.1. Study Design 
From the included studies 9 were RCTs, (Mueller et al. 1989, Caravaggi et al. 2000, 
Armstrong et al. 2001, Zimny et al. 2003, Armstrong et al. 2005, Katz et al. 2005, 
Piaggesi et al. 2007, Van de Weg et al. 2008, Faglia et al. 2010).  The remaining studies 
were 2 SRs (Mason et al. 1999, Spencer 2008), 1 observational study (Dumont et al. 
2009), 1 retrospective study (Birke et al. 2002) and 1 prospective data collection 
(Nabuurs-Franssen et al. 2005). 
 
4.4.2. Geographical Location 
In terms of the geographical location of the studies, 5 were carried out in the USA 
(Mueller et al. 1989, Armstrong et al. 2001, Birke et al. 2002, Armstrong et al. 2005, 
Katz et al. 2005), 3 in Italy (Caravaggi et al. 2000, Piaggesi et al. 2007, Faglia et al. 
2010), 2 in the UK (Mason et al. 1999, Spencer 2008), 2 in The Netherlands (Nabuurs-
Franssen et al. 2005, Van de Weg et al. 2008), 1 study was conducted between Belgium 
and France (Dumont et al. 2009) and 1 was conducted in Germany (Zimny et al. 2003). 
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4.4.3. Study Settings 
With regard to study settings where the participants of the studies were recruited and 
where the studies were carried out, 4 studies did not mention the type of setting 
(Caravaggi et al. 2000, Armstrong et al. 2001, Armstrong et al. 2005, Nabuurs-Franssen 
et al. 2005), 2 studies were conducted in diabetic foot clinics (Katz et al. 2005, Piaggesi 
et al. 2007) 1 study was conducted in a clinic, but the type or description of the clinic 
was not given (Zimny et al. 2003), 1 study was conducted between seven specialist 
units (Dumont et al. 2009), 1 was carried out in a health sciences centre diabetes foot 
program (Birke et al. 2002), 1 study was conducted in two centres specialised in DFUs 
management (Faglia et al. 2010), 1 was conducted in a diabetic foot clinic and physical 
therapy department (Mueller et al. 1989) and 1 study was conducted in a rehabilitation 
department of two hospitals (Van de Weg et al. 2008). 
 
4.4.4. Populations 
All participants were either adult men or women with an age ≥ 18 years old, all had type 
1 or type 2 DM and all presented with a DFUs. Besides this general information about 
the population in the studies, each study collected different population characteristics 
that are recorded in the detailed data extraction tables that can be found in appendix 13 
to 25. 
 
4.4.5. Sample Size 
The mean sample size was 65 participants, the smallest sample was 40 participants 
(Mueller et al. 1989, Piaggesi et al. 2007) and the biggest sample was 135 participants 
(Dumont et al. 2009). 
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4.4.6. Interventions 
4.4.6.1. TCC vs. RCW vs. Half-Shoe 
In the first study, by Armstrong et al. (2001), a TCC, a RCW and half-shoes were 
compared in terms of their effectiveness to heal neuropathic DFUs (see appendix 13). 
All participants were followed-up on a weekly basis for ulcer care and debridement, and 
device inspection. In terms of TCCs these were changed on a weekly basis or whenever 
it was clinically necessary. These were applied according to a technique by Kominsky 
that was modified by the authors of the study, which included the use of a cast boot 
instead of the rubber cast walker and a plywood platform. Relatively to the RCWs and 
half-shoes these were applied according to packaging instructions and participants were 
advised to use them at all times. The authors do not describe in detail how the casts 
were applied or the characteristics of the half-shoe. 
 
4.4.6.2. iTCC (“instant” TCC) vs. RCW 
In the second study, by Armstrong et al. (2005), an iTCC and a RCW were compared to 
assess their effectiveness in healing neuropathic DFUs (see appendix 14). All 
participants were followed on a weekly basis for ulcer care and debridement, and device 
inspection. The iTCC is a RCW rendered irremovable by wrapping it in a cohesive 
bandage. However, the authors do not describe how the casts were applied and refer it 
to another article where the characteristics of this application are explained. 
 
4.4.6.3. TCC, Accommodative Dressing, Healing Shoe, Walking Splint, Other 
The third study was a retrospective analysis, by Birke et al. (2002), where a TCC, an 
accommodative dressing, a healing shoe, a walking splint and other devices were 
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compared to assess their effectiveness in terms of healing time in days and percentage 
of healed forefoot nonsurgical DFUs (see appendix 15). In this study, 120 medical 
records were revised and diabetic patients that were referred for nonsurgical treatment 
of neuropathic foot ulceration during a 30 month period were included in this analysis. 
For devices characteristics see appendix 26. 
 
4.4.6.3.1. Accommodative Dressing 
Dry dressings were used and these were revised and changed on a weekly basis. 
 
4.4.6.3.2. Healing Shoe 
Patients in this group were instructed in daily dressing changes and were followed-up 
weekly for reassessment and ulcer debridement as needed. 
 
4.4.6.3.3. Walking Splint 
Patients in this group were instructed in daily dressing changes with moisture retentive 
dressings and were followed at 1 to 2 week intervals to observe the progress of wound 
healing, for ulcer debridement as needed and reassessment. 
 
4.4.6.3.4. TCC 
Ulcers in the TCC group were dressed with dry dressings and TCCs were changed at 1 
to 2 week intervals, depending on the amount of drainage.  
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4.4.6.3.5. Combination of devices 
In this group how the combination of the devices was determined and what was used, 
was not clearly described by the authors. 
 
4.4.6.4. Therapeutic Shoe vs. Fiberglass Cast 
In the fourth study, by Caravaggi et al. (2000), a therapeutic shoe and a fiberglass cast 
were compared to assess their effectiveness in the rate of neuropathic plantar ulcers 
surface area reduction (see appendix 16). All participants changed dressings every two 
days, ulcers were debrided and medicated with paraffin gauze. For devices 
characteristics see appendix 27. 
 
4.4.6.5. Ransart Boot 
The fifth study was an observational study, by Dumont et a.l (2009), where the 
effectiveness of the Ransart Boot for the management of DFUs was analysed (see 
appendix 17). All participants were followed on a weekly basis for ulcer care and 
debridement, and for device inspection. The dressings used were chosen by the 
supervising clinician. For device characteristics see appendix 28. 
 
4.4.6.6. TCC vs. Stabil-D 
In the sixth study, by Faglia et al. (2010), a TCC and Stabil-D were compared in terms 
of their effectiveness to heal plantar DFUs (see appendix 18). All participants were 
followed-up on a weekly basis for ulcer care and debridement, photograph and 
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measurement using the Visitrak
®
 system. Dressings were done with paraffin gauze and 
covered with sterile gauze. For device characteristics see appendix 29. 
 
4.4.6.7. TCC vs. iTCC 
In the seventh study, by Katz et al. (2005), a TCC and an iTCC were compared in terms 
of their effectiveness in healing neuropathic plantar DFUs (see appendix 19). All 
participants were followed on a weekly basis for ulcer care and debridement (by a 
clinician), for photograph and measurement on acetate sheet, and for device inspection.  
The TCCs were applied in a standard fashion by either a cast technician or certified 
pedorthodist. The iTCCs were applied by placing the patient in the DH Walker RCW in 
the manner recommended by the manufacturer. After the wound was treated additional 
padding was placed on the leg, to match treatment with patients in the TCC group. The 
iTCCs were then wrapped circumferentially with a single roll of fiberglass casting 
material, thus rendering them “irremovable”. The authors do not describe in detail how 
the TCC was fabricated and applied. 
 
4.4.6.8. TCC vs. Traditional Dressing Treatment (TDT) 
In the eighth study, by Mueller et al. (1989), a TCC and a TDT were compared in terms 
of their management of plantar DFUs (see appendix 20). In the TCC group, casts were 
applied by a physical therapist on the initial visit. If there were no complications, the 
cast was reapplied and changed every 2-3 weeks until the ulcer was completely healed. 
For the TDT group participants were followed at least every 2-4 weeks for routine 
wound care and debridement. For devices characteristics see appendix 30. 
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4.4.6.9. TCC, RCC (Removable Contact Cast), SMC (Shoe Model Cast) 
In the ninth study, by Nabuurs-Franssen et al. (2005), a TCC, RCC and a SMC were 
used (see appendix 21). Cats were fabricated and applied using a modification of the 
technique described by Kominsky however the authors do not explain how this was 
done. Nonetheless, they mention that felt was applied around the ulcer to reduce peak 
pressure. Patients with a removable cast were instructed to remove the device only 
during wound care. At every visit, necrotic tissue and callus were surgically debrided. 
TCCs were renewed every 1–2 weeks, and RCC and SMC devices were modified if 
necessary. Cast treatment was terminated when there was no reduction in wound size or 
depth during 4 consecutive weeks. 
 
4.4.6.10. TCC vs. Optima Diab Walker 
In the tenth study, by Piaggesi et al. (2007), a TCC and Optima Diab Walker were 
compared in terms of their effectiveness, safety and cost-effectiveness in the 
management of DFUs (see appendix 22). All patients were followed-up weekly, ulcers 
were debrided, measured, photographed, and dressed with paraffin gauze and a layer of 
sterile gauze, and a new cast was then manufactured by the same certified podologist. 
For devices characteristics see appendix 31. 
 
4.4.6.11. TCC vs. Custom Therapeutic Footwear (CTF) 
In the eleventh study, by Van de Weg et al. (2008), a TCC and CTF were compared in 
terms of their effectiveness to heal neuropathic DFUs (see appendix 23). Prior to device 
application all participants had ulcer care and debridement (by a podiatrist), and device 
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inspection. Authors do not mention periodicity of visits only mention that out-patient 
visits were regular. For devices characteristics see appendix 32. 
 
4.4.6.12. Felted Foam vs. Half-Shoe 
In the twelfth study, by Zimny et al. (2003), felted foam and a half-shoe were compared 
in terms of their effectiveness to heal DFUs (see appendix 24). The authors do not 
mention the characteristics of the half-shoe or how ulcers in this group were managed. 
In the felted foam group, ulcers were thoroughly debrided, with removal of necrotic 
tissue and wound margins were traced at entry and at each follow-up with an indelible 
marker for subsequent calculation of the wound area. For device characteristics see 
appendix 33. 
 
4.4.7. Characteristics of Included SRs 
One of the SRs addressed various types of treatment modalities for DFUs (Mason et al. 
1999) and the other SR focused on pressure relief interventions for prevention and 
treatment of DFUs (Spencer 2008), only the data relevant for the present SR were 
considered and analysed (see appendix 25). 
 
In both SRs the target populations had to have type 1 or 2 DM, but Spencer (2008) adds 
that patients had to have DFUs. Both reviews mention casts as a treatment (Mason et al. 
1999) and as a pressure relieving intervention for the treatment (Spencer 2008) of 
DFUs. In both reviews only one RCT (Mueller et al. 1989) was found and analysed 
pertaining to the role of offloading devices in the treatment of DFUs. 
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In the SR by Spencer (2008), and taking into account the outcomes of interest, the study 
by Mueller et al. (1989) only reported on one outcome – healing rate. Accordingly, 
Mason et al. (1999) analysed the same study in terms of healing rates, although this is 
not clearly identified as an outcome of the review. 
 
4.4.8. Quality Appraisal of Included Studies 
4.4.8.1. Quality Appraisal of included RCTs: Risk of Bias 
This SR analysed data from 9 RCTs for the risk of bias using the RevMan 5.2 tool (The 
Cochrane Collaboration 2013). 
 
4.4.8.1.1. Selection Bias (Randomisation) 
All the studies report that a randomisation sequence was developed showing that 
participants were randomly assigned to one of the treatment options (see appendix 34). 
However, in two studies (Armstrong et al. 2001, Armstrong et al. 2005) the 
randomisation was undertaken after initial screening. 
 
4.4.8.1.2. Selection Bias (allocation) 
In relation to allocation sequence and concealment the studies report different types of 
methods used for allocation sequence, however one study does not report the method of 
allocation sequence (Zimny et al. 2003) and it is no clear if there was concealment of 
allocation or not. Only two studies (Armstrong et al. 2005, Van de Weg et al. 2008) 
make reference to some degree of allocation concealment (see appendix 35). 
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4.4.8.1.3. Performance Bias 
In terms of performance bias, only the study by Van de Weg et al. (2008) reports the 
difficulty and even impossibility in blinding participants to the treatment, as offloading 
devices cannot be masked, and also the difficulty of blinding the investigator to the 
treatment as some patients made comments on the type of device they were using. All 
the other studies may have come across the same issues but it is not clear how they dealt 
with performance bias (see appendix 36). 
 
4.4.8.1.4. Detection Bias 
With regards to detection bias only the study by Van de Weg et al. (2008) reports that 
investigators were not involved in the treatment. In the other studies it is not clear if 
investigators had knowledge of the allocated interventions or if they had any direct 
participation in the interventions being studied (application of casts, ulcer care). In one 
study (Zimny et al. 2003) it is reported that the observer was not blinded to treatment 
group when measuring ulcer size. In the study by Faglia et al. (2010), Mueller et al. 
(1989) and Piaggesi et al. (2007), casts were applied by technicians but it is not clear if 
investigators were present and if they were involved in ulcer care. Katz et al. (2005) 
report that a clinician managed ulcer care and a cast technician or pedorthodist applied 
the casts however, it is not clear if the investigators add any involvement. Armstrong et 
al. (2001), Armstrong et al. (2005) and Caravaggi et al. (2000) do not mention if there 
was involvement of the investigators in the treatment (see appendix 37). 
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4.4.8.1.5. Attrition Bias 
In relation to attrition bias only three studies (Caravaggi et al. 2000, Zimny et al. 2003, 
Piaggesi et al. 2007) did not report any dropouts or losses to follow-up. In the other 
studies there are some issues in terms of incomplete data reporting that might influence 
the results in favour or against the interventions being studied (see appendix 38). 
 
4.4.8.1.6. Reporting Bias 
All RCTs analysed reported data on the outcomes that were under investigation 
therefore, not demonstrating any issues relating to selective data reporting (see appendix 
39). 
 
Some of the studies, present bias issues that could potentially influence the validity and 
applicability of the results obtained from the interventions studied. 
 
4.4.8.2. Quality Appraisal of other included quantitative studies 
Quantitative studies were quality appraised using the EBL Critical Appraisal check list. 
If the overall validity of the study (Yes/Total) is ≥75% or ((No+Unclear)/Total) is ≤25% 
then the study is valid. 
 
In the study by Birke et al. (2002) the overall validity was 60% (see appendix 40), in the 
Dumont et al. (2009) study the overall validity was 53% (see appendix 41) and in the 
Nabuurs-Franssen et al. (2005) study the overall validity was 68.4% (see appendix 42). 
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The overall validity of the studies, previously mentioned, show that conclusions are not 
widely generalizable to the general population. 
 
4.4.8.3. Quality Appraisal of SRs 
Taking into account that SRs are a research method, these have to follow a protocol 
identifying the steps taken to conduct a quality and reliable study (NHMRC 2000). For 
this reason the two SRs included in this study were quality appraised from the point of 
view of the steps that needed to be taken to conduct a SR. 
 
The SR by Mason et al. (1999) reports most of the steps needed to conduct a SR (see 
appendix 43). The SR by Spencer (2008) reports most of the steps however it fails to 
mention the research question and the aim of the review (see appendix 44). 
 
4.5. Results of Outcomes of interest for this review 
All the studies were analysed in terms of outcomes reported. Taking into account that 
no one study compared exactly the same intervention, it is impossible to synthesise the 
studies in terms of outcomes. Therefore, outcomes are presented individually for each 
intervention. Detailed tables relating to all studies, except the SRs, can be found in 
appendix 45 to 56. 
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4.5.1 How the results are presented and how to interpret the analysis 
The RevMan 5.2 tool (The Cochrane Collaboration 2013) was used for data analysis of 
all RCTs retrieved. For the remaining studies a narrative analysis of the results was 
undertaken. In relation to data analysed using the RevMan tool, dichotomous data was 
analysed in terms of RR and continuous data was analysed in terms of MD and were 
presented in a forest plot. 
 
Forest plots (see Figure 2) are graphics used to depict results of meta-analysis (Akobeng 
2005, Ried 2006). In this SR, although meta-analysis was not conducted, data analyses 
is displayed, were possible, using forest plots and instead of comparing studies only the 
groups in each study are compared. The square represents the RR or MD and is in line 
with the outcome value (Ried 2006). The size of the squares is related to the weight of 
the study, however if meta-analysis was being conducted different sized squares could 
be found and these would represent the weight given to each study (Ried 2006, Callcut 
and Branson 2009). The line through the square represents the Confidence Interval (CI) 
and the longer the line the less precise the study results are (Ried 2006). The 95% CI is 
the estimate of the range within which there is 95% certainty “…that the true population 
treatment effect will lie” (Akobeng 2005). The vertical line of the graphic represents the 
line of no effect (Akobeng 2005, Ried 2006). The value of this line is 1 for RR and 0 for 
MD (Ried 2006). The X axis is where outcomes are situated (Callcut and Branson 
2009).  
 
The last element of the graphic is the diamond and this demonstrates the overall 
result/effect of the comparison between the two groups (Ried 2006). The middle of the 
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diamond represents the estimate treatment effect (RR or MD) and the horizontal tips 
represent the 95% CI (Akobeng 2005, Ried 2006). If the diamond touches the line of no 
effect there is no significant statistical difference (SSD) among the groups being 
compared (Akobeng 2005, Ried 2006). 
 
 
 
 
 
Data in this SR was analysed in terms of RR and MD. RR looks at the proportion of 
participants who experience an event in the intervention group compared to the 
proportion in the control group (Gerrish and Lacey 2011). If the RR is equal to 1 then 
there is no difference among the groups (Ried 2006). In relation to MD this measures 
the “…absolute difference between the mean values in the experimental and control 
groups…” (Watson et al. 2008: 105). If the MD is equal to 0 then there is no difference 
among the groups (Ried 2006). 
 
 
 
Figure 2: Example of Forest Plot. 
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4.5.2. Primary Outcomes 
4.5.2.1. Healing Rate 
 
4.5.2.1.1. TCC vs. RCW vs. Half-Shoe 
In the study by Armstrong et al. (2001), healing rates were 89.5% (n=17) for the TCC, 
65% (n=13) for the RCW and 58.3% (n=14) for the half-shoe group. 
Comparing healing rates between the TCC and the RCW p=0.08. This means that there 
is no SSD in the healing rate between the TCC and the RCW. The overall effect in 
terms of RR is 1.38 and the 95% CI is 0.96 to 1.97. Despite this, the graphic confirms 
that more ulcers healed in the TCC group as the diamond lies to the right of the line of 
no effect (see figure 3). 
 
 
 
 
 
In terms of healing rates between the TCC and the half-shoe there is a SSD between the 
two devices as p=0.02. The overall effect in terms of RR is 1.53 and the 95% CI is 
between 1.06 and 2.22 (see figure 4). 
 
 
Figure 3: Forest plot 1 – TCC vs. RCW (healing rates) 
Favours TCC Favours RCW 
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Regarding the healing rates between the RCW and the half-shoe there is no SSD 
between the two devices as p=0.65. The overall effect in terms of RR is 1.11 and the 
95% CI is between 0.70 and 1.78 (see figure 5). 
  
 
 
 
 
4.5.2.1.2. iTCC vs. RCW 
In the study by Armstrong et al. (2005), healing rates at 12 weeks were 82.6% (n=19) 
for the iTCC and 51.9% (n=14) for the RCW group. Forest plot 4 shows that there is a 
SSD between the two groups as p=0.03. The overall effect in terms of RR is 1.59 and 
the 95% CI ranges from 1.06 to 2.40. In this intervention it is clear from the position of 
the diamond on the plot that more episodes of the outcome of interest happen in the 
iTCC group (see figure 6). 
 
Figure 4: Forest Plot 2 – TCC vs. Half-Shoe (healing rates) 
Figure 5: Forest Plot 3 – RCW vs. Half-Shoe (healing rates) 
Favours TCC Favours Half-Shoe 
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4.5.2.1.3. TCC, Accommodative Dressing, Healing Shoe, Walking Splint, Other 
In this retrospective study (Birke et al. 2002) from a total of 120 participants, only 113 
were accounted for, healing rates at 12 weeks was 81%. In terms of healing rates for the 
individual devices, 92% of ulcers healed in the TCC group (n=13), 93% healed in the 
accommodative dressing group (n=26), 81% healed in the healing shoe group (n=57), 
83% healed in the walking splint group (n=18) and of the 6 participants in the group 
were a combination of the aforementioned devices was used no healing rates were 
reported. It is clear that a higher percentage of ulcers healed in the TCC and 
accommodative dressing group, however the number of participants in each group is to 
disparate to allow comparisons. Furthermore the participants in the accommodative 
dressing used a modified surgical shoe in conjunction with the dressing.  
 
4.5.2.1.4. Therapeutic Shoe vs. Fiberglass Cast 
In the study by Caravaggi et al. (2002), at the end of the 30 days follow-up, 5 ulcers had 
healed in the therapeutic shoe group and 13 in the fiberglass group. Forest plot 5 shows 
a p=0.05 and the diamond being on the left side indicating that more episodes (ulcer 
healing) happened in the fiberglass cast group. There is a certain SSD in the healing 
rates between the groups (p=0.05) (see figure 7). 
Figure 6: Forest Plot 4 – iTCC vs. RCW (healing rates) 
Favours iTCC Favours RCW 
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4.5.2.1.5. Ransart Boot 
In this study (Dumont et al. 2009), only the Ransart Boot was used by the 135 
participants and from these only 117 were analysed as 22 underwent amputations. From 
the 117 participants only 70.1% (n=82) of the ulcers healed. Statistical analysis is not 
appropriate as there is no comparator group.  
 
4.5.2.1.6. TCC vs. Stabil-D 
In the study by Faglia et al. (2010), its healing rates at 90 days were 73.9% (n=17) for 
the TCC and 72.7% (n=16) for the Stabil-D group. It is possible to see in forest plot 6 
that p=0.93 which means that there is no SSD in the healing rate between the TCC and 
the Stabil-D. The 95% CI is between 0.71 and 1.45, and the overall effect in terms of 
RR is 1.02 (see figure 8). 
 
 
 
 
Figure 7: Forest Plot 5 – Therapeutic Shoe vs. Fiberglass Cast (healing rates) 
Figure 8: Forest Plot 6 – TCC vs. Stabil-D (healing rates) 
Favours Therapeutic Shoe Favours Fiberglass Cast 
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4.5.2.1.7. TCC vs. iTCC 
In the study by Katz et al. (2005), the mean healing rate at 12weeks was 74% (n=15) for 
the TCC and 80% (n=17) for the iTCC group. From forest plot 7 it is possible to see that 
p=0.47 which means that there is no SSD in the healing rate between the TCC and the 
iTCC. The 95% CI is between -7.40 and 3.40, and the overall effect in terms of MD, the 
influence that each device has in the overall result, is -2.00 (see figure 9). 
 
 
 
 
If the participants lost to follow-up are not included in the analysis there still is no SSD 
between the two groups, p=0.48 (see figure 10). 
 
 
 
 
 
4.5.2.1.8. TCC vs. TDT 
In the study by Mueller et al. (1989), the percentage of ulcers healed was 90% (n=19) in 
the TCC group and 32% (n=6) in the TDT group. Forest plot 9 shows that there is a 
SSD between the two types of devices as p=0.002, the diamond lies on the right of the 
Figure 9: Forest Plot 7 – TCC vs. iTCC (healing rates) 
Figure 10: Forest Plot 8 – TCC vs. iTCC (healing rates loss to follow-up data not included) 
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line of no effect showing that more ulcers healed on the TCC group. The overall effect 
in terms of RR is 2.87, and the 95% CI is between 1.46 and 5.63 (see figure 11). 
 
 
 
 
 
4.5.2.1.9. TCC, RCC, SMC 
In the study by Nabuurs-Franssen et al. (2005), although the 98 participants used 
different devices, the healing rate is not given for the individual devices. In general 76% 
(n=74) ulcers healed. The healing rates in this study are also given in terms of groups of 
patients with PAD and infection. Thus 90% of ulcers healed where there was no PAD 
and no infection; where there was only infection 87% healed; where only PAD was 
present 69% healed and where both PAD and infection were present only 36% of the 
ulcers healed. The authors give no indication of which device participants with PAD 
and/or with infection were using. 
 
4.5.2.1.10. TCC vs. Optima Diab Walker 
In the study by Piaggesi et al. (2007), the percentage of ulcers healed was 95% (n=19) 
on the TCC group and 85% (n=17) in the Optima Diab Walker. Forest plot 10 shows 
that there is no SSD between the two types of devices as p=0.30 and because the 
Figure 11: Forest Plot 9 – TCC vs. TDT (healing rates) 
Favours TCC Favours TDT 
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diamond is touching the line of no effect. The overall effect in terms of RR is 1.12, and 
the 95% CI is between 0.91 and 1.38 (see figure 12). 
 
 
 
 
 
4.5.2.1.11. TCC vs. CTF 
In the study by Van de Weg et al. (2008), the number of ulcers healed was 6 in the TCC 
group and 6 in the CTF group. Forest plot 11 shows that there is no SSD between the 
two types of devices as p=0.78 and because the diamond is touching the line of no 
effect. The overall effect in terms of RR is 0.87, and the 95% CI is between 0.33 and 
2.27 (see figure 13).  
 
 
 
 
 
4.5.2.1.12. Felted Foam vs. Half-Shoe 
No healing rates reported (Zimny et al. 2003). 
 
Figure 12: Forest Plot 10 – TCC vs. Optima Diab Walker (healing rates) 
Figure 13: Forest Plot 11 – TCC vs. CTF (healing rates) 
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4.5.2.1.13. Results from SRs 
In the review by Mason et al. (1999) and Spencer (2008) only the study by Mueller et 
al. (1989) was analysed. This study compares a TCC and a TDT which has already been 
analysed in the present review.  
 
4.5.2.2. Healing Time 
4.5.2.2.1. TCC vs. RCW vs. Half-Shoe 
In the study by Armstrong et al. (2001), healing times were expressed in terms of mean 
days to heal. In the TCC group the ulcer took 33.5 days to heal, in the RCW group it 
took 50.4 days to heal and in the half-shoe group it took 61.0 days to heal.  
 
Comparing the healing times between the TCC and the RCW in terms of MD, it is clear 
in forest plot 12 that there is a SSD amongst the two groups p<0.00001, that favours the 
TCC group. The 95% CI is between -21.02 and -12.78, and the overall effect in terms of 
MD is -16.90 (see figure 14). 
 
 
 
 
 
Figure 14: Forest Plot 12 – TCC vs. RCW (healing times) 
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In relation to the healing times between the TCC and the half-shoe forest plot 13 shows 
that there is a SSD between the two groups with a p<0.00001, that favours the TCC 
group. The 95% CI is between -31.21 and -23.79, and the overall effect in terms of MD 
is -27.50 (see figure 15). 
 
 
 
 
 
Comparing the healing times between the RCW group and half-shoe group forest plot 
14 indicates that there is a SSD between the two groups with a p<0.00001, but in this 
case the RCW is favoured. The 95% CI is between -14.69 and -6.51, and the overall 
effect in terms of MD is -10.60 (see figure 16). 
 
 
 
 
 
4.5.2.2.2. iTCC vs. RCW 
In the study by Armstrong et al. (2005), in the iTCC group the ulcers took 41.6 days to 
heal and in the RCW group they took 58.0 days to heal. From forest plot 15 it is 
Figure 15: Forest Plot 13 – TCC vs. Half-Shoe (healing times) 
Figure 16: Forest Plot 14 – RCW vs. Half-Shoe (healing times) 
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possible to see that p=0.0008 which means that there is a SSD in the healing times 
between the iTCC and RCW, being the iTCC favoured. The 95% CI is between -25.95 
and -6.85, and the overall effect in terms of MD is -16.40 (see figure 17). 
 
 
 
 
 
4.5.2.2.3. TCC, Accommodative Dressing, Healing Shoe, Walking Splint, Other 
In this retrospective study (Birke et al. 2002) the healing times were given for the 
individual devices. In general, all ulcers took a mean healing time of 45.5 days. In the 
TCC group the mean healing time was 47.7 days, in the accommodative dressing group 
it was 36.1 days, in the healing shoes it was 41.4 days, in the walking splint it was 50.5 
days and in the group where a combination of these devices were used healing times 
were not reported. From this data it appears that the accommodative dressing was more 
effective and ulcers healed quicker, however is important to note that participants that 
used the accommodative dressing were additionally fitted with a modified surgical shoe 
which could have influenced healing times. 
 
4.5.2.2.4. Therapeutic Shoe vs. Fiberglass Cast 
No healing times reported (Caravaggi et al. 2000). 
 
Figure 17: Forest Plot 15 – iTCC vs. RCW (healing times) 
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4.5.2.2.5. Ransart Boot 
In this study where all participants used the same offloading device the median healing 
time was 60 days (Dumont et al. 2009). 
 
4.5.2.2.6. TCC vs. Stabil-D 
In the study by Faglia et al. (2010), in the TCC group ulcers took 35.3 days to heal and 
in the Stabil-D group they took 39.7 days to heal. From forest plot 16 p<0.00001, this 
means that there is a SSD among the two groups being the TCC more effective. The 
95% CI is between -6.56 and -2.24, and the overall effect in terms of MD is -4.40 (see 
figure 18). 
 
 
 
 
 
4.5.2.2.7. TCC vs. iTCC 
In the study by Katz et al. (2005) in the TCC group ulcers took 5 weeks to heal and in 
the iTCC group they took 4 weeks to heal. 
 
4.5.2.2.8. TCC vs. TDT 
In the study by Mueller et al. (1989), in the TCC group ulcers took 42 days to heal and 
in the TDT group they took 65 days to heal. When analysing the results in terms of MD 
Figure 18: Forest Plot 16 – TCC vs. Stabil-D (healing times) 
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p=0.01 which means that there is a SSD in the healing times between the two groups, 
being the TCC favoured. The 95% CI is between -41.00 and -5.00, and the overall effect 
in terms of MD is -23.00 (see figure 19). 
 
 
 
 
 
4.5.2.2.9. TCC, RCC, SMC 
In the study by Nabuurs-Franssen et al. (2005), healing times are not reported for the 
individual devices. In general the median time for ulcers to heal was 33days. Healing 
times in this study are also given in terms of groups of patients with PAD and infection. 
Thus, where there was no PAD and no infection ulcers took 18 days to heal; where there 
was only infection ulcers healed in 29 days; where only PAD was present ulcers healed 
in 42 days and where both PAD and infection were present, authors report that a 
minority of ulcers healed being the numbers too small to calculate time to heal. 
Moreover the authors give no indication of which device participants with PAD and/or 
with infection were using. 
 
4.5.2.2.10. TCC vs. Optima Diab Walker 
In the study by Piaggesi et al. (2007), in the TCC group ulcers took 6.5 weeks to heal 
and in the Optima Diab Walker group they took 6.7 weeks to heal. From forest plot 18 it 
Figure 19: Forest Plot 17 – TCC vs. TDT (healing times) 
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is possible to see that there is no SSD between the groups as p=0.87. This suggests that 
both devices are equally effective in terms of time to heal.  The 95% CI is between -
2.64 and 2.24, and the overall effect in terms of MD is -0.20 (see figure 20). 
 
 
 
 
4.5.2.2.11. TCC vs. CTF 
In the study by Van de Weg et al. (2008), in the TCC group ulcers took 59 days to heal 
and in the CTF group they took 90 days to heal. In forest plot 19 p=0.0003, which 
means that TCC is more effective as this value shows a SSD between the two devices. 
The 95% CI is between -47.78 and -14.22, and the overall effect in terms of MD is -
31.00 (see figure 21). 
 
 
 
 
 
4.5.2.2.12. Felted Foam vs. Half-Shoe 
In the study by Zimny et al. (2003), in the felted foam group ulcers took 75.2 days to 
heal and in the half-shoe group they took 85.2 days to heal.  
Figure 20: Forest Plot 18 – TCC vs. Optima Diab Walker (healing times) 
Figure 21: Forest Plot 19 – TCC vs. CTF (healing times) 
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4.5.2.2.13. Results from SRs 
In the review by Mason et al. (1999) only the study by Mueller et al. (1989) was 
analysed and this has already been analysed in the present review. In the review by 
Spencer (2008) no healing times are mentioned. 
 
4.5.2.3. Reduction in Ulcer Size 
4.5.2.3.1. Therapeutic Shoe vs. Fiberglass Cast 
The authors only present a graphic in relation to ulcer area reduction, but do not explain 
it (Caravaggi et al. 2000). 
 
4.5.2.3.2. TCC vs. Stabil-D 
In the study by Faglia et al. (2010), the percentage of reduction in ulcer size was 73.6% 
(n=17) in the TCC group and 90% (n=20) in the Stabil-D group. In forest plot 20 
p=0.14, which means that there is no SSD between the TCC and the Stabil-D. The 95% 
CI is between 0.62 and 1.07, and the overall effect in terms of RR is 0.81 (see figure 
22). 
 
 
 
 
 
Figure 22: Forest Plot 20 – TCC vs. Stabil-D (reduction in ulcer size) 
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4.5.2.3.3. TCC vs. CTF 
In the study by Van de Weg et al. (2008) in terms of reduction in ulcer size, at the end 
of the 16 weeks follow-up both ulcers had a median size of 0.4cm
2
, from an initial 3.6 
cm
2
 in the TCC group and 1.9 cm
2
 in the CTF group. The authors report on ulcer 
reduction at 2, 4, 8 and 16 weeks, however the number of participants analysed, varies 
in the different weeks. 
 
4.5.2.3.4. Felted Foam vs. Half-Shoe 
In the study by Zimny et al. (2003), reduction in ulcer size was expressed in terms of 
mean radius reduction per week. In the felted foam group there was a reduction of 
0.48mm per week in ulcer radius and in the half-shoe group there was a reduction of 
0.39mm per week in ulcer radius. Forest plot 21 shows the mean area reduction after 10 
weeks, and it is possible to see that there is a SSD between the two groups, with 
p<0.00001. The 95% CI is between -7.15 and -3.25, and the overall effect in terms of 
MD is -5.20 (see figure 23). 
 
 
 
 
 
Figure 23: Forest Plot 21 – Felted Foam vs. Half-Shoe (reduction in ulcer size) 
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4.5.2.3.5. Results from SRs 
The systematic review by Mason et al. (1999) only reports on the study by Mueller et 
al. (1989) and this study did not analyse reduction in ulcer size. Spencer (2008) does not 
have reduction in ulcer size as an outcome measure. 
 
In the remaining studies (Mueller et al. 1989, Armstrong et al. 2001, Birke et al. 2002, 
Armstrong et al. 2005, Katz et al. 2005, Piaggesi et al. 2007, Nabuurs-Franssen et al. 
2005, Dumont et al. 2009) analysis in terms of ulcer size reduction was not reported. 
 
4.5.3. Secondary Outcomes 
4.5.3.1. Adverse Effects 
 
4.5.3.1.1. iTCC vs. RCW 
In the study by Armstrong et al. (2005), the adverse effects reported were maceration 
and infection. The percentage of participants with maceration and infection in the iTCC 
group were 37.5% (n=8) and 27.3% (n=6), respectively. In the RCW group the 
percentage of participants with maceration and infection, was 68.2% (n=18) and 41.7% 
(n=11), respectively.  
In relation to maceration there is no SSD between the two groups with p=0.07 (see 
figure 24). 
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With regard to infection there is also no SSD between the two groups with p=0.29 (see 
figure 25). 
 
 
 
 
 
4.5.3.1.2. Therapeutic Shoe vs. Fiberglass Cast 
In the study by Caravaggi et al. (2000), the adverse effect reported was increase in ulcer 
size. This happened in 2 participants of the therapeutic shoe group. Forest plot 24 shows 
that there is no SSD between the two groups with p=0.27. The overall effect in terms of 
RR is 5.40, with a 95% CI between 0.27 and 107.09 (see figure 26). 
 
 
 
 
Figure 24: Forest Plot 22 – iTCC vs. RCW (maceration) 
Figure 25: Forest Plot 23 – iTCC vs. RCW (infection) 
Figure 26: Forest Plot 24 – Therapeutic Shoe vs. Fiberglass Cast (increase in ulcer size) 
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4.5.3.1.3. Ransart Boot 
In the study by Dumont et al. (2009), the adverse effects reported were: abrasion in the 
instep (n=8); redness on the 5
th
 metatarsal head (n=2) and blister on the heel (n=1). The 
authors report that after modifications were made to the Ransart Boot, complications 
healed. 
 
4.5.3.1.4. TCC vs. Stabil-D 
In the study by Faglia et al. (2010), the adverse effects reported were itching in the TCC 
group and maceration in the Stabil-D group. 
In relation to itchiness there is no SSD between the two groups with p=0.51 (see figure 
27).  
 
 
 
 
 
With regard to maceration there is also no SSD between the two groups, p=0.48 (see 
figure 28). 
 
 
 
Figure 27: Forest Plot 25 – TCC vs. Stabil-D (itchiness) 
Figure 28: Forest Plot 26 – TCC vs. Stabil-D (maceration) 
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4.5.3.1.5. TCC vs. iTCC 
In the study by Katz et al. (2005), in the TCC group the percentage of participants who 
developed adverse effects were as follows: maceration 35%, second ulcer 10%, abrasion 
10%, toe amputation 5%, oedema 5%, kissing ulcer 5% and falls 0%.  In the iTCC 
group the percentage of participants who developed adverse effects were as follows: 
maceration 29%, second ulcer 5%, abrasion 0%, toe amputation 5%, oedema 0%, 
kissing ulcer 0% and falls 5%.  
In terms of maceration, from forest plot 27, it is possible to see that there is no SSD 
between the two groups with p=0.66 (see figure 29). 
 
 
 
 
 
In terms of second ulcer development, from forest plot 28 it is possible to see that there 
is no SSD between the two groups with p=0.53 (see figure 30). 
 
 
 
 
Figure 29: Forest Plot 27 – TCC vs. iTCC (maceration) 
Figure 30: Forest Plot 28 – TCC vs. iTCC (second ulcer) 
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In terms of abrasion, from forest plot 29, it is possible to see that there is no SSD 
between the two groups with p=0.28 (see figure 31). 
 
 
 
 
 
In terms of toe amputation, from forest plot 30, it is possible to see that there is no SSD 
between the two groups with p=0.97 (see figure 32). 
 
 
 
 
 
In terms of oedema, from forest plot 31, it is possible to see that there is no SSD 
between the two groups with p=0.48 (see figure 33). 
 
 
 
 
Figure 31: Forest Plot 29 – TCC vs. iTCC (abrasion) 
Figure 32: Forest Plot 30 – TCC vs. iTCC (toe amputation) 
Figure 33: Forest Plot 31 – TCC vs. iTCC (oedema) 
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In terms of development of a kissing ulcer, from forest plot 32, it is possible to see that 
there is no SSD between the two groups with p=0.48 (see figure 34). 
 
 
 
 
 
In terms of falls, from forest plot 33, it is possible to see that there is no SSD between 
the two groups with p=0.51 (see figure 35). 
 
 
 
 
 
4.5.3.1.6. TCC vs. TDT 
In the study by Mueller et al. (1989), the adverse effect reported was infection. This 
happened in 5 participants of the TDT group, 2 of which required forefoot amputation. 
From forest plot 34, it is possible to see that there is no SSD between the two groups 
with p=0.08 (see figure 36). 
 
Figure 34: Forest Plot 32 – TCC vs. iTCC (kissing ulcer) 
Figure 35: Forest Plot 33 – TCC vs. iTCC (falls) 
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4.5.3.1.7. TCC, RCC, SMC 
In the study by Nabuurs-Franssen et al. (2005), adverse effects were not reported for the 
individual devices. In general from the 98 participants: 9 developed infection of which 6 
required hospitalisation for antibiotics and 3 were amputated; 2 needed 
revascularisation; 3 needed a free-flap transplantation and 7 stopped using the cast due 
to discomfort. New ulcers developed in 9% of the participants, but healed in 13 days 
with a revised cast. There were also pre-ulcerative lesions of which 28% resolved in a 
few days after minor adaptations in the cast. There were 8% of patients with chafed skin 
and 7% with joint problems. 
 
4.5.3.1.8. TCC vs. Optima Diab Walker 
In the study by Piaggesi et al. (2007), the adverse effects reported in the TCC group 
were maceration and infection in 4 and 1 participants respectively. In the Optima Diab 
Walker group maceration occurred in 2 participants, infection, paraesthesia and 
haematoma occurred in 1 participant. 
In terms of maceration, from forest plot 35, it is possible to see that there is no SSD 
between the two groups with p=0.39 (see figure 37). 
Figure 36: Forest Plot 34 – TCC vs. TDT (infection) 
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In terms of infection, from forest plot 36, it is possible to see that there is no SSD 
between the two groups with p=1.00 (see figure 38). 
 
 
 
 
 
In terms of paraesthesia from forest plot 37, it is possible to see that there is no SSD 
between the two groups with p=0.49 (see figure 39). 
 
 
 
 
 
Figure 37: Forest Plot 35 – TCC vs. Optima Diab Walker (maceration) 
Figure 38: Forest Plot 36 – TCC vs. Optima Diab Walker (infection) 
Figure 39: Forest Plot 37 – TCC vs. Optima Diab Walker (paraesthesia) 
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In terms of haematoma development in the calf, from forest plot 38, it is possible to see 
that there is no SSD between the two groups with p=0.49 (see figure 40). 
 
 
 
 
 
4.5.3.1.9. TCC vs. CTF 
In the study by Van de Weg et al. (2008), in the TCC group complications (not 
specified) were reported in 5 participants, from which 2 had to discontinue treatment. In 
the CTF group abrasion occurred in 2 participants. 
In terms of complications, from forest plot 39, it is possible to see that there is no SSD 
between the two groups with p=0.12 (see figure 41). 
 
 
 
 
 
In terms of abrasion, from forest plot 40, it is possible to see that there is no SSD 
between the two groups with p=0.25 (see figure 42). 
Figure 40: Forest Plot 38 – TCC vs. Optima Diab Walker (haematoma) 
Figure 41: Forest Plot 39 – TCC vs. CTF (complications) 
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4.5.3.1.10. Felted Foam vs. Half-Shoe 
In the study by Zimny et al. (2003), the adverse effect reported was infection in 25% 
(n=6) of the participants in the felted foam group, and in 23% (n=7) of the participants 
in the half-shoe group. From forest plot 41 it is possible to see that there is no SSD 
between the two groups, with p=0.89 (see figure 43). 
 
 
 
 
 
4.5.3.1.11. Results from SRs 
In the review by Mason et al. (1999) only the study by Mueller et al. (1989) is analysed 
and this has already been analysed in the present review. In the review by Spencer 
(2008) the complications found in the studies reviewed (Mueller et al. 1989 was the 
only study significant for the present review) were considered to be reported 
insufficiently, so the author does not make any analysis in terms of adverse reactions. 
Figure 42: Forest Plot 40 – TCC vs. CTF (abrasion) 
Figure 43: Forest Plot 41 – Felted Foam vs. Half-Shoe (infection) 
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Only two studies (Armstrong et al. 2001, Birke et al. 2002) did not report on adverse 
effects. 
 
4.5.3.2. Cost 
4.5.3.2.1. TCC vs. Stabil-D 
In relation to cost-effectiveness the study by Faglia et al. (2010), reports on the cost of 
both devices. Relatively to the TCC this costs €73.5, although there is an increase to 
€89.5 for obese patients, as these require extra bandages. For a total of 91 casts, taking 
into account that these had to be changed, the cost was €6,688.50. Regarding the Stabil-
D device this costs €130 plus €20 for the Modus sole. In total €3,300.00 were spent in 
this device for 22 participants. It is possible to see that the Stabil-D is more cost-
effective allowing for savings of up to €3,388.50. 
 
4.5.3.2.2. TCC vs. iTCC 
In the study by Katz et al. (2005), cost is reported in terms of materials per week and 
then the direct cost of treatment. For the TCC group the cost of the materials per week 
was $38.36 and the cost of treatment was $210.67, which makes a total of $670.99. For 
the iTCC group the cost of the materials per week was $14.70 plus once the cost of the 
device $89.95 and the cost of treatment was $158.47, which makes a total of $424.82. It 
is possible to see that the iTCC is more cost-effective allowing for savings of up to 
€246.17 per patient per week. 
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4.5.3.2.3. TCC vs. Optima Diab Walker 
In the study by Piaggesi et al. (2007), cost was reported in terms of mean cost per cast 
and per patient in both groups. In the TCC group the mean cost per cast was €110.5, and 
€727.29 per patient. In relation to the Optima Diab Walker, the device cost was €130, 
and the mean cost per patient was €162.5. From forest plot 42, in terms of cost per 
patient there is a SSD between the two devices with a p<0.00001.  The 95% CI is 
between 348.01 and 781.57, and the overall effect in terms of MD is 564.79. It is 
possible to see that the cost per patient is lower in the Optima Diab Walker device (see 
figure 44). 
 
 
 
 
 
4.5.3.2.4. Results from SRs 
The SR by Mason et al. (1999) does not report on cost analysis. The SR by Spencer 
(2008), reports on cost-effectiveness but not in relation to offloading. 
In the remaining studies (Mueller et al. 1989, Caravaggi et al. 2000, Armstrong et al. 
2001, Birke et al. 2002, Zimny et al. 2003, Armstrong et al. 2005, Nabuurs-Franssen et 
al. 2005, Van de Weg et al. 2008, Dumont et al. 2009) cost analysis was not reported. 
 
Figure 44: Forest Plot 42 – TCC vs. Optima Diab Walker (cost) 
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4.5.3.3. Compliance 
4.5.3.3.1. Therapeutic Shoe vs. Fiberglass Cast 
In the study by Caravaggi et al. (2000), compliance was analysed in terms of device 
acceptance using a visual analogue scale ranging from 1 to 100. In the therapeutic shoe 
group the mean acceptance value was 91.15 and in the fiberglass cast group the mean 
acceptance value was 88.33. Forest plot 43 shows that there is no SSD in the acceptance 
of the devices, p=0.48. The 95% CI is between -4.92 and 10.56, and the overall effect in 
terms of MD is 2.82 (see figure 45). 
 
 
 
 
4.5.3.3.2. Ransart Boot 
In the study by Dumont et al. (2009), the authors report that 9.6% of participants (n=13) 
were judged non-compliant, as according to the authors of the study these participants 
were not using their devices as instructed. 
 
4.6.3.3.3. TCC vs. Optima Diab Walker 
In the study by Piaggesi et al. (2007), compliance was analysed in terms of device 
acceptance using a visual analogue scale ranging from 0 to 10. In the TCC group the 
mean acceptance value was 6.85 and in the Optima Diab Walker group the mean 
acceptance value was 8.45. Forest plot 44 shows that there is a SSD in the acceptance of 
Figure 45: Forest Plot 43 – Therapeutic Shoe vs. Fiberglass Cast (device acceptance) 
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the devices p=0.02. The 95% CI is between -2.91 and -0.29, and the overall effect in 
terms of MD is -1.60 (see figure 46). 
 
 
 
 
4.5.3.3.4. Results from SRs 
The SR by Mason et al. (1999) and Spencer (2008) do not report on compliance relating 
to offloading. 
 
In the remaining studies (Mueller et al. 1989, Armstrong et al. 2001, Birke et al. 2002, 
Zimny et al. 2003, Armstrong et al. 2005, Katz et al. 2005, Nabuurs-Franssen et al. 
2005, Van de Weg et al. 2008, Faglia et al. 2010) analysis on compliance was not 
reported. 
 
4.5.3.4. Quality of Life 
No QoL issues were identified as an outcome of all the studies included in this SR. Only 
the SR by Spencer (2008) looks at patient satisfaction and QoL but analysis is in 
relation to one study that does not look at offloading. 
 
 
Figure 46: Forest Plot 44 – TCC vs. Optima Diab Walker (device acceptance) 
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4.6. Summary 
From the search strategy 25 full text articles were retrieved, from which 11 were 
excluded and 14 were further included. From these 9 were RCTs, 2 were SRs, one was 
an observational study, one a retrospective study and one was a prospective data 
collection. From all the studies the samples sizes varied from 40 to 135 participants. 
Some studies did not report on the study setting, whereas others did, and care settings 
varied between diabetic foot clinics and hospitals. Geographically the locations were 
spread between America and Europe. The interventions under investigation in the 
different studies were analysed individually comparing the characteristics of the devices 
used. In terms of study analysis the 9 RCTs presented a few issues relating to bias, the 
SRs failed to report on some of the steps for conducting SRs, and the other 3 studies 
presented validity issues. All the studies reported one or more of the outcome measures 
of interest for this SR however these were analysed individually for every intervention, 
as these were not comparable. It was possible to see that a few of the outcomes 
presented SSDs, whereas others did not.  
 
From the results the TCC shows better healing rates and healing times, followed by the 
iTCCs and the RCWs. The remaining devices mainly the therapeutic shoes, felted foam 
and CTF show worst results when compared with casts. In terms of adverse reactions 
infection and maceration were the most predominant amongst devices, and all devices 
were responsible for the development of one or more adverse reactions. With regard to 
cost very few studies reported on the costs associated with devices and the studies that 
undertook cost-analysis show higher costs with the TCC when compared with RCWs. 
In relation to compliance few studies reported on compliance assessment. The studies 
where compliance was analysed, this was related with device acceptance and there was 
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no SSD in terms of device acceptance. QoL issues were not analysed in any of the 
studies.  
 
4.7. Conclusion 
Casts allow for better healing rates when compared with other devices like therapeutic 
shoes and accommodative dressings. From these, TCCs show better results followed by 
iTCCs and RCWs for the treatment of DFUs. 
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Chapter 5.Discussion 
5.1. Introduction 
This chapter will give a succinct summary of the key findings of this SR. It will also 
discuss the methodological issues of the included studies in this SR. Additionally, this 
chapter will discuss the findings in terms of primary and secondary outcomes and 
analyse them in terms of what is already know, if the studies bring new information for 
clinical practice or education and if further research is needed in the area. Finally this 
chapter will analyse the strengths and limitations of this SR and discuss its overall 
contribution to health and social gain. 
 
5.2. Summary of the key findings of this SR 
The key findings from the SR of the included studies are: 
 Offloading is an important strategy for the treatment of DFUs. 
 A variety of removable (therapeutic shoes) and irremovable (TCC) devices are 
being used worldwide for the treatment of DFUs. 
 Healing rates were in general higher with the TCC however the iTCC and RCWs 
when compared with the TCC did not show SSD in healing rates, showing that 
these devices are also effective in the treatment of DFUs. 
 Healing times were higher with the TCC. However when healing time with the 
TCC was compared with the Optima Diab Walker there was no SSD. 
 Reduction in ulcer size was reported in three studies (Zimny et al. 2003, Van de 
Weg et al. 2008, Faglia et al. 2010) but no SSD was found among devices 
compared. 
 The most reported adverse effects were infection and maceration. 
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 Cost analysis was reported in three studies, and the TCC had higher costs when 
compared with an iTCC, Stabil-D and Optima Diab Walker. 
 The studies where compliance was analysed, this was related with device 
acceptance and there was no SSD in terms of device acceptance.  
 No QoL assessment was undertaken in the studies included for this SR. 
 
5.3. Methodological issues of included studies 
5.3.1. Study Design 
The design of the studies, included in a SR, will impact on the reliability of the results 
of those studies and also in the validity of the effects relating to the study design (CRD 
2008). Further, it is important to recognise that some study designs are more robust than 
others (CRD 2008). For this SR, two SRs and twelve quantitative studies were included. 
 
From the three quantitative studies, one was a retrospective analysis (Birke et al. 2002), 
one an observational study design (Dumont et al. 2009) and the final a prospective data 
collection (Nabuurs-Fransen et al. 2005). Retrospective analysis is a type of design that, 
although of value, is subject to recall bias (Watson et al. 2008) as the authors may select 
cases, which show more positive results enhancing or devaluing the interventions being 
analysed. This, in consequence, will limit the applicability of the results to other 
populations (CRD 2008). The observational study design cannot be generalised to the 
general population as participants are not randomly selected (CRD 2008). In terms of 
prospective data collection, this design brings together data as it is produced making it a 
more reliable method (Watson et al. 2008). However, in the study included (Nabuurs-
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Fransen et al. 2005) the results within the individual groups, using different types of 
casts, were not compared and results were expressed in general for the total amount of 
participants, this does not allow for a better understanding of the individual efficacy of 
the different devices that were used (CRD 2008). Although of value, the designs 
mentioned do not allow for conclusions to be applied to the wider population (CRD 
2008, Higgins and Green 2011). 
 
The SR by Mason et al. (1999) analysed various methods for the treatment of DFUs, 
including casting, and only identified one RCT, which does not allow for firm 
conclusions or recommendations for practice to be made. Moreover this SR did not 
report a detailed search strategy, making it difficult to be replicated (Magarey 2001, 
Watson et al 2008). The SR by Spencer (2008) focuses on prevention and treatment of 
DFUs. It only reports on one RCT where offloading was used for the treatment of 
DFUs. This does not allow for firm conclusions to be reached as more studies are 
needed for comparisons to be made, in terms of which are the best devices for the 
treatment of DFUs (Cook et al. 1997, Muir Gray 1997 cited in Gerrish and Lacey 
2010). The findings of the SRs did not bring new information to the present SR. 
 
Regarding the RCTs retrieved, this type of design is extremely important, as it allows 
for the random allocation of subjects into the experimental and control group (Watson et 
al. 2008). This random allocation will avoid any bias that could devalue the findings 
(Watson et al. 2008). The RCTs analysed, compared different offloading devices so that 
results could allow for healthcare professionals to have a better understanding of which 
devices have better outcomes for patients (Mueller et al. 1989, Caravaggi et al. 2000, 
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Armstrong et al. 2001, Zimny et al. 2003, Armstrong et al. 2005, Katz et al. 2005, 
Piaggesi et al. 2007, Van de Weg et al. 2008, Faglia et al. 2010). Although, RCTs are 
considered the gold standard, through the use of controlled methods, random allocation 
of participants and concealment of which participants are assigned to the experimental 
or control group, this method is still subject to systematic errors, that can enhance or 
devalue the true effect of an intervention (CCGO 2013), potentially rendering the results 
invalid and unfit for generalisation. 
 
5.3.2. Sampling 
Sampling is a necessary method used in research as the sample will represent a subset of 
the population being investigated (Gerrish and Lacey 2010). Furthermore, it is 
important to obtain the correct sample size so that results obtained can be generalised 
back to the population of interest, and that a SSD may be detected, should one exist 
(Watson et al. 2008), for this to happen power analysis is necessary (Watson et al. 
2008) and important for the calculation of the adequate sample size, which will 
influence the estimated expected difference to be found between the interventions being 
compared among the groups.  
From the studies included, two (Piaggesi et al. 2007, Faglia et al. 2010) did not report 
power analysis in their methods. The studies by Mueller et al. (1989), Zimny et al. 
(2003), Katz et al. (2005) and Van de Weg et al. (2008) aimed for p values < 0.05 and 
CI of 95%, this means that there is 95% probability of finding a difference between the 
groups if one exists.  Nonetheless, none of the previously mentioned studies elaborate if 
their sample sizes are sufficiently large for the aimed power to be achieved and for a 
true SSD to be observed among the groups. From the remaining studies (Caravaggi et 
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al. 2000, Armstrong et al. 2001, Armstrong et al. 2005) sample sizes were calculated 
for the study to have a certain power and to find a possible SSD between groups.  
Although, sample sizes of these studies appear to be small, when compared with other 
RCTs, they were calculated to have a power between 80% and 95%. This will yield an 
80-95% probability of detecting a real difference between groups. Sample size 
calculation is important as it will influence the real significance and power of the results 
obtained, thus influencing the strength of the study as a whole. 
 
5.3.3. Sequence Generation 
Sequence generation is related to whether adequate methods, like randomisation, were 
used for the generation of the allocation sequence (Moore 2009). For example, the use 
of a table of random numbers is considered to be an adequate method of sequence 
generation whereas using case record numbers is considered to be an inadequate method 
(Higgins and Green 2011). All RCTs report that randomisation was done using a 
table/list of random numbers or a computer random number generator. Only Mueller et 
al. (1989) and Zimny et al. (2002) did not specify the method used for randomisation. 
Sequence generation prevents the occurrence of selection bias allowing balanced 
intervention groups and assuring that participants with the same characteristics receive 
each intervention (Higgins and Green 2011). This way the researchers of the study do 
not know which participants were attributed to which group preventing them from 
choosing a participant with particular characteristics, such as a smaller ulcer, that with a 
particular device could enhance its properties and result in better outcomes from that 
device. 
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5.3.4. Allocation Concealment 
Allocation concealment is another method to prevent selection bias. With this method 
researchers will not know how the randomisation sequence was generated (Moore 2009) 
and will not be able to alter it, to benefit a particular intervention. Allocation 
concealment will prevent results from having a weight that can be attributed, not to the 
interventions being studied, but to the changes that could have been made in the 
allocation of participants (Higgins and Green 2011). In the studies reviewed allocation 
concealment was done in the study by Van de Weg et al. (2008) through opaque sealed 
envelopes. In the study by Armstrong et al. (2005) allocation was provided to the 
treating clinician by a single study coordinator via telephone. This creates a risk of 
selection bias (Higgins and Green 2011), as both the clinician and a study coordinator 
are aware of the participants’ allocation and, although this was done via telephone there 
is no guarantee that changes were made to the allocation.  
 
5.3.5. Blinding 
Blinding will ensure that the allocation is not known for the participants, the healthcare 
professionals, the outcome assessors, and also data analysts and manuscript writers 
(Moore 2009, Higgins and Green 2011). The lack of blinding can magnify the estimate 
effect of the interventions under investigation thus, magnifying the effect of the results 
obtained (Higgins and Green 2011). Inadequate blinding can create performance bias, or 
detection bias (Higgins and Green 2011). In the studies reviewed only Van de Weg et 
al. (2008) address the impossibility of blinding the participants of each group to the 
devices being used. This is due to the fact that TCC and other devices cannot be masked 
and the participants are able to see its application. Although, blinding would be 
impractical in all the studies reviewed, it is important that researchers acknowledge this 
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fact and give some rational regarding any risk of bias that can arise. Even though, in 
some cases, blinding is not always achievable because of obvious differences of the 
interventions in each group (Moore 2009) it is important to consider how knowing the 
intervention can impact on behavioural outcomes (Higgins and Green 2011).  
In relation to blinding of outcome assessment, in the studies reviewed only Van de Weg 
et al. (2008) acknowledge that the researchers were not involved in the 
treatment/interventions studied. The study by Mueller et al. (1989), Katz et al. (2005), 
Piaggesi et al. (2007) and Faglia et al. (2010) report that other professionals such as 
certified cast technicians were involved in the fabrication of the casts, however it is no 
clearly stated that researchers were not involved in the treatment, cast application and/or 
ulcer care. No study addressed the risk of detection bias in its discussion. 
 
5.3.6. Outcome Assessment 
5.3.6.1. Incomplete Outcome Data 
Incomplete outcome data is related to missing data due to dropouts, such as losses to 
follow-up (Moore 2009, Higgins and Green 2011), this can create biased effect 
estimates, possibly compromising the true value of the results obtained. Linked to 
incomplete outcome data, is intention-to-treat analysis (ITT). ITT allows for low bias 
occurrence when estimating the intervention effects in RCTs (Higgins and Green 2011) 
as all the participants are analysed in the groups where they were originally assigned 
(Moore 2009). In the studies reviewed only three (Caravaggi et al. 2000, Zimny et al. 
2003, Piaggesi et al. 2007) did not report any dropouts. From the remaining six studies 
only one (Armstrong et al. 2005) reported the inclusion of dropouts in the ITT. The 
remaining studies report dropouts but do not include them in the ITT, except for one 
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cross-over participant, in Van de Weg et al. (2008), who was analysed in the original 
group they were allocated to. The studies where dropouts were not included in the ITT 
may be at risk of attrition bias that could alter the true estimate effect of the intervention 
and thus the results obtained, which in turn will limit its application to practice. 
Additionally, studies should have given more insight into how they dealt with missing 
data and how this might have affected results. 
 
5.3.6.2. Selective Outcome Reporting 
Selective outcome reporting is related to the deliberate exclusion of data derived from 
the primary or secondary outcomes of the study (Moore 2009). In this case researchers 
might decide to report only the significant statistical results obtained, creating a false 
estimate of the effect of the intervention (Moore 2009), which will further weaken a 
possible generalisation of the results to the wider population. In all the studies reviewed 
data were reported relating to primary and secondary outcomes. 
 
5.3.7. Heterogeneity of Studies 
Heterogeneity is related to the variability among studies that are included in a SR 
(Higgins and Green et al 2011). This variability can be related to study design, 
participants, interventions and outcomes (Higgins and Green et al 2011). From the 
studies included in this SR, heterogeneity is present in terms of study design, and in 
terms of interventions under investigation, as all studies compared different devices to 
ascertain the efficacy of offloading for the treatment of DFUs. Relating to participants, 
their demographic profile was similar across studies. In relation to outcomes, this varied 
amongst studies although the majority include healing rates, healing times and reduction 
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in ulcer size as primary outcomes. The results that arise from this comparability cannot 
be combined because all studies used different devices, making it impossible to conduct 
meta-analysis. Taking into account that the studies are not homogenous combining them 
would bring meaningless results and thus rendering any conclusions and 
recommendations unfit for EBP. 
 
5.4. Discussion on Outcomes of this SR 
5.4.1. Primary Outcomes 
The primary outcomes of this SR were healing rates, healing times and reduction in 
ulcer size. From the analysis of the results obtained it is possible to say that offloading 
is effective for the treatment of DFUs. However, it is necessary to highlight that in the 
studies all participants had neuropathy alone, and only the study by Nabuurs-Franssen et 
al. (2005) also included participants with PVD. Nonetheless, due to the fact that 
offloading devices are sometimes irremovable and stay in place for periods of at least 
one week, patients with impaired circulation should be continuously monitored when 
and if using offloading (Leung 2007).  
 
In the studies included, devices differed from self-applied, such as therapeutic shoes, to 
TCCs where trained technicians are needed for cast application. Furthermore, devices 
also varied in terms of removability where TCC and iTCC are known as irremovable 
whereas a half-shoe is removable. Additionally, dressings and felted foam were also 
used, and are considered offloading devices as they allow for pressure relief in the 
ulcerated area however they should be used in combination with a therapeutic shoe 
(Edmonds et al. 2008). In three studies (Mueller et al. 1989, Birke et al. 2002, Zimny et 
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al. 2003) devices were used in combination with therapeutic shoes, which could act as a 
cofounding factor, so the outcomes of these devices, in the mentioned studies, cannot be 
attributed to the device alone. 
From all the devices analysed TCCs have better outcomes in terms of ulcer healing, 
followed by the iTCC and RCWs. The higher efficacy of the TCC and iTCC is due to 
the fact that both devices are irremovable enforcing compliance, not only in terms of 
device use but also in clinic follow-up (Armstrong et al. 2001, Edmonds et al. 2008).  
 
It is important to emphasise that offloading is cornerstone for DFU healing regardless of 
the device used, as long as one is appropriately used (Bakker et al. 2012). Nonetheless, 
it is necessary to highlight that casts are, of all, the best devices and should be used as a 
first choice, because of their higher healing rates (Bakker et al. 2012). Other devices 
such as therapeutic shoes, accommodative dressings or modified insoles, should be used 
as a second line intervention when the ulcer is healed and pressure relief is necessary to 
prevent recurrence or, they may be used as a way to prevent ulcers in diabetic patients 
where neuropathy has been diagnosed (Cavanagh et al. 2000, Boulton 2004a, Cavanagh 
et al. 2005, Leung 2007). 
 
5.3.2. Secondary Outcomes 
5.3.2.1. Adverse Effects 
Offloading is an important treatment strategy (Boulton 2004b), however depending on 
the device used adverse effects might develop. The most common adverse effects 
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mentioned in the literature are the development of new ulcers, oedema, infection and 
maceration (Boulton 2004a, Boulton 2004b, Cavanagh et al. 2005).  
From the analysis of the adverse effects reported in the studies included for this SR, 
infection and maceration where the most common adverse effects observed (Mueller et 
al. 1989, Zimny et al. 2003, Armstrong et al. 2005, Katz et al. 2005, Nabuurs-Franssen 
et al. 2005, Piaggesi et al. 2007, Van de Weg et al. 2008, Faglia et al. 2010). These 
adverse effects occurred equally among the devices studied. Taking into account that, 
exudate might have been present, that casts could have been too tight and rubbed 
against the limb and due to the fact that participants were followed on a weekly basis, 
unless any discomfort symptoms became unbearable, this could have influenced the 
development of infection and maceration (Caravaggi et al. 2000, Jeffcoate and Harding 
2003, Edmonds et al. 2008). However, it is interesting to see that no SSD was found 
between devices in terms of adverse effects and all devices actually caused an adverse 
effect. Nonetheless, it is important to reduce the occurrence of adverse effects, 
particularly infection because if left unnoticed or improperly treated it could aggravate 
and result in limb amputation (Svensson et al. 2011, Schaper et al. 2012). One action 
that could decrease adverse effect rates is a more regular follow-up (Mueller et al. 
1989). Although, adverse effects are an issue of concern they should not be a reason to 
discontinue offloading, as this is key in the treatment of DFUs, a strategy that could be 
used is to change to a different device from the one the patient is currently using or 
doing modifications to the device being used (Dumont et al. 2009). 
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5.4.2.2. Cost 
In a period of challenging economic background, the reduction of health resources is a 
reality and policymakers and managers look for more cost-effective practices that can 
accompany the current economic climate (DoHC 2012). It is important to highlight that 
the expenditure with health services is expected to be reduced by €1.1billion (DoHC 
2012) which will greatly affect the care delivered and will therefore, affect the patient. 
Placing this reality into context, it is clear that the most cost-effective offloading device 
is going to be the primary choice for the treatment of DFUs because, resources are 
scarce in today’s economic climate and because policy makers need to measure and 
compare the cost of a treatment with the consequences it brings (Drummond et al. 
2005).  
From the studies included and, where cost analysis was undertaken, TCCs are the most 
costly devices not only due to fact that materials cannot be reused, but also because they 
need to be applied by qualified professionals, which adds extra cost to the treatment 
(Katz et al. 2005, Piaggesi et al. 2007, Faglia et al. 2010). However, one may argue that 
although, TCCs are more expensive they have proven to have better healing rates than 
RCWs (Caravaggi et al. 2000, Armstrong et al. 2005, Katz et al. 2005, Piaggesi et al. 
2007, Faglia et al. 2010). Therefore, if ulcers heal better and faster when TCCs are used, 
this means that the consequences of the treatment (shorter healing time and high healing 
rates) overcome the costs (Drummond et al. 2005), making the TCC more cost-
effective. Another, discussion point is the fact that, it is becoming current practice to use 
RCWs and rendering them irremovable through the application of fiberglass cast 
material, these become iTCCs and because the cast is re-usable, the cost decreases (Katz 
et al. 2005). Nevertheless, if devices are used based only on their cost, in the scenario 
where a patient is having his device continuously changed because ulcer healing is not 
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being achieved the cost will undoubtedly increase, whereas if a TCC or even a iTCC are 
used in the first place real savings might be achieved and most importantly ulcer healing 
will occur. 
 
5.4.2.3. Compliance 
Individuals behave in a way that allows them to detect and prevent any health issues and 
reach maximum well-being (Conner and Norman 2005). Compliance with therapeutic 
regimens is a health behaviour that can affect patients’ health (Conner and Norman 
2005). Compliance describes patients’ behaviours in relation to prescribed regimens, 
which are seen by healthcare professionals as paramount for patients to be healthy 
(German 1988, Murphy and Canales 2001). Compliance is the extent to which patients’ 
behaviours follow medical advice (Murphy and Canales 2001). However this definition 
puts the patient in a spectator position disregarding the way these regimens may affect 
their lives and bringing paternalism back to healthcare services (German 1988, Murphy 
and Canales 2001).  
Offloading is a regimen that aims at helping patients to achieve well-being by healing 
DFUs. However, if patients do not see that offloading is improving their well-being and 
health, because of mobility restrictions and discomfort using the device (Brod 1998, 
Armstrong et al. 2001) they will behave in a way to avoid the treatment and will be seen 
by healthcare providers as noncompliant (German 1988, Murphy and Canales 2001). To 
overcome this negative connotation it is important that nurses understand how 
offloading affects patients’ lives and if they have the necessary environmental and 
psychological support to deal with the difficulties inherent to offloading (German 1988, 
Murphy and Canales 2001). Furthermore, in collaboration with the patient and family, 
nurses need to give a clear explanation on how offloading might help patients restore 
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their health and well-being, so that patients perceive themselves as part of the process of 
decision making and that there is a joint responsibility in this process (German 1988, 
Murphy and Canales 2001). 
From the included studies, only three analysed compliance in terms of device 
acceptance (Caravaggi et al. 2000, Piaggesi et al. 2007, Dumont et al. 2009). 
 
5.4.2.4. QoL 
QoL is the way individuals see and assess the impact that their physical, psychological, 
social, and economic well-being has in their life, and it is dependent on the way each 
domain influences each other (WHO 1997). Currently research is mainly focused in 
treatment efficacy and cost-effectiveness (Moore 2009). However, it is important to 
understand patient’s experience of the treatment (Moore 2009), in this case offloading 
and also the impact that DFUs have in their life, in order to develop a better and more 
focused delivery of care. 
QoL issues were not addressed in any of the studies reviewed. According to other 
qualitative studies (Brod 1998, Vileikyte 2001, Vileikyte et al. 2004) DFUs affect 
patients QoL mainly in terms of mobility, which further impacts patients’ daily 
activities. Therefore, from the lack of results it is possible to recommend that future 
studies include QoL assessment for a better understanding of the impact that DFUs and 
offloading devices have on patient’s life. Additionally, one may deduce that if 
offloading and DFUs affect QoL this might influence compliance rates, thus affecting 
treatment outcomes, however, research is need to support this. 
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5.5. Summary and Conclusion 
In terms of the methodological issues in the studies included, these were mainly related 
with risk of bias. In relation to outcome measures analysed in this SR it is possible to 
conclude that offloading is an effective method for the treatment of DFUs. From the 
devices available TCCs seem to be the most effective in terms of healing rates, times 
and reduction in ulcer size, closely followed by iTCCs and RCWs. However, these can 
cause adverse effects mainly infection and maceration. Moreover, although devices, 
especially TCCs, seem to be costly for the current economic climate, in the long term, 
due to their high efficacy, costs might be reduced as more ulcers are healed in a shorter 
period of time. Besides cost issues, compliance and QoL are two variables also 
important for offloading to be acceptable for patients. However, these were rarely 
alluded to in the studies. Thus, more research relating to cost analysis, compliance and 
QoL is needed. 
 
5.6. Strengths and Limitations of this SR 
This SR followed and reported on all the steps necessary to conduct a SR as highlighted 
in appendix 57. Furthermore, it thoroughly reported on the search strategy implemented 
so that it can be replicated. However, in its search strategy, this SR focused on studies in 
English and/or Portuguese as these were the only languages known by the writer. This 
can be identified as language bias, because other important studies written in other 
languages could have been included and may have brought new information or evidence 
to the current body of knowledge around offloading for the treatment of DFUs. 
However, the writer did not have financial support for conducting this SR, which, if 
available, could have been used for the translation of research studies in other 
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languages. Another limitation of this SR is the fact that it was not possible to conduct 
meta-analysis as the RCTs retrieved were too disparate. 
 
5.7. Contributions of this SR 
This SR had the objective of identifying the most effective offloading device in the 
treatment of DFUs, identifying the strengths and limitations of the different offloading 
devices in the studies reviewed and to determine the impact that offloading devices have 
in the patient QoL. From what has been reviewed it is possible to say that TCC is the 
most effective offloading device in terms of percentage of ulcers healed and time to 
heal. However, other offloading devices like iTCCs and RCWs are also effective in the 
treatment of DFUs. This is corroborated by the IWGDF guidelines (2012) that 
recommend the use of TCCs and other casts for the treatment of DFUs. Nonetheless, 
they add that the use of these casts should be done when ulcers are present in the plantar 
aspect of the foot. In the studies reviewed the majority of the ulcers were plantar.  
Although this SR has not unearthed new evidence relating to offloading for the 
treatment of DFUs, it has showed and confirmed that casting is the first line of choice 
for the treatment of DFUs; that other devices such as therapeutic shoes, orthoses and 
felted foam are also of value, but might be more effective as a prevention measure. 
Furthermore, this SR showed that few RCTs and SRs of RCTs have been conducted to 
analyse and compare the effectiveness of offloading devices for the treatment of DFUs. 
Moreover, studies need to address other factors such as cost, compliance and QoL. 
These factors are of importance not only for clinical practice and management, but also 
for patients.  
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Research is fundamental for health and social gain so that a better understanding of the 
factors that influence changes in social structures that in turn will promote healthier 
environments for the population, is gained (DoHC 2003). DFUs as a consequence of 
diabetes are a health problem that hinders peoples’ health, QoL, social activity and 
financial stability. Through this SR, it is apparent that offloading as a treatment strategy 
needs to be put into practice. Nurses need to be aware of best practice in terms of the 
treatment of DFUs, so that they can refer their patients to specialist services which in 
turn will provide patients with best clinical practice. Further, it is important that on 
referral, such modalities are available for the management of DFUs. If best practice is 
implemented then patients can expect that all negative factors derived from DFUs that 
might impact on their life will be addressed, thus promoting better life conditions 
allowing patients to have a healthier and enhanced QoL. 
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Chapter 6.Summary and Conclusion of this SR 
6.1. Introduction 
This chapter will present and overall summary and conclusion of this SR. 
 
6.2. Summary and Conclusion 
Diabetes is a chronic disease, its prevalence in the Irish population is around 6% and it 
is growing (IDF 2012b).  As the number of people suffering from diabetes increases the 
incidence of its complications also increase (IDF 2012a, WHO 2012).  Diabetes causes 
tissue damage in the small and large bloods vessels that with time can develop into 
PVD, neuropathy and other complications (IDF 2012a, WHO 2012). Neuropathy and 
PVD play a primary role in the development of DFUs, another complication of diabetes 
(Laing 1998, Reiber et al. 1998, Boulton 2004b, Cavanagh et al. 2005). Neuropathy is 
characterised by nerve damage causing loss of protective sensation in the foot, whilst 
PVD leads to an impaired blood supply of the foot (Laing 1998, Boulton 2004a, Bakker 
et al. 2012). These two risk factors, in combination with trauma, foot deformities, 
callus, oedema, inappropriate footwear or pressure will contribute to skin breakdown 
and the progression of a small wound to a wider and deeper ulcer (Reiber et al. 1998, 
Boulton 2004b, Lavery et al. 2008). Although these factors are all important, pressure is 
a factor always present and will promote the development or maintenance of DFUs (van 
Deursen 2004). Pressure results in the mechanical loading of the foot in its entire 
surface, though this pressure concentrates more in the plantar aspect of the foot (van 
Deursen 2004). Therefore, offloading is a treatment intervention that will promote the 
redistribution of pressure in the feet. To achieve this various offloading devices can be 
used from orthoses, therapeutic shoes and casts. From these TCC appears in the 
literature as the “gold standard” for the treatment of DFUs (Boulton 2004a).  
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In order to analyse the efficacy of offloading devices for the treatment of DFUs and 
determine which device has better outcomes, a SR was conducted. This method was 
chosen because it is at the top of the hierarchy of evidence, as SRs summarise, analyse, 
interpret and report the results of a group of research in the same topic, either from 
qualitative or quantitative research (Cook et al. 1997, Mulrow et al. 1997, Watson et al. 
2008, McGowan 2012). This type of research is key as it will allow nurses to access 
best evidence information that can not only allow for EBP, but also for evidence based 
clinical decisions that are crucial for the quality of nursing care (Sackett et al. 1996, 
ABA 2007, Holland and Watson 2012). 
 
From the analysis of the studies retrieved for this SR it is evident that TCC is the best 
offloading device for the treatment of DFUs, followed by iTCCs and RCWs. It was not 
possible to conduct meta-analysis of the nine RCTs retrieved, because their methods 
and interventions where not similar. The results of the SR will inform clinical practice 
providing nurses with the evidence to develop guidelines and awareness through 
educational practices in their clinical area. Through this diabetic patients, in any service, 
that are identified as having a DFU can be promptly referred to a specialist nurse and 
offloading can be initiated to help in the treatment and management of DFUs. 
Furthermore, although this SR has not unearthed new information, it gives a clear 
insight into the need of conducting RCTs that address the risk of bias with more care, as 
this can hinder the quality of the study and consequently the results (Higgins and Green 
2011). 
It is already well established that offloading is an important strategy for the treatment of 
DFUs however it is necessary to develop more research around the impact that this 
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method has on health related QoL and compliance. These two domains will influence 
the impact of offloading in the treatment of DFUs (Armstrong et al. 2003). Further, 
such research can help to understand how patients view this treatment which could, in 
turn, allow for the development of new devices that will consider and address the 
restrictions that the current devices impose on patients. 
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Appendix 1: Offloading Devices 
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Casts: 
 Total Contact Casts (TCC) is a close fitting cast applied over minimal padding. 
Its advantages are redistribution of pressure, enforcing compliance, reducing 
oedema, and allowing for faster healing times. Some of its disadvantages are: it 
cannot be removed preventing a daily ulcer check, it reduces mobility, iatrogenic 
lesions are difficult to detect, it may lead to muscle wasting and weakness due to 
prolonged immobilisation. 
 Scotchcast Boot can be used for neuroischaemic ulcers and is effective in 
reducing pressure on the plantar surface and margins of the foot. 
 Removable Cast Walkers (RCW) like the Aircast is a device with two halves 
that are joined together with strapping, and it has air chambers that can be 
inflated to allow a comfortable fit. This cast allows for foot inspection, it is an 
immediate offloading device and can be reused. In terms of disadvantages they 
cannot accommodate severe deformity and it is easy to remove making 
compliance a challenge.  
(Edmonds et al 2008: 85-95, Spencer 2008). 
 
Therapeutic Shoes:  
 Dressing Shoes: can accommodate feet that need large dressings 
 Weight Relief Shoes:  
o  Orthowedge: is a shoe that allows offloading from metatarsal heads and 
toes, with a rocker-bottom wedge; 
o Forefoot-Relief: is a shoe that redistributes weight from the forefoot to 
the hindfoot and has a semi-rigid heel to provide stability; 
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o Heel Relief Shoe: is a shoe that offloads the posterior end of the foot, 
and transfers weight from the heel to the midfoot and forefoot; 
o Half Shoe: is a shoe were its front is cut to allow pressure relief on the 
forefoot and the posterior area of the sole is also cut for pressure relief of 
the hindfoot. 
(Edmonds et al 2008: 85-95, Spencer 2008). 
 
Orthoses:  
 Special made Insoles: are used in therapeutic shoes or in conventional footwear 
that besides cushioning also redistribute pressure and can be made of cork and 
other materials; 
 Patellar tendon weight-relieving Orthoses: is a patellar tibial brace where total 
offloading is possible while maintaining a moderate degree of mobility; 
 Ankle-Foot Orthoses: is a device that stabilises the foot and ankle. 
(Edmonds et al 2008: 85-95, Spencer 2008). 
 
Felt Padding or Felted Foam: are used to relief pressure from ulcers and can be lifted 
for ulcer examination however, they do not substitute therapeutic footwear and should 
not cover a large area that could prevent complications from being noticed (Edmonds et 
al 2008: 85-95, Spencer 2008). 
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Appendix 2: Search Strategy in CINAHL database 
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CINAHL SEARCH 
Limits: Research Article and Language – English/Portuguese 
MeSH Diabetic Foot 
AND 
(MeSH Orthoses+ OR 
MeSH Foot Orthoses) 
MeSH Diabetic 
Foot 
AND 
MeSH Shoes+ 
 
MeSH Diabetic 
Foot 
AND 
MeSH Casts 
 
171 147 337 
46 44 89 
Titles of all articles were read 
15 24 16 
From a total of 55 articles 43 will be considered 
From the 43 articles, 24 
were also found in the other 
searched data bases 
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Appendix 3: Search Strategy in MEDLINE database 
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MEDLINE SEARCH 
Limits: Language – English/Portuguese 
MeSH Diabetic Foot 
AND 
(MeSH Orthotic Devices+ 
OR MeSH Foot Orthoses) 
MeSH Diabetic Foot 
AND 
MeSH Shoes+ 
 
MeSH Diabetic Foot 
AND 
MeSH Casts, 
Surgical 
 
116 110 
351 
103 104 35 
Titles of all articles were read 
28 26 15 
Limits: CCT, Meta-Analysis, RCT, 
Language – English/Portuguese 
Limits: Language – 
English/Portuguese 
293 
From a total of 69 articles 57 will be considered 
From the 57 articles, 33 
were also found in the other 
searched data bases 
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Appendix 4: Search Strategy in EMBASE database 
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EMBASE SEARCH 
Limits: Research Article  
MeSH Diabetic Foot+ 
AND 
(MeSH Orthosis+ OR 
MeSH Foot Orthosis+) 
MeSH Diabetic Foot+ 
AND 
MeSH Shoes+ 
 
MeSH Diabetic Foot+ 
AND 
MeSH Plaster Cast+ 
 
164 111 
509 
84 62 48 
Titles of all articles were read 
8 10 8 
From a total of 26 articles 23 will be considered 
From the 23 articles, 20 
were also found in the other 
searched data bases 
Limits: CCT, RCT, Prospective Study 
and Retrospective Study 
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Appendix 5: Search Strategy in COCHRANE LIBRARY database 
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COCHRANE LIBRARY 
SEARCH 
MeSH Diabetic Foot+ 
AND 
*MeSH Orthotic Devices+ 
 
MeSH Diabetic Foot+ 
AND 
MeSH Shoes+ 
 
MeSH Diabetic Foot+ 
AND 
MeSH Casts, Surgical+ 
 
13 17 42 
Titles of all articles were read 
7 12 14 
From a total of 33 articles 19 will be considered 
From the 19 articles, 18 
were also found in the other 
searched data bases 
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Appendix 6: Search Strategy in WEB OF KNOWLEDGE database 
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WEB OF KNOWLEDGE 
SEARCH 
Limits: Research Article and Language – English/Portuguese 
MeSH Diabetic Foot 
AND 
(MeSH Orthoses OR MeSH 
Foot Orthoses) 
 
MeSH Diabetic Foot 
AND 
MeSH Shoes 
 
MeSH Diabetic Foot 
AND 
MeSH Casts 
 
50 64 312 
42 54 242 
Titles of all articles were read 
2 16 16 
From a total of 34 articles 31 will be considered  
From the 31 articles, 21 
were also found in the other 
searched data bases 
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Appendix 7: Data Extraction Table  
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Data Extraction Table 
Author and  
Date of 
Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics 
of Wound 
Inclusion/ 
Exclusion Criteria 
Sample size 
         
Patient 
Characteris
tics 
Design 
Details 
Study Type Allocation 
Intervention 
Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
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Appendix 8: Data Extraction Table for Included Systematic Reviews 
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Data Extraction Table for Included Systematic Reviews 
 
Review 
Author 
Data Assessed as 
up to date 
Title  Source 
Geographical 
Location 
Population 
Intervention and 
Comparison Interventions 
Outcomes for which Data 
was Reported 
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Appendix 9: EBL Critical Appraisal Checklist 
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Appendix 10: Quality Appraisal of Systematic Reviews 
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Steps for Conducting Systematic Reviews 
Systematic Review 
Yes 
(Y) 
No 
(N) 
Comment 
Background    
Research Question    
Aim    
Objectives    
Criteria for selecting studies for review: 
Types of studies 
Types of participants 
Types of interventions 
Types of outcome measures 
 
  
 
  
 
  
 
   
Search methods for identification of studies 
  
 
Data collection    
Data analysis    
Results: 
Description of studies 
Risk of bias in included studies 
Effects of interventions 
   
   
  
 
   
Discussion    
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Appendix 11: Table of Included Studies 
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Study Title  
Armstrong  et 
al (2001) 
Off-Loading the Diabetic Foot Wound: a randomized control trial. 
Armstrong et al 
(2005) 
Evaluation of Removable and Irremovable Cast Walkers in the Healing of 
Diabetic Foot Wounds.  
Birke et al  
(2002) 
Comparison of forefoot ulcer healing using alternative off-loading 
methods in patients with diabetes mellitus. 
Caravaggi et al 
(2000) 
Effectiveness and safety of a nonremovable fiberglass off-bearing cast 
versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a 
randomized study. 
Dumont et al 
(2009) 
 
A proof-of-concept study of the effectiveness of a removable device for 
offloading in patients with neuropathic ulceration of the foot: the Ransart 
boot. 
Faglia et al  
(2010) 
Effectiveness of removable walker cast versus nonremovable fiberglass 
off-bearing cast in the healing of diabetic plantar foot ulcer: a randomized 
controlled study. 
Katz et al  
(2005) 
 
A randomized trial of two irremovable off-loading devices in the 
management of plantar neuropathic diabetic foot ulcers 
Mason et al 
(1999) 
A systematic review of foot ulcer in patients with type 2 diabetes 
mellitus. II: treatment. 
Mueller et al  
(1989) 
Total contact casting in treatment of diabetic plantar ulcers: controlled 
clinical trial 
Nabuurs-
Franssen et al 
(2005) 
Total contact casting of the diabetic foot in daily practice: a prospective 
follow up study. 
Piaggesi et al  
(2007) 
 
An off-the-shelf instant contact casting device for the management of 
diabetic foot ulcers: a randomized prospective trial versus traditional 
fiberglass cast. 
Spencer (2008) 
 
Pressure relieving interventions for preventing and treating diabetic foot 
ulcers: review. 
Van De Weg et 
al (2008) 
Wound healing: total contact cast vs. custom-made temporary footwear 
for patients with diabetic foot ulceration. 
Zimny et al  
(2003) 
The effects of applied felted foam on wound healing and healing times in 
the therapy of neuropathic diabetic foot ulcers. 
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Appendix 12: Table of Excluded Studies with reasons 
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Study Reason for Exclusion 
Agas et al 
(2006) 
Main objective assessment of safety and efficacy of topical recombinant 
human platelet-derived growth factor in the treatment of diabetic 
neuropathic foot ulcers. 
Armstrong et al 
(2008) 
Focused on the impact of offloading on health-related quality of life. 
Boulton et al 
(1986) 
Case studies investigating the value of walking casts.  
Caravaggi et al 
(2007) 
Patients with Charcot neuroarthropathy deformities included in the 
sample. 
Gutekunst et al 
(2011) 
Primarily assessing reduction in foot load. 
Ha Van  et al 
(2003) 
Patients with Charcot neuroarthropathy deformities included in the 
sample. 
Holstein et al 
(1976) 
No clearly stated objectives, outcome measures and statistical analysis. 
Knowles & 
Boulton (1996) 
Study assessing satisfaction and usage of footwear. 
Laing et al 
(1991) 
From a sample of 46 patients, 10 had other disorders than diabetes. 
Myerson et al 
(1992) 
Neuropathic ulcers due to other causes (alcoholism, hereditary motor and 
sensory neuropathy and pathological conditions involving the spinal 
cord. 
Saltzman et al 
(2004) 
Patients with Charcot neuroarthropathy deformities included in the 
sample. 
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Appendix 13: Data Extraction Table Armstrong et al 2001 
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Data Extraction Table 
Author and  
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics 
of Wound 
Inclusion/ 
Exclusion Criteria 
Sample size 
 
 
Armstrong et al  
 
 
2001 
 
 
 
 
 
 
Off-loading the 
diabetic foot 
wound: a 
randomized clinical 
trial 
Diabetes Care USA  
 
 
 
 
 
 
Compare the 
effectiveness of 
TCC, RCW and 
half-shoes to heal 
neuropathic foot 
ulcers 
Health Care 
Setting not 
clearly 
mentioned 
Neuropathic foot 
ulcers 
 
All patients: 
Mean ulcer size 
(cm
2
) 1.3; mean 
ulcer duration 
(months) 5.2; 
Inclusion: Loss of 
protective sensation 
(>25V), at least one 
palpable foot pulse, 
TcPO2 >40mmHg, 
neuropathic DFU 
grade 1A 
(UTDFWCS), when 
there was more than 
one plantar ulcer 
present only the 
largest was used for 
inclusion 
 
Exclusion: Active 
infection, unable to 
walk without 
wheelchair 
assistance, wounds 
on the heel, rear foot, 
or other area than the 
plantar aspect of the 
foot, severe 
63 diabetic patients 
 
TCC: 19 
 
RWC: 20 
 
Half-shoe: 24 
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peripheral vascular 
disease. 
Patient 
Characteristics 
Design Details Study Type Allocation 
Intervention 
Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
All patients: 
Male 82.5%; 
duration of 
diabetes (years) 
16.9; TcPO2 
60.4; vibration 
perception 
threshold 
(Volts) 44.6 
 
 
 
 
 
 
 
 
Three-arm 
prospective RCT 
 
Randomisation 
Sequence: subjects 
were randomised 
through a 
computerised 
randomisation 
schedule, and this 
was preformed after 
initial screening. 
Quantitative  Blinding and 
concealment of 
allocation not 
mentioned  
19 subjects used 
TCC 
 
20 subjects used 
RCW 
 
24 subjects used 
half-shoes 
 
Subjects followed 
on a weekly basis 
for device 
inspection, wound 
care an 
debridement 
 
Ulcers were 
measured using 
computerized 
planimetric video 
wound system 
 
Subjects wore a 
pedometer that 
was calibrated at 
beginning of 
study and number 
Primary 
outcome 
measures were 
proportion of 
complete 
wound healing 
at 12 weeks 
and activity. 
An analysis of 
variance with 
Tamhane’s post-
hoc test for 
multiple 
comparisons was 
used to evaluate 
all continuous 
variables between 
off-loading 
groups. The effect 
of continuous 
variables on 
healing in general 
was evaluated 
using a Mann-
Whitney U test. 
Dichotomous 
variables were 
evaluated with an 
X
2
 -test with odds 
ratio and 95% CI. 
To evaluate the 
 Proportion of 
healing was 89.5% 
with TCC, 65% 
with RCW and 
58.3% with half-
shoes 
 At 12 weeks the 
proportion of 
healing was 
significantly higher 
in the TCC group 
 The mean time for 
healing within the 
12 weeks period 
was significantly 
shorter in the TCC 
group compared 
with the half-shoes 
group, but not with 
the RCW group 
 Subjects in the 
TCC group were 
significantly less 
active than those in 
the half-shoes 
group 
 There was no 
Conclusion 
The study concludes 
that TCC heal a higher 
proportion of wounds 
in a shorter amount of 
time based on the 
results obtained. 
Moreover the results 
show that patients are 
less active when using 
TCC than with the 
other devices. 
Recommendation 
More work in this area 
is needed to assess 
various treatments and 
to provide clinician 
with evidence to make 
informed treatment 
decisions. 
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of steps was 
recorded at each 
visit 
healing 
characteristics of 
each device as a 
function of weeks 
of therapy and 
mean time to 
closure among 
patients healing 
within the 12-
week study 
period, a Kaplan-
Meier life-table 
analysis (log-rank 
test) was used. 
Using the above 
analyses, a 
difference of 
40% between any 
two arms could be 
detected with a 
sample size of 60 
yielding a power 
exceeding 80%. 
For all analyses a 
α of 0.05 was 
used. 
significant 
difference in 
activity levels 
between the RCW 
and TCC group or 
between the RCW 
and the half-shoe 
group 
 No falls or 
cast/device  related 
ulceration was 
reported during the 
study 
 
 
172 
 
Appendix 14: Data Extraction Table Armstrong et al 2005 
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Data Extraction Table 
Author and  
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics of 
Wound 
Inclusion/ 
Exclusion Criteria 
Sample size 
 
 
Armstrong et al  
 
 
2005 
 
 
 
 
 
 
Evaluation of 
removable and 
irremovable cast 
walkers in the 
healing of 
diabetic foot 
wounds: a 
randomized 
controlled trial  
Diabetes Care USA 
 
Evaluate efficacy 
of a traditional 
RCW and iTCC 
to heal 
neuropathic foot 
ulcers 
Health Care 
Setting not 
clearly 
mentioned 
Neuropathic foot 
ulceration 
 
All patients: mean 
ulcer size 2.3cm
2
. 
Inclusion: loss of 
protective sensation, at 
least one palpable foot 
pulse, neuropathic 
plantar foot ulcer 
University Texas stage 
IA, when there was 
more than one plantar 
ulcer present only the 
largest was used for 
inclusion 
 
Exclusion: Active 
infection, unable to 
walk without a 
wheelchair, with 
wound in locations on 
the heel, rearfoot, or 
other than the plantar 
aspect of the foot, with 
severe peripheral 
vascular disease 
50 diabetic patients 
 
iTCC: 23 
 
RCW: 27 
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Patient 
Characteristics 
Design Details Study Type Allocation 
Intervention 
Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
All patients: 
mean age 
(years) 65.6; 
male 88%; BMI 
33.4; vibration 
perception 
threshold (volts) 
37.1; HbA1c 
8.2%. 
 
 
 
 
 
 
 
 
 
 
Two-arm RCT 
 
Randomisation 
Sequence: 
subjects were 
randomised 
through a 
computerised 
randomisation 
schedule. 
Randomisation 
was performed 
after initial 
screening, with 
allocation 
provided to the 
treating 
clinician by a 
single study 
coordinator via 
telephone. 
Quantitative Blinding and 
concealment of 
allocation not 
mentioned. 
23 subjects were 
assigned the iTCC 
 
27 subjects were 
assigned the 
RCW 
 
Subjects were 
followed on a 
weekly basis for 
ulcer care and 
debridement, cast 
inspection 
 
No clear 
mention of 
primary or 
secondary 
outcomes. 
 
Main objective 
ulcer healing. 
The influence of the 
effect of continuous 
variables on healing 
in general, were 
evaluated with a 
Mann-Whitney U 
test. Dichotomous 
variables were 
evaluated with an X
2
 -
test with odds ratio 
(OR) and 95% CI. 
To evaluate the 
healing 
characteristics of 
each device as a 
function of weeks of 
therapy and mean 
time to closure 
among patients 
healing within the 12-
week study period, 
we used a Kaplan-
Meier life table 
analysis (log-rank 
test). With the above 
analyses, a difference 
of 40% between 
groups could be 
 From the 50 
subjects, 4 did not 
complete the course 
of study and were 
considered treatment 
failures in the 
intention-to-treat 
analysis 
 Higher proportion of 
subjects healed at 12 
weeks in the iTCC 
group 82.6%/19 
compared with 
51.9%/14 in the 
RCW group 
 The subjects whose 
ulcers healed during 
the study period, 
those in the iTCC 
group healed sooner 
41.6 ±18.7days 
compared with the 
RCW, 58.0±15.2 
days 
 No falls and no re-
ulcerations related to 
the casts 
 More subjects in the 
iTCC group 
presented with at 
least one episode of 
peri-wound 
maceration than 
Conclusion: The 
application of a wrap 
around a traditional 
RCW, improves both 
the proportion and 
rate of wound healing 
by preventing 
patients from 
removing the device. 
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detected with a 
sample size of 18 per 
group, yielding a 
power exceeding 
80%. For all 
analyses, we used an 
α value of 0.05. 
those of the RCW 
group 
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Appendix 15: Data Extraction Table Birke et al 2002 
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Data Extraction Table 
Author and  Date of 
Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care 
Setting 
Type and 
Characteristics of 
Wound 
Inclusion/ 
Exclusion Criteria 
Sample size 
 
 
Birke et al  
 
2002 
 
 
 
 
 
Comparison of 
forefoot ulcer 
healing using 
alternative off-
loading methods 
in patients with 
diabetes mellitus 
Advances in 
Skin and 
Wound Care 
USA Compare the 
healing rate of 
forefoot ulcers in 
patients with 
diabetes treated 
using a total contact 
cast with those 
treated using 
alternative 
offloading methods. 
Louisiana 
State 
University 
Health 
Sciences 
Centre 
Diabetes 
Foot 
Program 
 
Diabetic forefoot 
ulcers 
 
Accommodative 
dressing: mean ulcer 
duration (days) 
149.2; mean Wagner 
Grade 1.8; mean 
length/width/ depth 
(cm) 1.3/0.9/0.4. 
 
Healing shoe: mean 
ulcer duration (days) 
67.9; mean Wagner 
Grade 1.7; mean 
length/width/ depth 
(cm) 1.2/0.7/0.3. 
Walking splint: 
mean ulcer duration 
(days) 98.6; mean 
Exclusion: 
Patients with 
postoperative 
wounds, recurrent 
ulceration, non-
plantar, midfoot, or 
rear foot ulcers, 
wound abscess, 
osteomyelitis with 
radiologic evidence 
of bone destruction 
and ischemic 
wounds. 
120 patients 
 
Accommodative 
dressing: 26 
 
Healing shoe: 57 
 
Walking splint: 18 
 
TCC: 13 
 
Other: 6 
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Wagner Grade 1.8; 
mean length/width/ 
depth (cm) 
1.6/1.1/0.5. 
 
TCC: mean ulcer 
duration (days) 
183.9; mean Wagner 
Grade 2.2; mean 
length/ width/depth 
(cm) 1.4/0.9/0.6. 
 
Other: mean ulcer 
duration (days) 
150.7; mean Wagner 
Grade 1.8; mean 
length/ width/depth 
(cm) 1.6/1.0/0.6. 
Patient 
Characteristics 
Design Details Study Type Allocation 
Intervention 
Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
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Accommodative 
dressing: female 
65%; mean age 
(years) 57.5. 
 
Healing shoe: female 
54%; mean age 
(years) 58.2. 
 
Walking splint: 
female 22%; mean 
age (years) 56.5. 
 
TCC: female 43%; 
mean age (years) 
47.3. 
 
Other: female 67%; 
mean age (years) 
56.8. 
 
 
Retrospective 
study. 
 
Medical records 
of 120 patients 
were 
retrospectively 
reviewed. 
Quantitative  None Patients with 
diabetic foot ulcers 
were offloaded with 
one of the 
following: 
accommodative 
dressing, healing 
shoe, walking 
splint, a total 
contact cast (TCC), 
or a combination of 
these methods 
(other). 
 
Accommodative 
dressing: 6-inch-
long piece of 
quarter-inch-thick 
adhesive felt 
attached to the 
forefoot with a cut 
out over the ulcer 
area. The foot with 
the accommodative 
dressing was fit in a 
surgical shoe 
modified with a 
half inch wedged 
sole to promote 
heel weight 
Study 
outcome was 
ulcer healing 
time. 
Analysis was done 
using a lognormal 
regression model 
where logn (healing 
time) was used as the 
dependent variable. 
 
 One hundred and 
thirteen of 120 
(94%) patients 
with forefoot 
ulcers healed in 
an average time 
of 45.5 ± 43.4 
days.  
 Seven of 120 
(5.8%) patients 
with ulcers either 
did not heal or 
were lost to 
follow-up. 
 Healing time was 
lower in the 
accommodative 
dressing 
compared with 
the healing shoe 
or the walking 
splint 
 Forefoot ulcers 
were closed 
within 12 weeks 
in at least 81% of 
the cases, 
irrespective of 
offloading 
Conclusion: The 
healing rate of 
forefoot ulcerations 
using alternative off-
loading methods or a 
TCC appeared to be 
comparable when the 
method was selected 
based on location of 
ulcer, patient age and 
duration of 
ulceration. 
 
Recommendation: 
Further investigation 
to determine the 
effect of the 
accommodative 
dressing and the 
surgical shoe in ulcer 
healing. 
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bearing. 
Healing shoe: 
surgical shoe 
modified with a 
quarter-inch non-
polyethylene foam 
inlay, a relief cut 
under the ulcer 
area, and a half-
inch wedged sole. 
 
Moisture retentive 
dressings, including 
a hydrogel, saline-
moistened gauze, 
alginate, or 
hydrocolloid, were 
applied to all 
wounds except 
those receiving the 
total contact cast 
and the 
accommodative 
dressing. 
 
Dry dressings were 
used with the total 
contact cast and the 
method. 
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accommodative 
dressing. 
Accommodative 
dressings were 
changed weekly; 
total contact casts 
were changed at 1- 
to 2-week intervals, 
depending on the 
amount of drainage. 
 
Patients who were 
not treated with the 
total contact cast 
were instructed in 
daily dressing 
changes and were 
followed at weekly 
intervals for re-
evaluation and 
wound 
debridement.  
 
The specific 
dressings or topical 
agents used were 
not controlled. 
 
182 
 
Appendix 16: Data Extraction Table Caravaggi et al 2000 
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Data Extraction Table 
Author and  
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics 
of Wound 
Inclusion/ 
Exclusion Criteria 
Sample size 
 
 
Caravaggi et al  
 
2000 
 
 
 
 
 
Effectiveness and 
safety of a non-
removable 
fiberglass off-
bearing cast versus 
a therapeutic shoe 
in the treatment of 
neuropathic foot 
ulcers: a 
randomized study 
Diabetes Care Italy 
 
 
 
 
 
Compare 
effectiveness of using 
the non-removable 
total off-loading cast 
made with fibreglass 
bandages or 
therapeutic shoes 
with rigid rocker-
bottom sole with 
unloading insole in 
the treatment of 
neuropathic plantar 
ulcers 
Health Care 
Setting not clearly 
mentioned 
Neuropathic 
plantar ulcers 
Inclusion: 
Neuropathic plantar 
ulcers, insensitivity 
to Semmes-
Weinstein 5.07 
monofilament and 
vibration perception 
threshold of 25V 
(measured on the 
malleolus with 
biothesiometer. 
 
Exclusion: Deep or 
superficial tissue 
infection, 
osteomyelitis, 
TcPO2 30mmHg, 
equilibrium 
problems, severe 
visual deficit, other 
skin lesions of the 
foot or leg, 
amputation of a 
50 diabetic patients 
 
Therapeutic shoe: 
24 
 
Fiberglass cast: 26 
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limb, plantar 
bilateral ulcers. 
Patient 
Characteristics 
Design Details Study Type Allocation Intervention Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
Shoe group: 
Mean age(years) 
59.2; male 16, 
female 8; 
insulin 
requirement 12; 
diabetes 
duration(years) 
16.2; prior 
ulcers 9; BMI 
27.3; smoking 
10; hypertension 
11; retinopathy 
13; ABI 1.03; 
transcutaneous 
oxygen tension 
on dorsum of 
the foot 52.6. 
Cast group: 
Mean age(years) 
60.5; male 18, 
female 8; 
Two-arm RCT 
 
Randomisation 
Sequence: subjects 
were assigned by 
phone to one of two 
pre-randomized 
treatment groups. 
The randomisation 
required that a 
patient was 
assigned to one of 
the groups by 
calling the 
Biometrics 
Institute, University 
of Milan, where a 
table of random 
numbers was 
consulted. 
Quantitative Blinding and 
concealment 
of allocation 
not mentioned 
24 patients received 
therapeutic shoe 
(cloth therapeutic 
shoe with rocker-
bottom sole and a 
rolling point situated 
under the metatarsal 
arch) 26 patients 
received fibreglass 
off- bearing cast 
(fiberglass bandages 
of two types: one was 
composed of 
fiberglass 
impregnated with a 
polyurethane resin 
with characteristics of 
flexibility and 
resistance; the second 
was composed of 
fiberglass 
impregnated with a 
polyurethane resin of 
two different 
concentrations that 
confers high 
resistance to loading)  
Primary outcome 
measure was to 
evaluate and 
compare the rate 
of reduction of the 
surface area of 
neuropathic 
plantar ulcers in 
diabetic patients 
treated with non-
removable 
rigidity-
differentiated 
fiberglass off-
bearing casts or a 
cloth shoe with a 
rigid sole with 
unloading 
alkaform insoles.  
 
Secondary 
outcome measure 
Mean values 
and standard 
deviations were 
calculated for all 
variables 
measured. 
Pearson X
2
 –test 
was used to 
compare the 
rates of events 
in the two 
groups and the 
Student’s t- test 
was used to 
compare the 
averages of 
continuous 
variables to 
follow the 
Gaussian 
distribution. 
Response rate 
was subdivided 
 Two patients in 
the group that 
used the 
therapeutic shoe 
presented an 
increase in ulcer 
size 
 No patient in the 
fibreglass off-
bearing cast 
group has an 
increase in ulcer 
size 
 5 subjects of the 
therapeutic shoe 
group reached 
ulcer healing 
 13 subjects of the 
fibreglass off-
bearing cast 
group reached 
ulcer healing 
 There was a 
significantly 
faster reduction 
in ulcer size in 
the fibreglass off-
Conclusion: 
Therapeutic shoe 
was effective in the 
treatment of 
neuropathic plantar 
ulcers. However 
non-removable 
fiberglass bandages 
with variable 
flexibility and 
rigidity represent 
the elective 
treatment of 
neuropathic plantar 
ulcers. 
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insulin 
requirement 13; 
diabetes 
duration(years) 
17.3; prior 
ulcers 10; BMI 
27.0; smoking 
5; hypertension 
13; retinopathy 
14; ABI 1.00; 
transcutaneous 
oxygen tension 
on dorsum of 
the foot 53.5. 
 
 
 
 
 
 
Ulcer area was 
calculated at 
beginning of study 
and at the end of 30 
days. 
 
Ulcers were debrided 
and medicated with 
paraffin gauze 
dressing throughout 
the study period and 
dressings were 
changed every 2 
days. 
 
At the end of study 
patients were asked 
to evaluate 
acceptance of device 
by using a visual 
analogic scale 
ranging from 1 to 
100. 
was to evaluate 
the side effects 
and degree of 
patient acceptance 
of treatment. 
in quintiles of 
the percentages 
of healing of the 
ulcer surface, 
starting from 
complete 
healing (100%) 
and ranging to 
<20% of healed 
surface. The test 
for trend in the 
quintiles of 
response in the 
two treatment 
arms was done 
by the Mann-
Whitney two-
sample test for 
independent 
samples. 
bearing cast 
group 
(P=0.0004) 
 No side effects 
were observed in 
both groups 
 There was no 
difference in 
patient 
acceptance of the 
two treatments 
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Appendix 17: Data Extraction Table Dumont et al 2009 
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Data Extraction Table 
Author and  
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics 
of Wound 
Inclusion/ Exclusion 
Criteria 
Sample size 
 
 
Dumont et al  
 
2009 
(conducted 
between January 
2005 and June 
2008) 
 
 
 
A proof-of-
concept study of 
the effectiveness 
of a removable 
device for 
offloading in 
patients with 
neuropathic 
ulceration of the 
foot: the Ransart 
boot 
Diabetic 
Medicine  
Belgium and 
France 
To undertake a 
formal 
observational 
study of the 
effectiveness of 
the Ransart boot 
and to compare 
outcomes with 
published reports 
of the use of non-
removable cast 
devices 
Seven specialist 
units where non-
removable 
fiberglass cast was 
or not available or 
not common 
practice 
Diabetic foot 
ulcer on the 
plantar or lateral 
aspect of the 
foot 
Inclusion: aged 18-85; 
type 1 or 2 diabetes 
mellitus complicated 
with distal symmetrical 
neuropathy; presence 
of ulcer on the plantar 
or lateral aspect of the 
foot for more than 7 
days. 
Exclusion: active 
Charcot disease or if 
patients were receiving 
any therapy including 
negative pressure 
therapy, larvae, bone 
resection or 
revascularization. 
155 patients were 
included 
 
20 were excluded from 
analysis: 
14 recruited in error, 6 
underwent surgery 
except amputation 
during course of 
follow-up 
135 were part of the 
study 
Patient 
Characteristics 
Design Details Study Type Allocation 
Intervention 
Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
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Mean age 60.3 
(23-85 years 
old); diabetes 
duration 15.2 
(0-42 years); 
118 patients 
were diabetes 
mellitus type 2; 
96 were male; 
mean HbA1c 
7.7%, median 
creatinine 
concentration 
79µmol/l; mean 
ulcer duration 
before 
presentation was 
90 days; 97 
ulcers were on 
the forefoot, 20 
in the mid foot 
and 18 on the 
heel 
 
Seven of the 
135 patients 
were lost to 
follow-up, 
seven developed 
serious co-
Uncontrolled 
observational 
study 
Quantitative Not 
applicable. 
 
 
All patients wore 
the Ransart boot 
and ulcer 
dressings were 
managed 
according to the 
principles of the 
International 
Consensus on the 
Diabetic Foot, 
these dressings 
were not 
standardized and 
were chosen by 
the supervising 
clinician and 
changed as often 
as judged 
necessary. Each 
patient was 
reviewed weekly 
and the wound 
debrided as 
necessary and the 
boot changed as 
necessary. 
Patients were 
managed as 
outpatients, were 
instructed to wear 
the device every 
No clear distinction 
between primary 
and secondary 
outcome measures.  
 
Study mentions rate 
of healing, healing 
time and looks at 
incidence of 
amputation, and at 
correlation 
between: baseline 
ulcer classification 
and both time to 
healing and 
incidence of 
amputation; ulcer 
duration at 
presentation and 
time to healing, 
University of Texas 
(UT) classification, 
HbA1c and 
incidence of 
amputation.  
Adverse effects/ 
complications of 
Ransart boot. 
Spearman’s 
rank correlation 
was used for 
continuous 
variables and X
2
 
-test for 
dichotomous 
variables. 
Student´s t-test 
was used to 
compare two 
sample means 
 Ulcers in 82 of the 
remaining 117 
patients healed in 
60days. 
 In 22 cases ulcer did 
not heal until 
amputation. 
 There were 21 minor 
amputations and one 
major amputation. 
 There was a 
significant 
correlation between 
baseline ulcer 
classification and 
both time to healing 
(p< 0.001) and the 
incidence of 
amputation (p< 
0.001) 
 There was a positive 
correlation between 
ulcer duration at 
presentation and time 
to healing (p< 0.02), 
UT classification (p< 
0.01), HbA1c (p< 
0.02), and incidence 
of amputation (p< 
0.04). 
 No correlation 
between time to 
healing and age, 
gender, type of 
diabetes mellitus, 
Conclusions: 82 ulcers 
of the 135 patients 
healed with a median 
time to healing of 60 
days. Rate of healing 
was 97.8%. The rate of 
healing using the 
Ransart boot may be 
comparable with those 
achieved using a non-
removable device and 
may be cheaper and 
very much more 
acceptable to the 
patient. 
Recommendations: 
There is a need for a 
prospective comparison 
of the effectiveness, 
acceptability and costs 
of irremovable and 
removable casts in 
routine management. 
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morbidities, and 
four died, 
thirteen patients 
were judge non-
compliant. 
 
time they were on 
their feet and 
were encouraged 
to undertake 
normal activities. 
duration of diabetes, 
HbA1c, serum 
creatinine 
concentration and 
previous amputation. 
 No correlation 
between the 
incidence of 
amputation and age, 
gender, type of 
diabetes mellitus, 
duration of diabetes, 
HbA1c, serum 
creatinine 
concentration. 
 There were 11 minor 
complications while 
wearing the Ransart 
boot: 8 skin 
abrasions on the 
instep, 2 areas of 
redness in the 5
th
 
metatarsal head and 
1 blister on the heel. 
All complication 
healed quickly after 
slight changes in the 
boot. 
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Appendix 18: Data Extraction Table Faglia et al 2010 
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Data Extraction Table 
Author and  
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics 
of Wound 
Inclusion/ 
Exclusion 
Criteria 
Sample size 
 
 
Faglia et al  
 
 
 
2010 
 
 
 
 
 
 
 
Effectiveness of 
removable walker 
cast versus non-
removable 
fiberglass off-
bearing cast in the 
healing of diabetic 
plantar foot ulcer: a 
randomized 
controlled study 
Diabetes Care Italy 
 
 
 
 
Evaluate healing 
outcomes in 
diabetic patients 
managed with TCC 
and new removable 
off-loading device 
(Stabil-D) 
specifically 
designed for the 
management of 
neuropathic plantar 
foot ulcers. 
Two centres 
specialised in 
DFU management 
Neuropathic 
plantar ulcers 
Inclusion: 
Neuropathic 
plantar forefoot 
ulcer with 
University Texas 
stage IA. 
 
Exclusion: 
Presence of ankle-
brachial pressure 
index <0.9 and/or 
TcPO2<50mmHg, 
signs of infection, 
osteomyelitis, use 
of steroids or 
antibiotics, visual 
impairment, 
active foot on 
contra lateral foot, 
previous major 
amputation of 
contra lateral 
limb, previous or 
45 diabetic patients 
 
3 patients did not 
complete study and 
were considered 
dropouts 
 
TCC group: 23 
 
Stabil-D group: 22 
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current deep 
venous 
thrombosis of the 
leg, mental 
disorder 
interfering with 
compliance 
Patient 
Characteristics 
Design Details Study Type Allocation 
Intervention 
Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
TCC group: 
Mean age 
(years) 59.0; 
female 8, male 
15; diet 4, 
insulin 16, oral 
therapy 3; 
duration of 
diabetes (years) 
17.7; BMI 32.3; 
HbA1c 9.1%; 
previous foot 
ulcer 15; 
previous minor 
amputation 11; 
mean area of 
lesion (cm
2
) 1.4. 
Stabil-D group: 
Mean age 
(years) 61.7; 
Two-arm RCT 
 
Randomisation 
Sequence: subjects 
were randomised by 
opening 
randomisation code 
break envelopes 
containing one of 
the two options, 
then separate 
randomisation was 
performed for each 
centre, and a copy 
of all randomisation 
envelopes was kept 
at the statistical 
department of the 
Quantitative Blinding and 
concealment of 
allocation not 
mentioned 
23 subjects were 
assigned the TCC 
 
22 subjects were 
assigned the Stabil-
D 
 
Ulcers were 
debrided, measured 
with Visitrak 
system, 
photographed and 
dressed with 
paraffin gauze and 
covered with single 
sterile gauze 
 
Patients were 
followed-up weekly 
for 90 days and 
devices were 
removed and 
dressings changed 
at each visit. 
Primary outcome 
measure was 
decrease in ulcer 
size. 
 
Secondary 
outcome measure 
was rate of 
complete healing 
at study 
completion 
Homogeneity of 
the initial 
distribution of 
baseline primary 
variables between 
groups was tested 
using a Fisher 
exact test for 
dichotomous 
variables and 
Student´s t-test 
for continuous 
variables. The 
differences 
in ulcer size 
reduction between 
the two groups 
were compared 
using the 
Mann-Whitney 
test. The 
Wilcoxon test was 
used for analysis 
of ulcer size 
 In the TCC 
group one 
subject 
presented 
partial rupture 
of the stirrup 
and another 
presented 
hitching that 
resolved after 
removal of 
German cotton 
 In the Stabil-D 
group one of 
subjects 
complained of 
odour and 
presented peri-
ulcer skin 
maceration 
which resolved 
 In the TCC 
group ulcer size 
decreased from 
Conclusion: This 
study concludes 
that off-loading 
using the Stabil-D 
or using TCC are 
equally effective in 
the treatment of 
neuropathic 
forefoot plantar 
ulcers. 
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female 7, male 
15; diet 5, 
insulin 10, oral 
therapy 7; 
duration of 
diabetes (years) 
17.2; BMI 30.3; 
HbA1c 7.5%; 
previous foot 
ulcer 15; 
previous minor 
amputation 12; 
mean area of 
lesion (cm
2
) 2.2. 
 
 
Multimedica centre 
 
reduction over 
time within 
groups. Healing 
rate over time was 
analysed by the 
Kaplan-Meier test 
and the log-rank 
test were used to 
detect differences 
between the two 
groups. 
1.41 to 0.21cm
2
 
 In the Stabil-D 
group ulcer size 
decreased from 
2.18 to 0.45cm
2 
 
 73.9% of 
subjects in the 
TCC group 
achieved 
complete 
healing and the 
same happened 
in 72.7% of 
subjects in 
Stabil-D group 
 The mean 
healing time 
was 35.3±3.1 
days in the 
TCC group and 
39.7±4.2 days 
in the Stabil-D 
group 
 The total cost 
of treatment 
with Stabil-D 
was €3,300 and 
for the TCC the 
total cost was 
€6,688.50 
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Appendix 19: Data Extraction Table Katz et al 2005 
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Data Extraction Table 
Author and 
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care 
Setting 
Type and 
Characteristics 
of Wound 
Inclusion/ Exclusion 
Criteria 
Sample size 
 
 
Katz et al  
 
 
2005 
 
 
 
A randomized 
trial of two 
irremovable off-
loading devices 
in the 
management of 
plantar 
neuropathic 
diabetic foot 
ulcers 
Diabetes 
Care  
USA 
 
 
Compare the efficacy 
of a RCW rendered 
irremovable (iTCC) 
with the TCC in the 
treatment of 
neuropathic plantar 
FU 
Hypothesised that 
iTCC if worn 
continuously should 
not differ in healing 
times and 
complications from 
the TCC 
Diabetic 
Foot Clinic 
Neuropathic 
diabetic foot 
ulcers 
Ulcer surface area 
3cm
2
 
Ulcer duration 
216 days 
Ulcer location 29 
forefoot,  11 
midfoot, 1 heel 
Inclusion: Chronic, non-
ischemic, non-infected 
University Texas stage IA or 
IIA ulcers, when there was 
more than one plantar ulcer 
present only the largest was 
used for inclusion 
Exclusion: Active infection 
at ulcer site, Charcot neuro-
arthropathy, significant 
peripheral arterial disease, 
inability to walk. 
41 diabetic patients 
Lost to follow up 
total of 7, 4 in the 
iTCC group and 3 
in the TCC group. 
TCC: 20 
iTCC: 21 
Patient 
Characteristics 
Design Details Study Type Allocation Intervention Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
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Mean age 50.9 
(23-65 years); 
28 subjects were 
male, 5 were 
white, 14 black 
and 25 hispanic; 
38 had type 2 
DM; the mean 
duration of 
diabetes was 
14.1 (2-33 
years); insulin 
dependents 19; 
current smokers 
5; ever smoked 
18; Neuropathy 
Disability Score 
was around 9.2 
and the 
vibration 
threshold in 
volts was 46. 
 
 
 
 
 
Two-arm 
prospective 
RCT 
 
Randomisation 
Sequence: 
subjects were 
randomised 
using a pre-
prepared 
random number 
table 
Quantitative Blinding and 
concealment 
of allocation 
not mentioned. 
21 subjects were 
assigned iTCC. 
20 subjects were 
assigned TCC. 
Initially ulcers were 
evaluated, debrided 
and dressed after 
which casts were 
applied. Subjects 
were followed on a 
weekly basis. At each 
visit devices were 
inspected, ulcers 
evaluated, debrided, 
measured on acetate 
sheet and 
photographed 
 
Outcome 
measures 
were 
assessed at 
the earlier of 
either 
complete 
wound 
healing or 12 
weeks.  
Primary end 
point was 
the 
proportion 
of patients 
with healed 
ulcers in ≤ 
12 weeks in 
each group. 
Secondary 
were 
complication 
rates,  
median 
healing 
times, time 
to place and 
remove the 
devices and 
A two sample t-
test was used to 
analyse normally 
distributed 
dichotomous 
variables. A 
Wilcoxon rank-
sum test was used 
for non-normally 
distributed 
variables. A log-
rank test was used 
for survival data.  
Study power was 
of 95% to detect a 
5% difference in 
the proportion of 
patients with 
healed ulcers at or 
before 12 weeks 
and a 355 power 
to detect a 25% 
difference in 
complication rates 
between the two 
groups. 
All parameters 
were analysed as 
intention to treat 
were two tailed, 
 From the 20 subjects in 
the TCC group four were 
lost to follow-up 
 From the 21 subjects in 
the iTCC group two were 
lost to follow-up 
 One subject was found to 
have osteomyelitis before 
entry in study 
 The proportion of subjects 
whose ulcers healed in 
≤12weeks was 74±45% 
for the TCC group and 
80±41% for the iTCC 
group 
 For subjects whose ulcers 
healed in the 12 week 
period the mean healing 
time was 5 weeks for the 
TCC group and 4 weeks 
for the iTCC 
 In the TCC group 65% of 
subjects had a form of 
complication, and of these 
54% was local skin 
maceration 
 In the iTCC group there 
were 38% of 
complications, of which 
75% were local skin 
maceration 
 When patients with 
maceration were removed 
from analysis, 
complication rates 
dropped to 46% and 13% 
Conclusion: This 
study suggests that 
iTCC may be as 
effective as TCC in 
healing DFU, no 
more or less 
associated 
complications, 
takes less time to 
place/remove and 
costs less. 
 
Recommendations 
None made 
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cost. and used an α 
value of 0.05. 
in the TCC and iTCC 
groups respectively, 
corresponding to a 71% 
relative risk reduction and 
an absolute risk reduction 
of 33% at week 12. 
 Other complications were: 
broken cast, second ulcer, 
abrasions, oedema, 
kissing ulcer and fall. 
 There was a single toe 
amputation in each group 
 Most of the patient wore a 
medium-sized iTCC 
which weighed 1.1kg 
compared to 1.5kg for the 
TCC and the large sized 
iTCC weighed 1.4kg. 
 The mean time for 
application of TCC was 
12.4±1.9min and for 
removal 3.6±0.8min 
 The mean time for 
application of iTCC was 
7.6±1.6min and for 
removal 2.3±0.6min 
 The direct cost of 
treatment course was for 
the TCC $210.67 and for 
the iTCC $158.47. 
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Appendix 20: Data Extraction Table Mueller et al 1989 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
199 
 
Data Extraction Table 
Author and 
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics 
of Wound 
Inclusion/ 
Exclusion 
Criteria 
Sample size 
 
 
Mueller et al  
 
 
1989 
 
Total contact 
casting in 
treatment of 
diabetic plantar 
ulcers: 
controlled 
clinical trial 
Diabetes 
Care  
USA Compare the effectiveness 
of TCC and traditional 
dressing treatment (TDT) 
for the management of 
neuropathic plantar ulcers 
in patients with diabetes 
mellitus. 
 
Diabetic foot 
centre and 
physical therapy 
department at 
Washington 
University School 
of Medicine 
Neuropathic 
plantar ulcers 
TCC group: 
Ulcer size mean 
area (cm
2
) 1.8 
and mean depth 
(mm) 3.6; Ulcer 
Wagner grade1 
15, grade2 6. 
TDT group: 
Ulcer size mean 
area (cm
2
) 2.8 
and mean depth 
(mm) 2.4; Ulcer 
Wagner grade1 
13, grade2 6. 
Inclusion: patient 
that had been 
diagnosed with 
diabetes mellitus 
and currently had 
a plantar ulcer but 
no evidence of 
gross infection 
(no significant 
oedema or 
drainage), 
osteomyelitis or 
gangrene. 
40 patients 
 
TCC: 21 
 
TDT: 19 
 
 
Patient 
Characteristics 
Design Details Study Type Allocation Intervention Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
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TCC group: 
Mean age 
(years) 54; male 
13, female 8; 
insulin 
dependent 5, 
non-insulin 
dependent 16; 
mean duration 
of diabetes 
(years) 17; mean 
ulcer duration 
(days) 155. 
 
TDT group: 
Mean age 
(years) 55; male 
14, female 5; 
insulin 
dependent 6, 
non-insulin 
dependent 13; 
mean duration 
of diabetes 
(years) 17; mean 
ulcer duration 
(days) 175. 
 
Two-arm 
prospective 
CCT 
 
Randomisation 
Sequence: 
Independent 
random 
sampling. 
Quantitative Blinding and 
concealment 
of allocation 
not mentioned 
In the TCC group the ulcer 
was covered with one thin 
layer of gauze, cotton was 
placed between toes; 
stockinet was applied to 
the lower leg with felt pads 
placed in the malleoli and 
anterior tibia, with foam 
pads placed around toes. A 
total contact plaster shell 
was then moulded around 
the lower leg. The shell 
was reinforced with plaster 
splints, and a walking heel 
was attached to the plantar 
surface. A fiberglass roll 
was applied around the 
plaster for extra durability 
and to allow bearing 
weight sooner than would 
be allowed with plaster 
alone.  
Casts were removed after 
5-7 days, and the ulcer and 
skin inspected. If there 
were no complications the 
cast was reapplied and 
changed every 2-3 weeks 
until the ulcer was 
completely healed. Other 
devices like crutches or 
No clear stated 
outcome measures 
but main 
objective is 
looking at ulcer 
healing. 
A two-way X
2
 -
test test for two 
independent 
variables with 
two levels was 
used to 
determine 
whether there 
was a 
significant 
difference in the 
distribution of 
healed 
compared with 
not healed 
ulcers in the two 
groups. The α-
level was 0.05. 
 In the TCC 
group, 19 of 21 
(90%) ulcers 
healed in a 
mean time of 42 
± 29 days 
(range 8-91 
days) 
 In the TDT 
group, 6 of 19 
(32%) ulcers 
healed in a 
mean time of 65 
± 29 days 
(range 12-92 
days).  
 Five of 19 
(26%) patients 
in the TDT 
group showed 
serious foot 
infection that 
required 
admission to a 
hospital. Two 
of these patients 
required a 
forefoot 
amputation. 
 None of the 
TCC group 
required 
hospitalization 
during this 
study.  
Conclusion: The 
use of TCC was 
more effective in 
the number of 
ulcers healed than 
conventional 
treatment with. 
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walkers were provided to 
patient who needed them. 
In the TDT group the 
wound was covered with a 
wet-to-dry dressing (sterile 
saline), and patients were 
instructed to change the 
dressing two to three times 
daily. All patients were 
prescribed appropriate 
accommodative footwear 
(healing sandal and extra 
depth shoe with plastazote 
insert) 
Patients who refused to 
receive treatment from 
their assigned treatment 
group before complete 
wound closure were 
considered not healed. 
Ulcers that became grossly 
infected, increased in size, 
or showed no 
improvement after 6 weeks 
were considered not 
healed. 
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Appendix 21: Data Extraction Table Nabuurs-Franssen et al 2005 
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Data Extraction Table 
Author and  
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics of 
Wound 
Inclusion/ Exclusion 
Criteria 
Sample size 
 
Nabuurs-
Franssen et al  
 
 
2005 
Total contact 
casting of the 
diabetic foot 
in daily 
practice: a 
prospective 
follow up 
study 
Diabetes 
Care 
The Netherlands This study was 
undertaken to 
determine the 
outcome and 
complication rate 
of TCC in a wide 
range of diabetic 
foot ulcers in 
daily practice. 
Not mentioned Neuropathic 
diabetic foot ulcers 
Off all ulcers: 
Mean ulcer size 
(cm
2
) 1.3; mean 
duration (days) 31; 
infection 29%; 
location: digit 1 
plantar 22, 
metatarsal 1 plantar 
15, ray 2,3,4 plantar 
30, ray 5 plantar 14, 
dorsum/ midfoot 9, 
heel 9 
Inclusion: diabetic patients 
with polyneuropathy and a 
foot ulcer were offloading 
was indicated but not possible 
with simple measures. 
Exclusion: critical limb 
ischaemia and major illness 
affecting wound healing, 
infection higher than grade 2 
of the PEDIS system. 
98 patients 
TCC group: 50 
RCC group: 22 
SMC group: 26 
Patient 
Characteristics 
Design 
Details 
Study Type Allocation 
Intervention 
Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
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Off all 
patients: mean 
age (years) 67; 
male 65%; mean 
duration of 
diabetes (years) 
18; PAD 44%; 
Type 2 diabetes 
70%. 
 
 
 
 
 
 
 
 
 
 
 
 
Prospective 
data collection  
 
 
Quantitative Not applicable At every visit, 
patient 
characteristics, 
cast details, and 
complications 
were registered 
electronically. 
Three total 
contact casting 
modalities were 
used: a non-
removable TCC, a 
removable TCC 
(RCC) and a 
shoe-model cast 
(SMC) that could 
not be removed 
by the patient. 
Choice of cast 
was based on both 
patient and cast 
characteristics.  
At every visit, 
necrotic tissue 
and callus were 
surgically 
debrided. TCCs 
were renewed 
every 1–2 weeks, 
Primary 
outcomes 
percentage of 
ulcers healed 
with a cast, 
time to heal, 
and number of 
complications. 
Data are expressed 
as median and 
interquartile ranges. 
Comparisons were 
performed using 
Fisher’s exact, 
Mann-Whitney U 
and Kruskal-Wallis 
tests. In all 
analyses, correction 
was made for ulcer 
duration. 
Multivariate 
analyses were 
performed to 
further delineate the 
effect of PAD and 
infection on the 
percentage healed 
and cast failure 
(logistic 
regression). In this 
analysis we 
included PAD, 
infection at 
baseline, type and 
duration of 
diabetes, age and 
sex, size and 
duration of the 
ulcer at baseline, 
PAD was present in 44% and 
infection at baseline in 29% 
of the patients. Overall, 
healing was achieved in 74 
(76%) of the patients, with a 
median healing time of 33 
days (interquartile range 14–
63). In 22 patients, the ulcer 
did not heal during cast 
treatment (cast failure). 
Nine of these patients 
developed progressive 
infection, six were 
hospitalized for intravenous 
antibiotics, and three 
underwent amputation 
Due to impaired healing, a 
revascularization procedure 
was performed in two patients 
and free-flap transplantation 
in three patients.  
Seven patients, casting was 
stopped due to discomfort 
with the cast and 
noncompliance in one patient. 
In all the above mentioned 
patients, alternative 
offloading techniques were 
used, which resulted in 
Conclusion: Best 
results were 
obtained in patients 
with non-infected 
pure neuropathic 
ulcers. Due to poor 
outcome, alternative 
strategies should be 
used in patients with 
the combination of 
PAD and 
(superficial) 
infection and in 
patients with heel 
ulcers. 
205 
 
 
 
 
and RCC and 
SMC devices 
were modified if 
necessary. 
Felt was applied 
around the ulcer 
to reduce peak 
pressure.  
Patients with a 
removable cast 
were instructed to 
remove the device 
only during 
wound care. 
Cast treatment 
was terminated 
when there was 
no reduction in 
wound size or 
depth during 4 
consecutive 
weeks. 
and type of cast. 
The SPSS statistical 
package, version 
11.0 (Chicago, IL), 
was used. 
healing of 20 of the 22 ulcers 
at the end of the study period.  
Two patients were lost to 
follow-up before healing had 
occurred and were included in 
the analyses as cast failures 
(n= 24 in total). 
In patients without infection 
and without PAD, healing 
occurred in 90%, and in 
patients without PAD but 
with infection, healing was 
observed in 87%. 
In patients without infection 
but with moderate PAD, 
healing occurred in 69%.  
In patients with infection and 
PAD, healing was markedly 
impaired; only 36% of the 
ulcers healed during cast 
treatment. 
Time to heal was 18 days in 
the patients without infection 
and without PAD (range 10–
41 days) and 29 days in 
patients without PAD but 
with infection (range 27–68 
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days). 
In patients without infection 
but with moderate PAD, the 
time to heal was 42 days 
(range 14–65 days).  
Only a minority of patients 
with infection and PAD 
healed during cast treatment, 
so the numbers were too 
small to calculate the time to 
heal. 
No differences were observed 
between the healing rates of 
the three types of cast. 
Patients with cast failure had, 
in comparison with patients in 
whom the ulcer healed, more 
frequent moderate PAD (75 
vs. 34%), longer duration of 
the ulcer (61 vs. 21 days), and 
more frequent infection at 
baseline (46 vs. 24%). 
Anatomical location was 
clearly related to outcome, all 
ulcers (n =15) in the 
metatarsal head 1 region 
healed, irrespective of the 
presence of PAD and/or 
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infection. In contrast, the 
minority of heel ulcers 
healed. Logistic regression 
analysis showed that infection 
at baseline (OR3.6), PAD 
(OR7.4), and the location at 
the heel (OR11.4) were 
associated with a lower 
percentage of healing in the 
cast. 
Complications: New 
superficial ulcers were 
observed in 9% of the patients 
and were not related to 
ischemia, infection, or the 
anatomical location of the 
primary ulcer. These ulcers 
healed within a maximum of 
13 days in a revised cast. Pre-
ulcerative lesions developed 
in 28% of the patients but 
resolved within a few days 
after minor adaptations of the 
cast. Abrasions were found in 
8% of the patients, and 
temporary joint problems 
were reported in 7% of the 
patients. 
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Appendix 22: Data Extraction Table Piaggesi et al 2007 
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Data Extraction Table 
Author and  
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics 
of Wound 
Inclusion/ Exclusion 
Criteria 
Sample size 
 
 
Piaggesi et al  
 
 
2007 
 
 
 
 
 
 
An off-the-shelf 
instant contact 
casting device for 
the management of 
diabetic foot ulcers: 
a randomized 
prospective trial 
versus traditional 
fiberglass cast 
Diabetes Care Italy 
 
 
 
 
 
Test the safety, 
efficacy and cost 
between TCC and 
Optima Diab 
Walker in the 
management DFU 
Diabetic foot 
clinic of the 
University of 
Pisa between 
April and 
October 2005 
Diabetic foot 
ulcers 
Inclusion: type 1 or 2 
DM for at least 
5years, peripheral 
neuropathy, forefoot 
plantar ulcer for a 
period of at least 3 
weeks with an area 
wider than 1cm
2
, 
University Texas 
stage IA or IIA 
Exclusion: peripheral 
vascular disease, 
signs of infection, 
previous ulcer in the 
same site in the past 
6months, probing to 
bone or 
osteomyelitis, 
Charcot 
neuroarthropaty, 
bilateral ulcers, 
serum creatinine 
43 patients were 
screened but three 
did not enter the 
study one refused to 
release informed 
consent and two 
were unable to 
attend follow-up 
visits due to 
distance to travel. 
 
40 diabetic patients 
were actually part 
of the study 
TCC: 20 
Optima Diab 
Walker: 20 
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>2mg/dl, any 
systemic pathology or 
therapy that could 
interfere with the 
healing process, 
severe visual and 
motor impairment, 
life expectancy 
<1year 
 
Patient 
Characteristics 
Design Details Study Type Allocation 
Intervention 
Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
TCC: Mean age 
(years) 59.8; 
duration of 
diabetes (years) 
14.7; A1C 
7.9%; Vibration 
perception 
threshold (volts) 
36.8; area of 
lesion (cm
2
) 3.7. 
Optima Diab 
Walker: Mean 
age (years) 61.1; 
duration of 
diabetes (years) 
13.4; A1C 
7.6%; Vibration 
perception 
Two-arm 
prospective RCT 
Randomisation 
Sequence: subjects 
were randomised 
through a computer 
generated 
randomisation list. 
Quantitative Blinding and 
concealment of 
allocation not 
mentioned 
20 subjects were 
assigned the TCC 
(group A). 
 
20 subjects were 
assigned the 
Optima Diab device 
(group B).  
 
Subjects received 
instructions on how 
to manage the off-
loading devices. 
Ulcers were 
debrided and 
measured with 
Visitrak and 
photographed 
 
Ulcers were dressed 
with paraffin gauze 
and covered with 
Primary 
outcome 
measure was the 
rate of healing 
at 12 weeks. 
Secondary 
outcome 
measures were 
number and 
severity of 
adverse events, 
mean healing 
time, time of 
application and 
removal of the 
devices, cost of 
treatment, and 
level of 
Data was 
analysed 
according to the 
intention to treat 
model, with 
Student’s t-test 
for normally 
distributed 
variables. 
Kaplan-Meier 
analysis of 
survival data, 
and the X
2
 tests 
for dichotomous 
variables using 
commercially 
available 
software Stat 
 Five subjects of the 
TCC group 
reported minor 
adverse events, in 
one the TCC was 
partially ruptured 
and in other four 
skin maceration 
was present 
 Subjects of the 
Optima Diab 
device reported, 
one an episode of 
paraesthesia, two 
showed skin 
maceration and 
one superficial 
haematoma due to 
trauma 
 No new ulcers 
were observed in 
both groups 
Conclusions: This 
study confirms the 
effectiveness and 
the safety of non-
removable off-
loading devices in 
the management of 
DFU at an equal 
level as TCC and is 
superior to the 
previous in terms of 
practicability, cost 
and patient 
satisfaction. 
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threshold (volts) 
39.1; area of 
lesion (cm
2
) 3.9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
single sterile gauze 
before off-loading 
application 
 
Time to apply and 
remove off-loading 
devices was 
calculated 
 
Level of subjects 
satisfaction was 
recorded using a 
visual analogic 
scale were 0 is no 
satisfaction at all 
and 10 maximum 
satisfaction 
 
satisfaction 
expressed by 
patients. 
View.  One subject in 
each group 
develop infection 
which was treated 
with antibiotic and 
resolved in one 
week 
 95% of ulcers 
healed in TCC 
group and 85% in 
Optima Diab group 
within the 12 week 
study period 
 The mean duration 
of healing time 
was 6.5±4.4weeks 
in TCC group and 
6.7±3.4 weeks in 
optima Diab group 
 Time for 
application of 
devices differed 
significantly, in the 
TCC group 
15.1±2.3 min and 
in the Optima Diab 
group 2.1±0.7 min 
 Time devices for 
removal also 
differed 
significantly, in the 
TCC group 
2.1±0.9 min and in 
the Optima Diab 
group 0.9±0.4 min 
 The cost of 
212 
 
treatment was 
higher in the TCC 
group compared to 
the Optima Diab 
group 
 Patient satisfaction 
was higher in the 
Optima Diab group 
compared to the 
TCC 
  group 
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Appendix 23: Data Extraction Table Van de Weg et al 2008 
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Data Extraction Table 
Author and  
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics 
of Wound 
Inclusion/ Exclusion 
Criteria 
Sample size 
 
 
Van De Weg et 
al  
 
 
2008 
 
 
 
 
 
 
Wound healing: 
total contact 
cast vs. custom-
made temporary 
footwear for 
patients with 
diabetic foot 
ulceration 
Prosthetics 
and Orthotics 
International  
The 
Netherlands 
Compare the 
effectiveness of 
irremovable total-
contact casts (TCC) 
and custom-made 
temporary footwear 
(CTF) to heal 
neuropathic foot 
ulcerations in 
individuals with 
diabetes. 
Rehabilitation 
departments of 
two hospitals. 
Diabetic plantar 
ulcers. 
TCC group: 
Median duration 
of ulcer (weeks) 
4; mean WSA 
(cm
2
) at baseline 
4.2; ulcer grade1 
2; forefoot 
location 20. 
CTF group: 
Median duration 
of ulcer (weeks) 
5; mean WSA 
(cm
2
) at baseline 
3.0; ulcer grade1 
2; forefoot 
location 18. 
Inclusion: Confirmed 
diabetes, sensory 
neuropathy and a 
plantar ulcer Grade 1 
or 2 using the Wagner 
scale 
Exclusion: Patients 
unable to walk indoors, 
with dementia or life-
threatening co-
morbidity, ABI50.4 
and/or osteomyelitis 
were excluded. 
43 patients 
 
TCC: 23 
 
Shoe (CTF): 20 
Patient 
Characteristics 
Design Details Study Type Allocation Intervention Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
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TCC group: 
mean age 
(years) 64.8; 
gender 32% 
females; median 
duration of 
diabetes (years) 
12; mean 
HbA1c 7.8; 
mean ABI 0.69; 
prescription of 
antibiotics 41%. 
CTF group: 
mean age 
(years) 58.1; 
gender 10% 
females; median 
duration of 
diabetes (years) 
12; mean 
HbA1c 8.7; 
mean ABI 0.65; 
prescription of 
antibiotics 45%. 
 
 
 
Two-arm 
prospective 
RCT 
Randomisation 
Sequence: An 
independent 
person prepared 
a randomization 
list in advance 
with an equal 
number of 
treatment 
assignments 
(5/5) per block 
of ten to ensure 
approximately 
equal numbers 
of patients in 
each treatment 
group. 
Quantitative Allocation 
was concealed 
using opaque, 
sealed 
envelopes. 
Before the 
intervention ulcers 
were debrided of 
necrotic tissue and 
hypertrophic edges 
were removed. All 
patients received the 
same educational 
guidelines on foot 
care and general 
information on the 
importance of 
appropriate footwear. 
All patients attended 
the out-patient 
department regularly 
for device inspection.  
Wound care and 
wound debridement 
was carried out by a 
podiatrist blinded to 
treatment mode, and 
antibiotics dispensed 
if necessary. Patients 
having difficulty 
performing dressing 
changes were 
provided with 
assistance from a 
home care nurse. 
Primary 
outcome 
measure was 
reduction of 
wound surface 
area (WSA) 
during the 16 
weeks follow-
up. 
Secondary 
outcome 
measure was 
time to wound 
healing in days.  
Subjects who 
discontinued 
were considered 
not healed and 
wound size 
recorded as last 
measured during 
follow-up. 
The analysis of 
effectiveness was 
done according to 
the intention-to-
treat principle. 
WSA changes 
since baseline 
were calculated 
for each 
participant for 
each moment of 
follow-up. 
Subsequently 
differences in 
these changes 
between groups 
were analysed 
using linear 
regression 
analysis. All 
analyses were 
adjusted for 
potential 
confounding by 
difference in 
baseline WSA by 
entering the 
baseline WSA in 
the regression 
analysis. The 
authors present 
Four patients were lost 
to follow-up: one died, 
one was amputated on 
the affected side and 
two withdrew from 
follow-up (all from the 
TCC group). 
At baseline the median 
WSA was 3.6 cm
2
 in 
the TCC group and 1.9 
cm
2
 in the CTF group. 
At 16 weeks the 
median WSA was 0.4 
cm
2
 in both groups. 
After adjustment for 
differences in baseline 
values, the difference 
between groups in 
reduction of wound 
surface was 0.10 cm
2
. 
Six patients wearing 
shoes and six patients 
using a cast had a 
completely healed 
ulcer. The mean time to 
healing was shorter for 
the patients using a 
cast: 59 (SD 39) days 
for TCC vs. 90 (SD 12) 
Conclusions: The 
authors found little 
difference in the 
effectiveness 
between the TCC 
and CTF and 
suggest further 
investigation 
regarding the 
benefits of the CTF. 
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Interventions: TCC, 
a well-moulded and 
minimally padded 
non-removable 
below-knee cast that 
maintains contact 
with the entire plantar 
aspect of the foot and 
lower leg, which was 
changed on a weekly 
basis. 
CTF was a custom-
made of felt and 
supplied with a rigid 
leather socket 
stiffened with 
Rhenoflex, a 
composite of rubber 
and plastic with 
thermoplastic 
properties. This 
ensures that 
movement of the foot 
in the shoe is 
restricted to an 
absolute minimum. 
both crude and 
adjusted mean 
differences 
between groups in 
the reduction of 
WSA, including 
95% CI, p values 
<0.05 were 
considered 
significant. 
Analyses were 
carried out using 
SPSS 12.01 
software. 
days for CTF. 
Ulcers that did not 
healed completely has 
a size of 0.8cm
2
 
(1.1±1.2) for the CTF 
group, and 0.9cm
2
 
(1.5±1.6) for the TCC 
group. 
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Appendix 24: Data Extraction Table Zimny et al 2003 
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Data Extraction Table 
Author and  
Date of Study 
Title Source 
Study 
Geographical 
Location 
Research 
Question/Aim/ 
Objective 
Care Setting 
Type and 
Characteristics of 
Wound 
Inclusion/ Exclusion 
Criteria 
Sample size 
 
 
Zimny et al  
 
2003 
The effects of 
applied felted 
foam on wound 
healing and 
healing times in 
the therapy of 
neuropathic 
diabetic foot 
ulcers 
Diabetic 
Medicine   
Germany The aim of this study 
was to evaluate the 
effects of the felted 
foam padding on 
wound radius 
reduction and healing 
times in neuropathic 
foot ulcers. 
Clinic, no 
mention of the 
type of clinic. 
Diabetic 
neuropathic foot 
ulcers 
Felted foam 
group: ulcer 
location metatarsal 
head I-III 19, IV-V 
5; Wagner grade1 
6, grade2 18 
Half-shoes group: 
ulcer location 
metatarsal head I-
III 24, IV-V 6; 
Wagner grade1 7, 
grade2 23 
Inclusion: Patients with 
plantar ulcers with a 
Wagner grade 1 or 2 
were included in the 
study 
Exclusion: Patients with 
ulcers under the heel or 
midfoot, multiple ulcers, 
or those suggestive of 
osteomyelitis and 
patients with peripheral 
vascular occlusive 
disease were not 
included. 
54 patients 
 
Felted foam 
group: 24 
 
Half-shoes group 
(conventional 
group): 30 
Patient 
Characteristics 
Design Details Study Type Allocation Intervention Details 
Outcome 
Measures Analysis 
Results 
Conclusions/ 
Recommendations 
Felted foam 
group: Mean 
age (years) 62.1; 
mean BMI 27.4; 
male 13, female 
Two-arm 
prospective 
RCT 
Randomisation 
Quantitative Concealment 
of allocation 
not mentioned.  
When wounds 
All patients received 
identical standard 
ulcer wound care that 
included debridement 
and daily careful 
Outcome 
measures not 
clearly 
mentioned, 
however main 
The statistical 
analyses included 
descriptive 
statistics, the 
standard error of 
 In the felted foam 
group, the initial 
average wound area 
was 102.3 ± 45.3mm
2 
and 5.4 ± 3.1mm
2
 after 
Conclusion: The 
main finding 
indicates that the 
application of felted 
foam underneath 
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11; type 1 
diabetes 7, type 
2 diabetes 17; 
mean diabetes 
duration (years) 
18.2; mean 
HbA1 7.9%; 
mean TcPO2 
8.9; mean ABI 
1.0. 
Half-shoes 
group: Mean 
age (years) 62.1; 
mean BMI 28.5; 
male 17, female 
13; type 1 
diabetes 13, 
type 2 diabetes 
17; mean 
diabetes 
duration (years) 
22.1; mean 
HbA1 7.5%; 
mean TcPO2 
8.7; mean ABI 
1.0. 
Sequence: not 
mentioned 
were 
measured the 
observer was 
no blinded to 
the treatment 
group. 
monitoring of the 
ulcer. 
In one group pressure 
relief in the ulcerated 
area was 
accomplished using 
felted foam dressings 
and the other group 
received half-shoes 
(Thanner, 
Hoechstaedt) 
objective is 
evaluation of 
wound radius 
reduction and 
healing times. 
the mean and 
analyses of the 
variance using the 
t-test. Differences 
between the groups 
regarding the 
patients’ sex, type 
of diabetes and 
ulcer depth were 
calculated using 
Fisher’s exact test. 
The relationship 
between the mean 
wound radius 
reduction and 
healing times was 
then calculated by 
linear regression 
analysis, the 95% 
confidence intervals 
were also 
calculated. 
The proportion of 
healed ulcers over 
time was assessed 
by Kaplan–Meier 
curve. The 
statistical analyses 
were done using 
JMP V4.0 for 
10 weeks.  
 In the conventional 
therapy group, the 
initial average wound 
area was 
112.5±50.8mm
2
and 
10.6±4.2 mm
2 
after 10 
weeks. 
 Regarding the ulcer 
depths, there were 
more ulcers with a 
Wagner grade 2 than1 
in both groups, but the 
ulcer areas were not 
dependent on the ulcer 
depths (P=0.27, 
P=0.78, respectively). 
 The frequency of soft 
tissue infections did 
not differ between the 
treatment groups (25% 
felted foam group, 
23% conventional 
group). 
 The average healing 
time in the felted foam 
group was 75.2 days 
[95% confidence 
interval (CI) 67–84] 
and 85.2 days (95% CI 
79–92) in the 
conventional group 
(P= 0.03).  
 The statistical power to 
detect a difference of 5 
the foot reduced the 
wound area as 
effectively as the 
half-shoes. Thus, 
the felted foam 
technique seems to 
be as effective as 
the half-shoes for 
the treatment of 
diabetic plantar 
ulcers.  
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windows. days in healing time 
was 0.91 (α= 0.05).  
 The mean wound 
radius reduction in 
both groups appears to 
have a near linear 
relationship with the 
healing time. It 
decreased by 0.48 mm 
(95% CI 0.42–0.56) 
per week in the felted 
foam group, and by 
0.39 mm (95% CI 
0.35–0.42) per week in 
the conventional group 
(P=0.005). 
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Appendix 25: Data Extraction Table for Included Systematic Reviews 
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Data Extraction Table for Included Systematic Reviews 
Review 
Author 
Data 
Assessed as 
up to date 
Title  Source 
Geographical 
Location 
Population 
Intervention and 
Comparison Interventions 
Outcomes for which Data was 
Reported 
Spencer 2008 
Pressure Relieving 
Interventions for 
Preventing and Treating 
Diabetic foot Ulcers 
(Review) 
Cochrane  
Library 
UK Patients with diagnosis 
of type / and/or type 2 
diabetes and with foot 
ulcers or callus 
Relief or redistribution of 
pressure in the neuropathic 
and/or neuro-ischaemic 
diabetic foot with or without 
the presence of ulceration. 
 
No comparison of 
interventions. 
 
Healing rate, patient satisfaction and 
quality of life, complication and 
Morbidity, economic analysis 
Mason et 
al 
1999 
A systematic review of 
foot ulcer in patients 
with Type 2 diabetes 
mellitus. II: treatment. 
Diabetic 
Medicine 
UK No clear identification 
of characteristics that 
populations in articles 
to be reviewed should 
have.  
 
Only mentions that 
type1 and type 2 
diabetes mellitus will 
be included. 
Systematic review looking at 
studies that address an 
intervention for patients with 
diabetic foot ulcers. 
 
Not focused in any specific 
intervention, but assessing 
various treatments. 
 
No comparison of 
interventions present. 
No primary or secondary outcomes 
reported. 
 
Aims to assess the value of treatment 
for foot ulcers in patients with type 2 
diabetes mellitus. 
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Appendix 26: Description of devices characteristics from the study by Birke et al 
(2002) 
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Accommodative Dressing 
The accommodative dressing consisted of a 6-inch-long piece of quarter-inch-thick 
adhesive felt attached to the forefoot with a cut out over the ulcer area. The foot was fit 
into a surgical shoe modified with a half inch wedged sole to promote heel weight 
bearing.  
 
Healing Shoe 
Patients in this group were instructed in daily dressing changes and were followed up 
weekly reassessment and ulcer debridement as needed. In this group 54% were females; 
the mean age was 58.2 years; the mean ulcer duration was 67.9 days; the mean ulcer 
grade was 1.7 (Wagner Grade): the mean ulcer length, width and depth was 1.2, 0.7 and 
0.3 cm respectively (Birke et al 2002: 212-13). 
 
Walking Splint
2
 
The walking splint was fabricated as follows: the leg was generously wrapped with 
cotton cast padding. Relief areas for the posterior heel and plantar lesion were provided 
with adhesive-backed foam-rubber padding. Bony prominences, such as the malleoli 
and the navicular, were padded with 0.32-cm (1/8 in) felt. The inner shell was made of 
two sets (five layers each) of plaster splints overlapped in the centre. The strength of the 
device was improved by extending the medial and lateral trim lines to the midline of the 
                                                          
2 The information relating to the fabrication of the walking splint for the study by Birke et al (2002) was 
adapted from the study of Birke et al (1991: 117,119) ‘ Methods of Treating Plantar Ulcers’. 
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malleoli and reinforcing the plastic layers with fiberglass casting tape. A rubber walking 
heel (positioned and levelled as described for the walking cast) was secured to the 
bottom of the splint with a second roll of fiberglass casting tape. The fiberglass taping 
that covers the dorsum of the foot was removed. The inner layer of cast padding was cut 
along the anterior leg and dorsum of the foot to allow removal of the device. An elastic 
wrap was used to secure the splint to the leg.  
 
TCC
3
 
The fabrication of the TCC involves thin cotton stocking that is the innermost layer. 
Orthopaedic felt (0.32 cm [1/8 in] thick) was used to pad the malleoli, navicular, and 
tibia1 crest. Adhesive-backed foam-rubber padding encloses the toes and covers the 
ulcer area. The toes are covered to prevent direct trauma or entry of foreign objects. In 
recent years, we have added cotton cast padding to minimize the risk of secondary 
lesions from friction within the cast. The cast padding is layered over the less prominent 
bony areas, such as the posterior heel, base of the fifth metatarsal, and dorsum of the 
foot. To obtain an optimal total contact fit, the inner layers of plaster are applied without 
stretching and are carefully moulded over the contours of the foot. The combination of 
selective padding and moulding, results in pressure redistribution from the lesion area to 
the remaining foot and leg. Plaster splints reinforce the posteroplantar and mediolateral 
aspects of the cast. A 0.64-cm (l/4 in) section of plywood and a rubber walking heels 
are positioned such that the centre of the heel is at a location 40% of the distance from 
the heel to the toe. This heel placement creates a smooth rocking motion during walking 
the plywood board reinforces the bottom of the cast to prevent the heel from penetrating 
                                                          
3
 The information relating to the fabrication of the TCC for the study by Birke et al (2002) was adapted 
from the study of Birke et al (1991: 117,119) ‘Methods of Treating Plantar Ulcers’. 
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the plaster. Small pieces of plaster are used to fill the space between the plywood board 
and the plantar surface of the cast, so that the board appears level when viewed from the 
side and the front. Additional plaster bandages are used to strengthen the cast and secure 
the walking heel. 
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Appendix 27: Description of devices characteristics from the study by Caravaggi et 
al (2000) 
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Therapeutic Shoe 
The therapeutic shoe consists of a cloth with a rocker-bottom sole and a rolling point 
situated beside the metatarsal arch during walking. The therapeutic shoe is predisposed 
(extra depth) for lodging an 8-mm–thick cushioned elastic insole made of plastazote 
(alkaform) on which an area of unloading is prepared in the area of the plantar ulcer. 
The unloading area must be 5–8 mm larger than the perimeter of the ulcer. The shoe is 
opened dorsally with Velcro straps that permit the dressing to stay in place (Caravaggi 
et al 2000: 1748) 
 
Fiberglass Cast 
The fiberglass cast was fabricated as follow, two types of fiberglass bandages were used 
for the construction of the pressure-relief apparatus. The first type of bandage was 
composed of fiberglass imbued with a polyurethane resin with characteristics of 
flexibility and resistance. The other bandage was composed of fiberglass imbued with a 
polyurethane resin of two different concentrations that confers high resistance to 
loading. Before using both types of bandages, a tubular stockinet was placed onto the 
lower limb, which was first covered with German cotton to protect the skin adequately, 
especially on bony protrusions. To further protect bony protrusions, such as the 
malleolus and tibial crista, some pieces of protective rubber foam were also applied. 
The plaster bandages were applied so that the boot conformed to the shape of the leg as 
much as possible. The first two layers were applied using the Softcast bandage. The 
structure was then reinforced with a stick made with a Scotchcast bandage placed in the 
middle of the two malleoli, extending beyond them for at least 20 cm, giving rigidity to 
the cast. The same material was used to build a rigid plantar sole. The number of layers 
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applied to construct the sole depended on the weight of the patient (range 3–8 
layers).The final structure was reinforced with more Softcast bandages. An aluminium 
stirrup or rubber heel was anchored to the structure as a support to allow walking. The 
side supports were secured with an outer layer of Softcast. The choice of using the 
stirrup or the rubber heel as a support for walking depends on the position of the ulcer. 
The stirrup is used if the ulcer is localized in the midfoot region. This support leaves the 
entire plantar surface of the boot free from pressure and permits the construction of an 
opening precisely in the ulcerated region. Therefore, examination and changes of 
dressing to the ulcer can be performed as frequently as needed. A rubber heel is used 
when lesions are located on the forefoot, the plantar surface of the toes, or the heel 
because it allows an open window directly above the ulcer. The rubber heel is 
positioned in the centre of the plantar surface to allow comfortable walking. In all 
subjects, the sole of the unaffected foot’s shoe was elevated to ease walking. After very 
brief training, all patients were able to walk properly without crutches (Caravaggi et al 
2000: 1748). 
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Appendix 28: Description of device characteristics from the study by Dumont et al 
(2009) 
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Ransart boot 
For the use of the Ransart boot, the ulcer is protected with a simple protective dressing. 
The foot or lower leg is covered with stockinet and this is then encased in a roll of Soft 
Cast
®
. The sole of the device is reinforced with Scotch Cast
®
 before the application of a 
second roll of Soft Cast
®
. The cast is moulded to the foot and no special protection is 
applied to bony prominences. The cast is left open just below the malleoli and an 
additional window is cut out over the ulcerated area. The cast is then shaped to make it 
more easily removable and secured with Velcro
®
 (Dumont et al 2009: 779). 
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Appendix 29: Description of device characteristics from the study by Faglia et al 
(2010) 
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TCC 
The TCC was casted according to the technique described previously by Caravaggi et al 
(2000). All casts were made by personnel with particular expertise in the use of this 
device. Two types of fiberglass bandages were used for construction of the pressure-
relief apparatus. The first type of bandage was composed of fiberglass imbued with a 
polyurethane resin with characteristics of flexibility and resistance. The other bandage 
was composed of fiberglass imbued with a polyurethane resin of two different 
concentrations that confers high resistance to loading. A bandage with German cotton 
and tubular stockinet was placed on the limb. To further protect bony protrusions, such 
as the malleolus and tibial crista, pieces of protective rubber foam were also applied. 
The structure was then reinforced with a stick made of a Scotchcast bandage placed in 
the middle of the two malleoli, extending beyond them for at least 20cm to give rigidity 
to the cast. The same material was used to build a rigid plantar sole. The number of 
layers applied to construct the sole depended on the weight of the patient (range 3–8 
layers). An aluminium stirrup was anchored to the structure as a support to allow 
walking. The side supports were secured with an outer layer of Softcast3M. After very 
brief training, all patients were able to walk properly without crutches (Faglia et al 
2010:1420) 
 
Stabil-D 
The Stabil-D was composed of a specifically designed rigid, boat-shaped and fully 
rocker bottom sole: its rounded extremities (at the heel and tiptoe) facilitate gait, and its 
middle section improves the mid-stance phase. The insole height (24mm) avoids 
excessive lifting of the contralateral limb during walk, thus lowering the barycentre and 
favouring more stable walking. The cover is made of Elastam
®
, a yarn composed of 
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polyurethane segments and block copolymers that confer high transparency and stability 
to the system, mixed with polyethylene glycol segments with the characteristic of 
elasticity. At the ankle, the cast is provided with removable, lateral stabilizer inserts 
made of ABS, which ensure stability to the tibiotarsal joint and/or adequate support 
during gait. Moreover, a rigid brace made of a thermo formable polymer material 
properly supports the Achilles tendon and contributes to stability during rolling steps; 
such a brace can be adapted to the foot deformity using a hot air gun and malleolar 
forceps. The cast is closed dorsally with Velcro wrap placed over the forefoot to relieve 
skin pressure and Velcro straps with self-fitting rings placed against the instep to secure 
perfect fastening, provide foot stability, and ensure a perfect fit of the heel in the rigid 
brace. Finally, more Velcro
® 
straps are placed or secured with rings against the tibia to 
provide a secure fit. The cast has a special foot arch support (Modus) with small 
adaptable inserts. This modular insole is made of multiple layers of different stiffness 
and is specifically designed to allow proper offloading by removing the small inserts 
from the ulcerated area, without the need for traditional milling procedures. The bottom 
layer is composed of chemically knitted closed cell polyphenylic foam. The middle 
layer is composed of knitted, expandable, and mouldable closed cell polystyrene foam 
(plastazole). The Diapod cover, specifically designed for feet at risk of ulcer formation, 
is composed of chemically knitted dermo compatible Eva Diflex Vibram (closed cell 
polyphenylic foam), which also has bactericidal and fungicidal properties. Patients in 
the Stabil-D group were carefully trained for proper cast wearing, in particular for 
accurate closure of Velcro straps, and were prescribed continuous cast wear of the 
Stabil-D, patients were allowed to remove the cast only during nocturnal rest (Faglia et 
al 2010:1420). 
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Appendix 30: Description of device characteristics from the study by Mueller et al 
(1989) 
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TCC 
In the TCC group, the ulcer was covered with one thin layer of gauze, cotton was placed 
between the toes to prevent maceration, and a stockinette was applied to the lower leg 
with 1/8-inch felt pads applied to the malleoli and anterior tibia and a foam pad placed 
around the toes. A total contact plaster shell was then moulded around the lower leg and 
this was reinforced with plaster splints, and a walking heel was attached to the plantar 
surface. Then a fiberglass roll was applied around the plaster for extra durability and to 
allow bearing weight sooner than would be allowed with plaster alone. Patients were 
given a written list of precautions and instructed to limit ambulation to 33% of their 
usual activity. Assistive devices (walkers or crutches) were provided to patients who 
required them. TCCs were removed after 5-7 days, and the ulcer and skin inspected 
(Mueller et al 1989: 386). 
 
TDT 
For the TDT group the wound was covered with a wet-to-dry dressing (using sterile 
saline), and patients were instructed to change the dressing two to three times daily. If 
patients had difficulty performing dressing changes home-health nurse visits were 
provided to assist patients and monitor their treatment. All patients were prescribed 
appropriate accommodative footwear (healing sandal and extra-depth shoe with 
plastazote insert), were instructed to avoid bearing weight on the involved lower 
extremity (with walkers or crutches) (Mueller et al 1989: 386). 
 
 
 
237 
 
Appendix 31: Description of device characteristics from the study by Piaggesi et al 
(2007) 
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TCC 
In the TCC group a layer of isolating foam was positioned in relation to the ulceration 
site, in this way the lesion was better isolated from contact with the cast, to avoid 
friction or trauma with bony prominences extra layers of cotton-wool were applied. The 
fiberglass material used for manufacturing each cast was produced by 3M
®
 and 
consisted of two Scotchcast longuettes (10x90 or 7.5x70 cm, depending on the size of 
the foot) to create the plantar support and block the ankle, and three Sofcast rolls (10.1 
or 7.6 cm) to make the boot. Each cast was provided with one or two rubber heels to 
allow the patients to stand and walk, and at each visit TCCs were removed with an 
oscillating saw (Piaggesi et al 2007: 587). 
 
Optima Diab Walker 
The Optima Diab Walker was adapted according to the patient’s foot condition and 
secured to the patient’s leg with a plastic non-removable lace, which was an integral 
part of the device. The patients’ foot and leg were protected by a layer of cotton-wool to 
avoid friction with the device, and the three-layer insoles were modelled to 
accommodate the position of the ulcer site and the Optima Diab Wallker was removed 
cutting the non-removable lace (Piaggesi et al 2007: 587). 
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Appendix 32: Description of device characteristics from the study by Van de Weg 
et al (2008) 
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TCC 
The TCC group casts were well-moulded and minimally padded non-removable below-
knee maintaining contact with the entire plantar aspect of the foot and lower leg. These 
were applied by a cast technician with at least five years’ experience using the 
Kominsky technique. Technique not explained. Prior to casting, ulcers were debrided 
and dressed with Aquacell
®
, a single layer of cast padding was applied and adhesive 
foam was used over bony prominences. Cast shoes with a polyphasic rocker were 
supplied and patients with poor postural stability were advised to use a crutch/cane to 
maintain balance. The casts were changed on a weekly basis for the duration of the trial 
(Van de Weg et al 2008: 5). 
 
CTF 
The CTF was composed of a custom-made felt and supplied with a rigid leather socket 
stiffened with Rhenoflex
®
, a composite of rubber and plastic with thermoplastic 
properties, which ensures that movement of the foot in the shoe is restricted to an 
absolute minimum. The height of the shoes was twice the distance from the foot base to 
the lateral malleolus. The custom full-length insoles were made from cork and a 
plastazote and polyethylene foam and polyurethane covering. Extra depth was provided 
in the inlay for the ulcer. To ensure maximal relief of pressure under the MTPs, the 
pivot point of the rocker bar was placed proximal to the MTPs and the outsole stiffened 
to facilitate the distribution of forces exerted on the foot. A plastic trial cast was always 
made for a test fitting to check the last measurements, innersole accommodation and 
balance before the shoe was completed. Patients were instructed to wear their footwear 
at all times whilst out of bed. Detailed instructions regarding routine care of the cast and 
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shoes were given to all patients. All patients were advised to decrease their activity 
levels considerably (Van de Weg et al 2008: 6). 
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Appendix 33: Description of device characteristics from the study by Zimny et al 
(2003) 
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Felted Foam 
In the Felted foam group, a combination of 0.635 cm thick rubber foam with a 0.158cm 
layer of felt adhered, rubber glue was used. The felted foam was measured exactly to fit 
the plantar aspect of the foot. Using a scalpel, an aperture was cut in the felted foam at 
the exact location of the ulcer, allowing clear visualization of the ulcer. A gauze Peha-
haft
®
 was then wrapped around the foot and the felted foam pad to secure the pad. The 
wound was covered with a saline-soaked sponge VacuSeal
®
, which was changed every 
day. A compress was placed over the wet sponge and fixed with Peha-haft®. The felted 
foam dressing was exclusively used for plantar ulcerations under the forefoot and was 
changed, every third day (Zimny et al 2003: 623). 
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Appendix 34: Selection Bias (Randomisation) 
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Study Judgment  Selection Bias (Randomisation) 
Armstrong et al 2001 
Low risk 
All patients were reported to be have been 
randomised 
Armstrong et al 2005 
Caravaggi et al 2000 
Faglia et al 2010 
Katz et al 2005 
Mueller et al 1989 
Piaggesi et al 2007 
Van de Weg et al 2008 
Zimny et al 2003 
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Appendix 35: Selection Bias (Allocation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
247 
 
 
 
 
Study Judgment  Selection Bias (Allocation) 
Armstrong et 
al 2001 
Low risk Allocation sequence through a computerised randomisation 
schedule. 
High Risk No allocation concealment reported. 
Armstrong et 
al 2005 
Low risk Allocation sequence through a computerised randomisation 
schedule. 
High risk Allocation provided to the treating clinician by a single study 
coordinator via telephone. 
Caravaggi et 
al 2000 
Low risk  
 
Allocation sequence by phone to one of two pre-randomized 
treatment groups. 
High Risk No allocation concealment reported. 
Faglia et al 
2010 
Low risk Allocation sequence through code break envelopes containing 
one of the two options. Then separate allocation was 
performed for each centre, and a copy of all envelopes was 
kept. 
High Risk No allocation concealment reported. 
Katz et al 
2005 
High risk 
Allocation sequence using a pre-prepared random number 
table. No allocation concealment reported. 
Mueller et al 
1989 
High risk 
Allocation sequence was done through independent random 
sampling. No allocation concealment reported. 
Piaggesi et al 
2007 
Low risk Allocation sequence through a computer generated 
randomisation list. 
High Risk No allocation concealment reported. 
Van de Weg 
et al 2008 
Low risk 
Allocation sequence through an independent person who 
prepared a randomization list in advance with an equal 
number of treatment assignments (5/5) per block of ten to 
ensure approximately equal numbers of patients in each 
treatment group.  
Allocation was concealed using opaque, sealed envelopes. 
Zimny et al 
2003 
High risk 
No allocation sequence or concealment reported. 
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Appendix 36: Performance Bias 
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Study Judgment  Performance Bias 
Armstrong et al 2001 
High risk No blinding reported 
Armstrong et al 2005 
Caravaggi et al 2000 
Faglia et al 2010 
Katz et al 2005 
Mueller et al 1989 
Piaggesi et al 2007 
Van de Weg et al 2008 
Zimny et al 2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
250 
 
Appendix 37: Detection Bias 
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Study Judgment  Detection Bias 
Armstrong et al 2001 
High Risk No blinding reported 
Armstrong et al 2005 
Caravaggi et al 2000 
Faglia et al 2010 
Katz et al 2005 Unclear Risk  
Mueller et al 1989 
High risk No blinding reported 
Piaggesi et al 2007 
Van de Weg et al 2008 Low Risk Not involved in treatment 
Zimny et al 2003 High Risk Not blinded 
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Appendix 38: Attrition Bias 
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Study Judgment  Attrition Bias 
Armstrong et al 2001 
High risk 
12 participants did not complete study and were 
excluded from analysis 
Armstrong et al 2005 
High Risk 
4 participants did not complete the course of study 
and were considered treatment failures in the 
intention-to-treat analysis. 
Caravaggi et al 2000 Low Risk  
Faglia et al 2010 
High Risk 
3 patients did not complete study and were 
considered dropouts, data relating to these 
participants was not analysed. 
Katz et al 2005 
High Risk 
7 participants were lost to follow up however it is 
not clear if they were included in the intention-to-
treat analysis as treatment failures. 
Mueller et al 1989 
High Risk 
Patients who refused to receive treatment from their 
assigned treatment group before complete wound 
closure were considered not healed however there is 
no mention in the study if any participants did 
refuse treatment and how these data would be 
interpreted. 
Piaggesi et al 2007 Low Risk  
Van de Weg et al 
2008 High Risk 
1 cross-over to the other group but data was 
analysed in original group; 2 discontinuations not 
included in analysis. 
Zimny et al 2003 Low Risk  
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Appendix 39: Reporting Bias 
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Study Judgment  Reporting Bias 
Armstrong et al 2001 
Low Risk No issues 
Armstrong et al 2005 
Caravaggi et al 2000 
Faglia et al 2010 
Katz et al 2005 
Mueller et al 1989 
Piaggesi et al 2007 
Van de Weg et al 2008 
Zimny et al 2003 
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Appendix 40: EBL Critical Appraisal Checklist Birke et al (2002) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
257 
 
 
EBL Critical Appraisal Checklist  Birke et al (2002) Yes No Unclear N/A 
 Is the study population representative of all users, actual and eligible, who might be 
included in the study? 
 
 
 
 
  
Are inclusion and exclusion criteria definitively outlined?     
Is the sample size large enough for sufficiently precise estimates?     
Is the response rate large enough for sufficiently precise estimates?     
Is the choice of population bias-free?     
If a comparative study: 
 
Were participants randomized into groups? 
Were the groups comparable at baseline? 
If groups were not comparable at baseline, was incomparability addressed by the 
authors in the analysis? 
  
  
    
    
Was informed consent obtained?     
 
 
 
 
 
 
 
 
 
Are data collection methods clearly described?     
If a face-to-face survey, were inter-observer and intra-observer bias reduced?     
Is the data collection instrument validated?     
If based on regularly collected statistics, are the statistics free from subjectivity?     
Does the study measure the outcome at a time appropriate for capturing the 
intervention’s effect? 
    
Is the instrument included in the publication?     
Are questions posed clearly enough to be able to elicit precise answers?     
Were those involved in data collection not involved in delivering a service to the 
target population? 
  
 
 
 
 
 
 
 
Is the study type / methodology utilized appropriate?     
Is there face validity?     
Is the research methodology clearly stated at a level of detail that would allow its 
replication? 
    
Was ethics approval obtained?     
Are the outcomes clearly stated and discussed in relation to the data collection?     
 
 
 
 
 
 
Are all the results clearly outlined?     
Are confounding variables accounted for?     
Do the conclusions accurately reflect the analysis?     
Is subset analysis a minor, rather than a major, focus of the article?     
Are suggestions provided for further areas to research?     
Is there external validity?     
Calculation for section validity: (Y+N+U=T) 
 
If Y/T <75% or if N+U/T > 25% then you can safely 
conclude that the section identifies significant omissions 
and that the study’s validity is questionable. It is important 
to look at the overall validity as well as section validity. 
Calculation for overall validity: (12+6+2=T) 
 
If Y/T ≥75% or if N+U/T ≤ 25% then you can safely conclude that the 
study is valid. 
 
Section A validity calculation: 43% or 57% 
Section B validity calculation: 100% or 0% 
Section C validity calculation: 25% or 75% 
Section D validity calculation: 83% or 17% 
Overall validity calculation: 12/20= 60% 
 8/20= 40% 
 
Section A: 
Population 
Section B:  
Data 
Collection 
Section C:  
Study 
Design 
Section D:  
Results 
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Appendix 41: EBL Critical Appraisal Checklist Dumont et al (2009) 
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EBL Critical Appraisal Checklist:  Dumont et al (2009) Yes No Unclear N/A 
 Is the study population representative of all users, actual and eligible, who might be 
included in the study?     
Are inclusion and exclusion criteria definitively outlined?     
Is the sample size large enough for sufficiently precise estimates?     
Is the response rate large enough for sufficiently precise estimates?     
Is the choice of population bias-free?     
If a comparative study: 
Were participants randomized into groups? 
 
Were the groups comparable at baseline? 
 
If groups were not comparable at baseline, was incomparability addressed by the 
authors in the analysis? 
    
    
    
Was informed consent obtained?     
 
 
 
 
 
 
 
 
 
Are data collection methods clearly described?     
If a face-to-face survey, were inter-observer and intra-observer bias reduced?     
Is the data collection instrument validated?     
If based on regularly collected statistics, are the statistics free from subjectivity?     
Does the study measure the outcome at a time appropriate for capturing the 
intervention’s effect?     
Is the instrument included in the publication?     
Are questions posed clearly enough to be able to elicit precise answers?     
Were those involved in data collection not involved in delivering a service to the target 
population?     
 
 
 
 
 
Is the study type / methodology utilized appropriate?     
Is there face validity?     
Is the research methodology clearly stated at a level of detail that would allow its 
replication? 
    
Was ethics approval obtained?     
Are the outcomes clearly stated and discussed in relation to the data collection?     
 
 
 
 
 
 
Are all the results clearly outlined?     
Are confounding variables accounted for?     
Do the conclusions accurately reflect the analysis?     
Is subset analysis a minor, rather than a major, focus of the article?     
Are suggestions provided for further areas to research?     
Is there external validity?     
Calculation for section validity: (Y+N+U=T) 
If Y/T <75% or if N+U/T > 25% then you can safely 
conclude that the section identifies significant omissions 
and that the study’s validity is questionable. It is important 
to look at the overall validity as well as section validity. 
Calculation for overall validity: (10+7+2=19) 
If Y/T ≥75% or if N+U/T ≤ 25% then you can safely conclude that the 
study is valid. 
 
Section A validity calculation: 40% or 60% 
Section B validity calculation: 75% or 25% 
Section C validity calculation: 40% or 60% 
Section D validity calculation: 80% or 20% 
Overall validity calculation: 10/19=53% 
 9/19=47% 
Section A: 
Population 
Section B:  
Data 
Collection 
Section 
C:  
Study 
Design 
Section 
D:  
Results 
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Appendix 42: EBL Critical Appraisal Checklist Nabuurs-Fransen et al (2003) 
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EBL Critical Appraisal Checklist  Nabuurs-Franssen et al (2003) Yes No Unclear N/A 
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Appendix 43: Quality Appraisal Mason et al (1999) 
 Is the study population representative of all users, actual and eligible, who might be 
included in the study? 
 
 
 
 
  
Are inclusion and exclusion criteria definitively outlined?     
Is the sample size large enough for sufficiently precise estimates?     
Is the response rate large enough for sufficiently precise estimates?     
Is the choice of population bias-free?     
If a comparative study: 
Were participants randomized into groups? 
 
Were the groups comparable at baseline? 
 
If groups were not comparable at baseline, was incomparability addressed by the 
authors in the analysis? 
    
    
    
Was informed consent obtained?     
 
 
 
 
 
 
 
 
 
Are data collection methods clearly described?     
If a face-to-face survey, were inter-observer and intra-observer bias reduced?     
Is the data collection instrument validated?     
If based on regularly collected statistics, are the statistics free from subjectivity?     
Does the study measure the outcome at a time appropriate for capturing the 
intervention’s effect?     
Is the instrument included in the publication?     
Are questions posed clearly enough to be able to elicit precise answers?     
Were those involved in data collection not involved in delivering a service to the 
target population?     
 
 
 
 
 
Is the study type / methodology utilized appropriate?     
Is there face validity?     
Is the research methodology clearly stated at a level of detail that would allow its 
replication? 
    
Was ethics approval obtained?     
Are the outcomes clearly stated and discussed in relation to the data collection?     
 
 
 
 
 
 
Are all the results clearly outlined?     
Are confounding variables accounted for?     
Do the conclusions accurately reflect the analysis?     
Is subset analysis a minor, rather than a major, focus of the article?     
Are suggestions provided for further areas to research?     
Is there external validity?     
Calculation for section validity: (Y+N+U=T) 
 
If Y/T <75% or if N+U/T > 25% then you can safely 
conclude that the section identifies significant omissions 
and that the study’s validity is questionable. It is important 
to look at the overall validity as well as section validity. 
Calculation for overall validity: (13+1+5=19) 
 
If Y/T ≥75% or if N+U/T ≤ 25% then you can safely conclude that the 
study is valid. 
 
Section A validity calculation: 40% or 60% 
Section B validity calculation: 75% or 25% 
Section C validity calculation: 100% or 25% 
Section D validity calculation: 80% or 20% 
Overall validity calculation: 13/19= 68.4% 
1+5/19= 32% 
 
Section A: 
Population 
Section B:  
Data 
Collection 
Section C:  
Study 
Design 
Section D:  
Results 
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Steps for Conducting Systematic Mason et al (1999) 
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Appendix 44: Quality Appraisal Spencer (2008) 
 
                                                          
4
 Adapted from The Cochrane Handbook – Protocol for Cochrane Reviews (Higgins& Green 2011) 
Reviews
4
 Yes 
(Y) 
No 
(N) 
Comment 
Background 
  
Concise background mentions incidence 
of diabetes and DFU, potential 
complications and enumerates 
traditional treatments and new 
developments. 
Research Question   Not mentioned. 
Aim   Reported. 
Objectives   Not differentiated in the main text. 
Criteria for selecting studies for 
review: 
Types of studies 
 
Types of participants 
Types of interventions 
Types of outcome measures 
 
  
 
  
Characteristics of participants not 
clearly mentioned. Only mentioned type 
1 and type 2 diabetes and patients with 
DFU. 
  
Looking at individual types of treatment. 
  Not mentioned. 
Search methods for identification of 
studies 
  
Incomplete, only databases and other 
resources used for searching are 
mentioned. Did not report terms used or 
a flow chart with results of search. 
Data collection   Does not report how this will be done. 
Data analysis   Does not report how this will be done. 
Results: 
Description of studies 
 
Risk of bias in included studies 
Effects of interventions 
  
 
  
Presented in tables on author, date of 
study, intervention, trial details and 
results. 
  
Not reported. 
  
Summarises findings of studies 
individually, poor critical appraisal. 
Discussion 
  
Critically appraises study quality, not 
too detailed. 
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5
 Adapted from The Cochrane Handbook – Protocol for Cochrane Reviews (Higgins& Green 2011) 
Steps for Conducting 
Systematic Reviews
5
 
Spencer (2008) 
Yes 
(Y) 
No 
(N) 
Comment 
Background   Detailed. 
Research Question   Not mentioned. 
Aim    
Objectives    
Criteria for selecting 
studies for review: 
Types of studies 
Types of participants 
 
Types of interventions 
Types of outcome measures 
 
  
 
  
 
  
 
  
 
Search methods for 
identification of studies   
No mention of databases except Wounds 
Group Trial Register. 
Data collection    
Data analysis    
Results: 
Description of studies 
Risk of bias in included 
studies 
Effects of interventions 
   
  
 
  
 
  
 
Discussion 
  
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Appendix 45: Outcome Measures Armstrong et al 2001 
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Systematic Review Primary Outcome 
Measures 
Other Relevant Aspects  
Systematic Review Secondary Outcome 
Measures 
Study Sample 
Healing 
Rates 
Healing 
Times 
Reduction in 
Ulcer Size 
Activity 
Daily steps  
Ulcer Size (cm
2
) 
Adverse 
Effects 
Cost QoL Compliance 
 
Armstrong et 
al (2001) 
 
Prospective 
RCT 
63 patients 
 
TCC: 19 
 
 
 
89.5% 
(n=17) 
 
 
 
33.5±5.9 days 
Not reported 
 
 
 
600.1±320.0 
Healed ulcers were 
smaller at baseline 
than unhealed 
ulcers. 
 
HU 1.1±1.0  
UHU 1.9±1.3  
Not 
reported 
None 
reported 
None 
reported 
None 
reported 
RWC: 20 
65.0% 
(n=13) 
50.4±7.2 days 767.6±563.3 
Half-shoe: 24 
58.3% 
(n=14) 
61.0±6.5 days 1,461.8±1,452.3 
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Appendix 46: Outcome Measures Armstrong et al 2005 
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  Systematic Review Primary Outcome Measures 
Other Relevant 
Aspects  
Systematic Review Secondary Outcome Measures 
Study Sample 
Healing Rates 
Healing Times 
(days) 
Reduction in 
Ulcer Size 
Ulcer Size (cm
2
) 
At Baseline 
Adverse 
Effects 
Cost/ 
Compliance/ 
QoL 
12 weeks 
ITT  
12 weeks 
(n=46) 
Armstrong 
et al 
(2005) 
 
RCT 
50 patients 
 
 
iTCC: 23 
 
 
 
 
82.6% 
 
 
 
86.4% 
 
 
 
41.6±18.7  
Not reported 
 
 
 
2.7±1.3 
Peri-wound 
maceration 
 
37.5% 
Infection 
(on antibiotic) 
 
27.3% 
Not reported 
RCW: 27 51.9% 58.3% 58.0±15.2  2.0±1.1 68.2% 41.7% 
271 
 
Appendix 47: Outcome Measures Birke et al 2002 
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6
 Seven ulcers (5.8%) did not heal or were lost to follow-up. 
  Systematic Review Primary Outcome Measures Other Relevant Aspects  
Systematic Review 
Secondary Outcome 
Measures 
Study Sample Healing Rates at 12w 
Healing 
Times (days) 
Reduction in 
Ulcer Size 
Ulcer Size (cm) 
Adverse 
Effects 
Cost/QoL/ 
Compliance 
At baseline 
Length Width Depth 
Birke et al 
(2002) 
 
 
Retrospective 
analysis 
120 patients
6
 
n=113 (94%) 
 
81% of forefoot ulcers 
closed 
 
45.5±43.4 
Not reported 
   
Not 
reported 
Not reported 
TCC: 13 92% 
47.7±41.4 
 
1.4±0.9 0.9±0.5 
0.6±0.5 
 
Accommodative 
dressing : 26 
93% 
36.1±36.3 
 
1.3±1.2 0.9±0.7 0.4±0.4 
Healing shoe: 57 81% 
41.4±41.9 
 
1.2±0.9 
 
0.7±0.5 
 
0.3±0.6 
 
Walking splint: 18 83% 
50.5±29.0 
 
1.6±1.3 
 
1.1±0.9 
 
0.5±0.6 
 
Other: 6 Not reported Not reported 1.6±0.7 1.0±0.5 0.6±0.8 
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Appendix 48: Outcomes Measures Caravaggi et al 2000 
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Systematic Review Primary Outcome 
Measures 
Other Relevant 
Aspects  
Systematic Review Secondary Outcome Measures 
Study Sample 
Healing 
Rates 
Healing 
Times 
Reduction in 
Ulcer Size 
Ulcer Size (mm
2
) 
At Baseline 
Adverse 
Effects 
Cost Compliance QoL 
Caravaggi 
et al (2000) 
 
 
RCT 
50 patients 
 
 
Therapeutic 
shoe: 24 
 
 
 
 
n= 5 
Not 
reported 
 
 
 
 
 
431.7  [391.7] 
Increase in ulcer 
size 
 
 
n= 2 
Not 
reported 
Acceptance of 
device 
 
 
91.15±9.9 
Not 
reported 
Fiberglass 
cast: 26 
After 30days 
n= 13 587.3 [587.7] n= 0 88.33±17.3 
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Appendix 49: Outcome Measures Dumont et al 2009 
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7
 Seven patients were lost to follow-up, seven developed co-morbidities, four died. 
8
 22 (18.8%) patients ulcer unhealed until amputation of which 21 minor and one major amputation. 
  
Systematic Review Primary Outcome 
Measures 
Other 
Relevant 
Aspects  
Systematic Review Secondary Outcome Measures 
Study Sample Healing Rates 
Healing Times 
Median (IQR) 
Reduction in 
Ulcer Size 
Ulcer Size Adverse Effects Compliance 
Cost / 
QoL 
Dumont et al 
(2009) 
 
Observational 
study 
135 patients
7
 
 
 
n=117
8
 
 
 
 
 
 
 
 
n=82 (70.1%) 
 
 
 
 
 
60 days (43-99) 
 Not reported 
Not 
reported 
Abrasions in instep:  n=8 
Redness on 5
th
 metatarsal head:  n=2 
Blister  on the heel:  n=1 
 
Complications healed after modifications of 
the Ransart boot. 
Judge non-
compliant  
n=13 (9.6%) 
Nothing 
reported 
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Appendix 50: Outcome Measures Faglia et al 2010 
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9
 For an obese patient extra bandage was required increasing the price to €89.5. 
  Systematic Review Primary Outcome Measures 
Other Relevant 
Aspects  
Systematic Review Secondary Outcome Measures 
Study Sample 
Healing 
Rates 
Healing Times 
(days) 
Reduction in Ulcer 
Size 
Ulcer Size (cm
2
) 
At Baseline 
Adverse 
Effects 
Cost 
Compliance/ 
QoL 
Faglia et al 
(2010) 
 
RCT 
45 patients 
 
 
TCC: 23 73.9% 
( n= 17) 35.3±3.1 
1.41 to 0.21 cm
2
 
73.6% reduction 1.4±1.2 
Peri-wound 
maceration 
 
 
n= 0 
Hitching 
 
 
 
n= 1 €73.59 
t=91 casts 
€6,688.50 
Not reported 
Stabil-D: 
22 
72.7%  
( n= 16) 
39.7±4.2 
2.18 to 0.45
 
 cm
2
 
90% reduction 
2.2±2.2 n= 1 n= 0 
 
€130 plus 
€20 
(Modus 
sole) 
t=22 casts 
€3,300.00 
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Appendix 51: Outcome Measure Katz et al 2005 
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10
 TCC group 4 lost to follow-up, iTCC group 2 lost to follow-up and 1had osteomyelitis before study entry. 
  Systematic Review Primary Outcome Measures 
Other Relevant 
Aspects  
Systematic Review Secondary Outcome Measures 
Study Sample
10
 
Healing Rates 
Healing Times 
(mean) 
Reduction 
in Ulcer 
Size 
Ulcer Size 
At Baseline 
Adverse Effects Cost 
Compliance 
QoL 
≤ 12 weeks 
TCC iTCC 
Materials/ 
Week 
Direct cost of 
treatment 
course 
n=41 n=34 
Katz et al 
(2005) 
 
Prospective 
RCT 
41 patients 
 
 
 
 
 
TCC: 20 
 
 
 
 
 
 
 
74±45% 
 
 
 
 
 
 
93±26% 
(1
st
 quartile 
3weeks to 3
rd
 
quartile 
7weeks) 
 
 
5weeks  
Not 
reported 
 
 
 
 
 
 
2.9 (1.9, 0.9-3.9) 
Maceration 
n=7 (35%) 
Second ulcer 
n=2 (10%) 
Abrasions 
n=2 (10%) 
Toe amp. 
n=1 (5%) 
Oedema 
n=1 (5%) 
Kissing Ulcer 
n=1 (5%) 
Fall 
n=0 (0%) 
Maceration 
n=6(29%) 
Second ulcer 
n=1(5%) 
Abrasions 
n=0 (0%) 
Toe amp. 
n=1 (5%) 
Oedema 
n=0 (0%) 
Kissing Ulcer 
n=0 (0%) 
Fall 
n=1 (5%) 
 
 
 
 
 
 
$38.36 
 
 
 
 
 
 
$210.67 
Not 
reported 
 
 
 
iTCC: 21 
 
 
 
80±41% 94±24% 4weeks 3.1 (1.6, 0.9-3.5) 
$14.70 + 
$89.95 
$158.47 
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Appendix 52: Outcome Measure Mueller et al 1989 
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Systematic Review Primary Outcome 
Measures 
Other Relevant Aspects  
Systematic Review Secondary Outcome 
Measures 
Study Sample Healing Rate 
Healing 
Time (days) 
Reduction 
in Ulcer 
Size 
Ulcer Size 
Adverse 
Effects 
Cost 
Compliance/ 
QoL 
At Baseline 
Area (cm
2
) Depth (mm) 
Mueller et 
al (1989) 
 
RCT 
40 patients 
 
 
 
TCC: 21 
 
 
 
 
90% ( n= 19) 
 
 
 
 
 
42±29  
(range 8-91) 
 
Not 
reported 
 
 
 
 
 
1.8±2.5 
 
 
 
 
3.6±3.2 
Foot Infection that 
required hospitalisation 
 
 
n=0 
Not 
reported 
Not reported 
TDT: 19 
 
32% ( n= 6) 
 
65±29 
(range 12-
92) 
 
2.8±3.4 
 
2.4±0.9 
n=5 (26%) of which 2 
required forefoot 
amputation 
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Appendix 53: Outcome Measures Nabuurs-Franssen et al 2005 
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Systematic Review Primary Outcome 
Measures 
Other Relevant 
Aspects  
Systematic Review Secondary Outcome Measures 
Study Sample 
Healing 
Rates 
Healing Times 
(median) 
Reduction 
in Ulcer 
Size 
Ulcer Size 
[median (IQR)] 
Adverse Effects Compliance  
Cost/ 
QoL At baseline 
n=98 
n=74 
Nabuurs-
Franssen et 
al (2005) 
 
 
Prospective 
data 
collection 
 
 
 
98 patients 
 
 
 
 
 
 
TCC: 50 
RCC: 22 
SMC: 26 
 
 
 
n=74 (76%) 
 
 
 
 
33 days  
(14-36) 
 
 
 
 
 
 
 
 
1.3 cm
2
  
(0.6-7.1) 
 
 
 
1.2 cm
2
  
(0.6-3.1) 
Infection: n=9  
 Hospitalise for IV ant. n=6 
 Amputations n=3 
Revascularisation n=2 
Free-flap transplantation n=3 
Cast stopped due to discomfort n=7 
 
New superficial ulcers: 9% which  healed in 
13days with new revised cast 
 
Pre-ulcerative lesions: 28% resolved in few 
days after minor adaptations in cast 
 
Chafed skin: 8% 
 
Joint problems: 7% 
Non-compliance  
n=1 
 
Lost to follow-
up  n=2 
Not 
reported 
Healing Rate (Patient groups) Healing Times (Patient groups) 
No PAD + No infection = 90% 
No PAD + Infection = 87% 
PAD + No infection = 69% 
PAD + Infection = 36% 
No PAD + No infection = 18 days (10-41) 
No PAD + Infection = 29 days (27-68) 
PAD + No infection = 42 days (14-65) 
PAD + Infection = only a minority healed, being the numbers too small 
to calculate time to heal 
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Appendix 54: Outcome Measures Piaggesi et al 2007 
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Systematic Review Primary Outcome 
Measures 
Other 
Relevant 
Aspects  
Systematic Review Secondary Outcome Measures 
Study Sample 
Healing Rate  Healing 
Time 
(weeks) 
Reduction 
in Ulcer 
Size 
Ulcer Size 
(cm
2
) 
At Baseline 
Adverse Effects Cost Compliance QoL 
At 12 weeks 
Piaggesi et 
al (2007) 
 
Prospective 
RCT 
40 patients 
 
 
 
 
TCC: 20 
 
 
 
95% 
 
 
 
6.5±4.4 
(2-14) 
Not 
reported 
 
 
 
3.7±1.6 
 
Maceration 
 
 
 
 
n=4 
 Local 
skin 
infection 
 
 
n=1 
 
 
 
110.5±4.38 (€) 
per cast 
727.29±491.25 
(€) per patient 
 
Acceptance of 
device 
 
6.85±2.39 
 
 
Not 
reported 
 
Optima 
Diab 
walker: 20 
85% 
6.7±3.4 
(2-17) 
3.9±1.8 
 
n=2 
Paraesthesia 
n=1 
Haematoma 
of calf 
n=1 
 
n=1 
€130 each 
162.5±57.75 (€) 
per patient 
 
8.45±1.79 
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Appendix 55: Outcome Measures Van de Weg et al 2008 
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11
 Follow-up not achieved for 4 patients: one died, one was amputated and two withdrew from study. 
12
 Not described, but all identified as device related. 
  Systematic Review Primary Outcome Measures Other Relevant Aspects  Systematic Review Secondary Outcome Measures 
Study Sample 
Healing 
Rates 
Healing 
Times 
Reduction in Ulcer 
Size 
Ulcer Size (cm
2
) Adverse 
Effects 
Cost 
Compliance/ 
QoL 
At Baseline 16 weeks 
Van de Weg 
et al (2008) 
 
 
Prospective 
RCT 
 
43 patients 
 
 
 
TCC: 23
11
 
 
 
 
 
 
 
n=6 
 
 
 
 
 
59±39 days 
 
 
 
 
 
 
 
 
 
 
 
 
4.2±3.1 
 
Median US 
 
 
 
0.4 
 
Minor 
Abrasion 
 
 
n=0 
 
Complications
12
  
 
  
 
n=5 (2 had to d/c) Not 
reported 
Not reported 
CTF: 20 n=6 90±12 days 3.0±3.1 0.4 n=2 n=0 
289 
 
Appendix 56: Outcome Measures Zimny et al 2003 
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Systematic Review Primary Outcome 
Measures 
Other Relevant Aspects  
Systematic Review Secondary Outcome 
Measures 
Study Sample Healing Rate 
Healing 
Time 
(days) 
Reduction in 
Ulcer Size 
Ulcer Size (mm
2)
 Adverse 
Effects 
Cost 
Compliance/ 
QoL 
At Baseline After 10 weeks 
Zimny 
et al 
(2003) 
 
Prospect
ive RCT 
54 patients 
 
 
 
Felted 
Foam: 24 
Not reported 
 
 
 
 
75.2 
(67-84) 
 
 
 
 
 
0.48mm per week 
(0.42-0.56) 
 
 
 
 
102.3±45.3 
 
 
 
 
5.4±3.1 
 
Soft tissue infection 
 
 
25%  
Not 
reported 
Not reported 
Half shoes: 
30 
85.2 
(79-92) 
0.39mm per week 
(0.35-0.42) 
112.5±50.8 10.6±4.2 23% 
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Appendix 57: Systematic Review Checklist
13
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
13
 Systematic Review Checklist. Adapted from Prisma 2009 Checklist, Moher D, Liberati A, Tetzlaff J, Altman DG, 
The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA 
Statement. 
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Section/topic  # Checklist item  
Reported 
on page # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  0 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
13 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  14 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
24-25 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
49 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
50 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
148 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
50-51 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
51-52 
293 
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
50 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
52 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  52 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
51-52 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
51-52 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
52 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
56, 168 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
169-223 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  64-66 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
70-98, 267-
290 
Synthesis of results  21 Present in the main results of the review. If meta-analyses are done, include for each, confidence intervals and 
measures of consistency.  
70-98 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  64-66, 245-
256 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  66-67 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
101-115 
294 
 
 
 
 
 
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
116-117 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  118-120 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
298 
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Appendix 58: Gantt chart 
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Proposed Timetable for conducting the Systematic Review, to be submitted May 9
th
 of 2013 
 
Systematic Review Sept. Oct. Nov. Dec. Jan. Feb. March April May 
Research Question          
Literature review 
Search Databases 
 
 
        
Chapter on Background for Systematic Review          
Chapter on Methodological issues in 
Systematic Review 
         
Data Extraction          
Data analysis          
Chapter on Results          
Chapter on Discussion of Results          
Chapter on Summary, Conclusion and 
Recommendations  
         
Submit Thesis          
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Appendix 59: Resources 
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Photocopying          €100 
 
Printing          €300 
 
Stationary          €10 
 
Dislocations          €50 
______________________________________________________________________ 
Total           €460 
 
The writer had no sponsorship to conduct this systematic review.  
 
 
 
 
 
 
 
 
 
